

Market snapshot



Today's top research idea

Rubicon Research (Initiating Coverage): Gains in the gale

- ❖ Rubicon is a fast-growing R&D driven pharma manufacturing with focus on regulated markets. Rubicon has built a sustainable moat - a) full spectrum capabilities across multiple dosage forms with a track record of specialty projects b) manufacturing capacities with a consistent compliance c) focus on commercial success.
- ❖ Over FY22-25, Rubicon's revenue has a CAGR of 60% to INR12.8b. From an opex loss of INR392m in FY22, it has EBITDA of INR2.5b in FY25. ROE - 29% in FY25. Over FY25-28, we est. a CAGR of 29%/32%/43% in revenue/ EBITDA/PAT to INR27.8b/INR5.8b/INR3.9b, driven by a) new launches, including nasal sprays; b) prescription-led business in CNS therapy; c) stable R&D productivity d) curated SCM to maintain high commercialization rate.
- ❖ A earnings CAGR of 43% over FY25-28 and 30%+ RoE (adj. for recent fresh issue). We believe Rubicon should command a premium valuation. Rubicon scores well-ahead of peers on ROE*earnings CAGR matrix. We assign 35x (30% premium to sector multiple) 12M fwd earnings (TP of INR740. Initiate -BUY.


Research covered

Cos/Sector	Key Highlights
Rubicon Research (Initiating Coverage)	Gains in the gale
Other Updates	Dabur ITC NTPC Hyundai Motor Cipla Canara Bank Union Bank of India Aditya Birla Capital SAIL Nippon Life India AMC United Breweries Radico Khaitan LIC Housing Finance Metro Brands Bandhan Bank Brigade Enterprises Navin Fluorine International Manappuram Finance Bata India Mahanagar Gas Transport Corporation of India Queso Corp Automobiles EcoScope DLF Pidilite Inds. Lodha Developers United Spirits Coromandel Inter. IIFL Fin. Vedant Fashions Dr. Agarwal's L T Foods Indian Energy Ex. Gravita India Restaurant Brand Indostar Capital



Chart of the Day: Rubicon Research | Initiating Coverage (Gains in the gale)

Rubicon has much higher R&D turnover than its peer in FY25



Note: 1) R&D Turnover: FY25 US Revenue/FY22-23 R&D; Source: MOFSL, RHP

Research Team (Gautam.Duggad@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.



Kindly click on textbox for the detailed news link

1

Cochin Shipyard to raise ₹6,000 cr for capex

Cochin Shipyard is set to invest ₹6,000 crore over the next five to six years. Funding will come from government schemes, multilateral loans, blue bonds, and internal accruals. This investment will support shipbuilding, ship repair, and other ventures.

2

Reliance to take a leaf out of the 'Campa' book for electronics business

Reliance Retail is set to launch its Kelvinator and BPL electronics brands using a proven strategy. Expect aggressive pricing, higher dealer margins, and widespread availability across stores and online.

3

Dabur India launches ₹500 cr venture arm to back digital-first brands

Dabur India on Thursday announced the launch of Dabur Ventures, a ₹500 crore investment platform which will focus on digital-first consumer businesses of the home-grown fast-moving consumer goods (FMCG) firm.

4

HUL gets NCLT nod to hive off ice-cream biz into Kwality Wall's

Under the approved Scheme of Arrangement, HUL will transfer its entire ice cream business—including brands such as Kwality Wall's, Cornetto, Magnum, Feast, and Creamy Delight—to the new subsidiary.

5

Swiggy to consider raising Rs 10,000 crore on Nov 7 via QIP amid increasing competitive intensity in quick commerce

The proposed Rs 10,000-crore QIP comes as rivals Zepto and Blinkit expand aggressively and new entrants like Reliance and Flipkart intensify competition in quick commerce.

6

Apple, Samsung slow production, offer discounts, halt launches as lightweight models fail to get off the ground

Retailers ET spoke to said initially, the iPhone Air—Apple's thinnest smartphone ever—contributed about 8-10% of the latest iPhone 17 series sales.

7

Megha Engineering unit to acquire Neyveli Power from Abu Dhabi's TAQA

MEIL Energy has acquired TAQA Neyveli Power for Rs. 926 crore, marking a strategic shift from an EPC conglomerate to an owner and operator of infrastructure assets.



BSE Sensex 84,997	S&P CNX 26,054
----------------------	-------------------

**Stock Info**

Bloomberg	RUBICON IN
Equity Shares (m)	164
M.Cap.(INRb)/(USDb)	100/1.1
52-Week Range (INR)	-
1, 6, 12 Rel. Per (%)	-
12M Avg Val (INRM)	-

Financials Snapshot

Y/E MARCH	FY26E	FY27E	FY28E
Sales (INRb)	17.0	22.1	27.8
EBITDA (INRb)	3.5	4.5	5.8
Adj PAT (INRb)	2.2	2.9	3.9
EPS (INR)	13.1	17.8	24.0
EPS Gr. (%)	60.4	35.9	34.7
BV/Sh (INR)	73.0	88.7	109.9
Ratios			
RoE (%)	24.7	22.0	24.2
RoCE (%)	23.1	22.8	25.1
Payout (%)	11.8	11.8	11.8
Valuations			
P/E (x)	46.2	34.0	25.2
P/BV (x)	8.3	6.8	5.5
EV/EBITDA (x)	28.2	21.9	16.9
Div Yield (%)	0.2	0.3	0.4

CMP: INR607**TP: INR740 (+22%)****Buy****Gains in the gale**

- Rubicon Research is a fast-growing research and development-driven pharmaceutical manufacturing company with a focus on regulated markets (particularly the US).
- Notably, over the past decade, Rubicon has built a sustainable moat through a) full spectrum capabilities across multiple dosage forms (oral solids, oral liquids, Nasal Sprays, Topicals) with a track record of successful specialty projects (170 scientist pool); b) building supporting manufacturing capacities with a consistent compliance track record of supplying to US markets; and c) focusing on commercial success.
- Over FY22-25, Rubicon's revenue has increased at a CAGR of 60% to INR12.8b. From an operational loss of INR392m in FY22, it has posted EBITDA of INR2.5b in FY25 with a margin of 19.9%. Effectively, from a net loss of INR671m in FY22, it has reported PAT of INR1.3b in FY25. Accordingly, Rubicon delivered ROE of 29% in FY25.
- Over FY25-28, we estimate a CAGR of 29%/32%/43% in revenue/ EBITDA/PAT to INR27.8b/INR5.8b/INR3.9b, driven by a) new launches in generics, including nasal sprays; b) enhanced focus on prescription-led business in CNS therapy; c) stable R&D productivity; and d) curated approach toward supply chain management to maintain high commercialization rate/minimize supply failure.
- Considering a strong earnings CAGR of 43% over FY25-28 and 30%+ RoE (adj. for recent fresh issue), we believe Rubicon should command a premium valuation. Rubicon scores well-ahead of peers in pharma space on ROE*earnings CAGR matrix (pls refer Exhibit 50). Hence, we assign 35x (30% premium to sector multiple of 27x) 12M forward earnings to arrive at a TP of INR740. Initiate with BUY.

Rubicon scales despite US generics headwinds

- After enjoying prosperous US generics business opportunities over CY05-15, Indian pharma companies have faced multiple challenges since then, such as a) consolidation of PBMs/buyers, b) faster ANDA approvals increasing competition, and c) rising adverse inspection outcomes prolonging incremental approvals.
- Against this backdrop, Rubicon has achieved a commendable scale-up in business (from INR390m revenue in FY15 to INR12.8b in FY25), backed by a curated approach to R&D, product approvals, efficient manufacturing and sound compliance.

Scaled up portfolio with faster launches; 70 commercialized by Jun'25

- Rubicon has considerably scaled up its commercial product base from 18 in FY22 to 70 by Jun'25. It achieved a strong commercialization rate of 86.4% (conversion from approval to launches) as of Q1'FY26, reflecting efficient product launches.

Multiple dosage forms development capability

After 13 years, approval for Fluticasone Propionate generic in the industry was granted to Rubicon

Raldesy – an easy-to-swallow oral solution

R&D turnover at 7.6x, considering annualized 1QFY26 revenue to FY23-FY24 R&D spent

- Rubicon's current product portfolio spans four dosage forms -- oral solids (OS), oral liquids (OL), nasal sprays, and topicals. Revenue from OS increased at a 57% CAGR to INR11b over FY22-25. OL revenue scaled up from INR43m in FY22 to INR1.3b in FY25. OS/OL revenue grew 7%/25% YoY to INR3b/INR355m in 1QFY26. After product launches in FY24, Nasal spray dosage revenue was INR124m/INR80m in FY25/1QFY26.
- R&D spending of INR2.8b over FY24-1QFY26 indicates that Rubicon will sustain its product filing momentum going forward, providing increased certainty to revenue growth prospects over FY25-28. Notably, it has filed six ANDAs and received approval for six ANDAs in 1QFY26.

Nasal sprays – Promising growth driver

- Nasal sprays' contribution to Rubicon's revenue has been increasing, 2.3%/1.0%/0.4% over 1QFY26/FY25/FY24, supported by the approval of the Ambernath nasal spray manufacturing facility in May'24.
- Nasal spray US generics industry is poised to be the fastest-growing formulations, projected to clock 9.5% CAGR over CY25-30, led by innovations in nasal drug delivery technologies and a growing patient preference for non-invasive, rapid-acting treatments.
- Nasal spray approvals remain relatively limited, with only a few companies securing ANDA approvals over the past five years. Rubicon distinguishes itself by obtaining four of the 25 nasal spray approvals granted over CY23-Jun'25.
- Among recent approvals, Fluticasone Propionate nasal spray, a corticosteroid used for allergic rhinitis, holds an estimated market size of USD1b, with nasal sprays contributing USD482m. Notably, Rubicon is the fourth generic company to receive approval, with the first two firms receiving approval in CY07/CY12. Ipratropium Bromide, an anticholinergic for rhinitis relief, has a total market size of USD247m in FY25, with nasal sprays accounting for USD65m. There are five generic companies having ANDA approval for this product, including Rubicon.

From ANDAs to Rx brands: Rubicon's CNS playbook

- Rubicon is implementing efforts toward building prescription-led business in CNS space. Rubicon has three branded products - Equetro, Raldesy, and Lopressor OS, which do not have any other AB-rated generics as of Jul'25.
- Raldesy is the first FDA-approved oral liquid formulation of Trazodone Hydrochloride, offering a novel dosage option in the antidepressant category.
- Equetro is the only FDA-approved carbamazepine formulation indicated as a mood stabilizer for bipolar I disorder.
- Lopressor OS, a liquid formulation of metoprolol tartrate, addresses the need for flexible dosing in conditions such as hypertension, heart failure, and post-MI care.
- In addition to enhanced offerings, we expect increased focus on marketing to drive better business prospects in this segment for Rubicon.

Enhanced focus on R&D; superior productivity

- Rubicon's R&D spending stands at 11% of revenue, significantly higher than the industry median of 6%, highlighting its strategy of building a broad product portfolio rather than relying on a narrow range.
- The company demonstrated strong efficiency in converting R&D investments into revenue, with one of the highest R&D turnovers among peers, measured as US revenues relative to R&D spending from two years ago.
- With FY25 US revenue nearly 6x its FY22-23 R&D expenditure, Rubicon's disciplined product selection and development approach is delivering solid results.

- *Note: While some peers allocate R&D spending toward other geographies as well, we understand that the primary focus is on the US market, which aligns with our comparison of R&D to US sales.*

Amid rising USFDA scrutiny, Rubicon's record stays unblemished

- While India remains a cornerstone of global generic drug supply, the sector continues to face intensified regulatory scrutiny from the USFDA.
- India's share of non-US inspections increased significantly, from 5% in CY21 to 33% in 1HCY25, with 486 inspections conducted during CY23-24 and 40 facilities receiving OAI classifications.
- Rubicon's unblemished compliance record serves as a key differentiator. It has faced 10 USFDA inspections till date at its manufacturing site. It has never received an OAI classification, underscoring its disciplined quality systems, strong governance practices, and deep-rooted culture of regulatory integrity.

Valuation and view: Initiate coverage with BUY rating

- The business models in the US pharma market have been evolving, considering limited buyers and a large number of global manufacturers supplying medicines. Companies like Sun Pharma have scaled up NCE-led prescription business, while other generic companies are building a complex to develop/manufacture products to overcome competitive pressures. This has led to a significant increase in R&D spending. With USFDA approval timelines being unpredictable, the return on investment and investor interest in this space are limited.
- We believe Rubicon is creating a robust business model with a multi-disciplinary, data-driven, R&D-centric product selection framework. The consistent compliance track record provides a strong backbone for superior growth in earnings and return ratios.
- **We model** a 29% revenue CAGR, 110bp margin expansion, and 43% PAT CAGR over FY25-28 under our **base case scenario**. We also assign a 35x 12M forward earnings multiple to arrive at our TP of INR740, implying a potential upside of 22%.
- **The bull case scenario** builds in 32% revenue CAGR with 220bp margin expansion, and 50% PAT CAGR over FY25-28, aided by a higher commercialization rate, a steady flow of product approvals, continued regulatory compliance, and a supportive market environment. This would lead to a TP of INR930, based on 38x 12M forward earnings multiple, implying a potential upside of 54%.
- **The bear case scenario** assumes 26% revenue CAGR with 50bp margin expansion due to a less favorable market, delays in product development, slower commercialization, and operational setbacks due to regulatory challenges. These factors would result in a TP of INR550, based on the 29x 12M forward earnings multiple, implying a potential downside of 10%.

We initiate coverage on the stock with a **BUY rating**.

Key risks

- Adverse policy changes affect pricing. Regulatory aspects may impact business performance.
- Adverse classification of inspections may prolong growth prospects of the company.
- Changes in regulatory guidelines for product approval may delay the business opportunity for Rubicon.
- Geopolitical conflicts involving major suppliers, including China, the US, or Europe, could disrupt supply chains and weigh on revenue growth.
- Lower-than-expected market share gains in commercialized products may affect the operating leverage of the company.

Ambernath site received EIR in Dec'24; Satara site received EIR in Mar'23; Pithampur site received EIR in Jan'22

Base case implies potential upside of 22%; Bull case implies potential upside of 54%; Bear case implies limited downside of 10%


Estimate changes

TP change
Rating change

Bloomberg	DABUR IN
Equity Shares (m)	1774
M.Cap.(INRb)/(USDb)	901.1 / 10.2
52-Week Range (INR)	577 / 420
1, 6, 12 Rel. Per (%)	-3/-2/-12
12M Avg Val (INR M)	1362

Financials & Valuations (INR b)

Y/E March	2026E	2027E	2028E
Sales	133.1	144.9	156.4
Sales Gr. (%)	5.9	8.9	7.9
EBITDA	25.0	27.7	30.3
EBITDA mrg. (%)	18.8	19.1	19.4
Adj. PAT	19.2	21.6	23.7
Adj. EPS (INR)	10.8	12.2	13.4
EPS Gr. (%)	6.7	12.4	9.7
BV/Sh.(INR)	65.4	67.2	68.7
Ratios			
RoE (%)	17.2	18.4	19.7
RoCE (%)	15.9	16.9	18.1
Payout (%)	87.6	90.2	93.4
Valuation			
P/E (x)	46.1	41.0	37.4
P/BV (x)	7.6	7.4	7.3
EV/EBITDA (x)	32.0	28.6	25.9
Div. Yield (%)	1.9	2.2	2.5

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	66.2	66.2	66.3
DII	17.4	16.2	13.7
FII	10.9	11.8	15.0
Others	5.5	5.7	5.0

FII Includes depository receipts

CMP: INR508 TP: INR525 (+3%) Downgrade to Neutral
Execution weakness persists; weak commentary for 2HFY26

- Dabur's 2QFY26 performance was largely in line with our estimates. Consolidated revenue grew ~5% YoY. India business revenue grew 6% YoY and domestic volume growth stood at 2%. The GST transition and prolonged monsoon weighed on performance during the quarter. The GST transition and trade pipeline adjustments impacted revenue growth by ~3-4%.
- Home & personal care revenue rose 9%, backed by strong performance in oral care, home care, and skin care. The healthcare portfolio remained muted, posting 1% growth. F&B clocked 2% YoY growth, while the food portfolio reported double-digit growth. Beverages were impacted by heavy rainfall. The international business grew 5.5% YoY in cc terms and 7.7% in INR terms.
- GM expanded 10bp YoY to 49.4% (est. 48.8%), and EBITDA margin rose 20bp YoY to 18.4% (est: 18.3%). EBITDA grew 6% despite a favorable base (-16% in 2QFY25). Management highlighted that there was ~8% inflation during the quarter, which was mitigated by price hikes of ~4% and cost-saving initiatives.
- The company has been witnessing muted sales growth over the past two years, primarily due to weak rural demand and unfavorable seasonal conditions. The performance has become more sluggish since 2QFY25 post channel destocking. Given the GST 2.0 benefits, shift of channel filling in 2HFY26, and expectations of better growth of its winter portfolio (favorable base too), we were expecting a much better 2HFY26 print. However, management commentary remained weak, with expectations of only mid- to high-single-digit revenue growth in 2HFY26, supported by mid-single-digit volume growth. Dabur's consistent weak execution is limiting our confidence in its growth recovery despite macros turning positive. Given the slower-than-expected turnaround, we lower our valuation multiple from 45x to 40x and **downgrade the stock from BUY to Neutral, with a revised TP of INR 525 (40x Sep'27E EPS)**.

In-line performance; 2% volume growth

- Mid-single digit revenue growth:** Dabur's 2QFY26 consolidated sales grew by 5.4% (inline) to INR31.9b (est. INR32.1b). Indian business revenue grew by 5.7% YoY. Indian business volume growth stood at 2%. (est. 6%).
- HPC business grew 9% YoY:** Oral Care grew in double digits YoY. The toothpaste business grew 14%, backed by Dabur Red and Meswak. Skin care grew in high single digits. Home care and hair care grew in mid-single digits.

- **Healthcare portfolio up 1% YoY:** Health supplements grew in mid-single digits, backed by Dabur honey's double-digit growth (high twenties). Digestives grew in low single digits. OTC & Ethicals decline in mid-single digit due to the discontinuation of the Diaper Baby Super pants and temporary disruption in trade due to the GST transition.
- **Foods and beverages grew 2%:** Foods portfolio grew in double digits. The 100% Fruit Juice portfolio under the Real Active brand grew by over 45%, while Real Juices' portfolio was impacted during the quarter on account of heavy rainfalls, floods, and landslides.
- International growth was at 5.5% in CC terms and 7.7% in INR terms.
- **Flat margins:** Gross margin expanded marginally 10bp YoY to 49.4% (est. 48.8%). Employee expenses rose 3%, ad spends increased 4%, and other expenses rose 8% YoY. EBITDA margin expanded 20bp YoY to 18.4% (est. 18.3%).
- In 1HFY26, net sales, EBITDA, and APAT grew 3%, 4% and 4%, respectively.

Highlights from the management commentary

- For the last six consecutive quarters, rural markets have outperformed urban markets.
- GST rate reductions across nearly 66% of the Indian portfolio are likely to boost consumption in the coming quarters by improving affordability and channel confidence. Currently, 86% of the company's portfolio falls under the 5% tax bracket.
- Key inflation drivers during the quarter included higher costs of packaging materials (PET, laminates) and certain agri-linked inputs like sugar and honey, leading to a weighted average inflation of ~8%.
- In international markets, key markets such as the UK, Turkey, Bangladesh, Nigeria, and Dubai witnessed healthy performance, while Nepal saw a temporary slowdown due to political disruptions.

Valuation and view

- We cut our EPS estimates by 2% for FY26 and 3% each for FY27 and FY28.
- The company has been witnessing muted sales growth over the past two years. After delivering only 1.3% growth in FY25, revenue growth improved modestly to 3% in 1HFY26, and management is guiding for mid- to high-single-digit growth in 2HFY26, supported by mid-single-digit volume growth.
- We remain positive on consumption recovery, supported by improving macros and GST reforms; however, Dabur's weak execution is limiting our confidence in the company's near-term revival.
- Given the slower-than-expected turnaround, we lower our valuation multiple from 45x to 40x and **downgrade the stock from BUY to Neutral, with a revised TP of INR 525 (40x Sep'27E EPS).**

Quarterly Performance (Consolidated)										(INR m)		
Y/E March	FY25				FY26				FY25	FY26E	FY26E	Var. (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
Domestic FMCG vol. growth (%)	5.2	-7.0	1.2	-5.0	-1.0	2.0	10.5	8.0	-1.4	4.9	6.0	
Net sales	33,491	30,286	33,553	28,301	34,046	31,913	36,342	30,788	1,25,631	1,33,089	32,067	-0.5%
YoY change (%)	7.0	-5.5	3.1	0.6	1.7	5.4	8.3	8.8	1.3	5.9	5.9	
Gross profit	16,005	14,943	16,124	13,211	16,013	15,778	17,735	14,623	60,282	64,149	15,649	0.8%
Margin (%)	47.8	49.3	48.1	46.7	47.0	49.4	48.8	47.5	48.0	48.2	48.8	
EBITDA	6,550	5,526	6,819	4,269	6,678	5,881	7,559	4,903	23,163	25,021	5,868	0.2%
Margins (%)	19.6	18.2	20.3	15.1	19.6	18.4	20.8	15.9	18.4	18.8	18.3	
YoY growth (%)	8.3	-16.4	2.1	-8.6	2.0	6.4	10.9	14.9	-3.5	8.0	6.2	
Depreciation	1,091	1,110	1,086	1,169	1,141	1,154	1,194	1,172	4,456	4,661	1,130	
Interest	327	474	442	393	346	397	375	357	1,635	1,475	375	
Other income	1,294	1,515	1,280	1,412	1,440	1,401	1,400	1,462	5,501	5,703	1,475	
PBT	6,427	5,457	6,571	4,119	6,630	5,731	7,390	4,836	22,573	24,588	5,839	-1.8%
Tax	1,481	1,284	1,418	992	1,543	1,282	1,810	1,387	5,175	6,023	1,430	
Rate (%)	23.0	23.5	21.6	24.1	23.3	22.4	24.5	28.7	22.9	24.5	24.5	
Adjusted PAT	5,084	4,333	5,306	3,284	5,222	4,608	5,742	3,650	18,006	19,222	4,570	0.8%
YoY change (%)	7.7	-17.2	1.6	-8.2	2.7	6.4	8.2	11.2	-4.0	6.7	5.5	

E: MOFSL Estimates

Estimate change	
TP change	
Rating change	

Bloomberg	ITC IN
Equity Shares (m)	12527
M.Cap.(INRb)/(USDb)	5246 / 59.1
52-Week Range (INR)	472 / 390
1, 6, 12 Rel. Per (%)	-1/-8/-16
12M Avg Val (INR M)	6945

Financials & Valuations (INR b)

Y/E March	2026E	2027E	2028E
Sales	826.8	889.2	958.8
Sales Gr. (%)	7.7	7.5	7.8
EBITDA	275.9	303.1	325.9
EBITDA Mrg. %	33.4	34.1	34.0
Adj. PAT	210.9	231.3	248.4
Adj. EPS (INR)	16.9	18.5	19.8
EPS Gr. (%)	5.5	9.6	7.4
BV/Sh.(INR)	58.0	60.1	62.1
Ratios			
RoE (%)	29.6	31.3	32.5
RoCE (%)	29.1	30.8	32.1
Payout (%)	94.0	93.9	95.0
Valuations			
P/E (x)	24.9	22.7	21.1
P/BV (x)	7.2	7.0	6.7
EV/EBITDA (x)	17.4	15.8	14.6
Div. Yield (%)	3.8	4.1	4.5

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	0.0	0.0	0.0
DII	47.4	46.9	44.6
FII	37.4	38.0	40.6
Others	15.2	15.1	14.8

FII Includes depository receipts

CMP: INR419
TP: INR515 (+23%)
Buy
Core business remains healthy; pressure points abate

- ITC continued to deliver a healthy performance in core segments despite a challenging consumption environment. Though margins remained under pressure YoY, sequential improvement was seen. Consol. gross cigarette sales grew 6% YoY (est. 7%), and volume growth was ~6% (vs. est. 6%). The premium cigarette segment continued to outperform. Cigarette EBIT grew by 4.2% YoY (est. 5% YoY). EBIT margin contracted 100bp YoY to 58% (est. 58%), impacted by the inflationary leaf tobacco prices.
- Consol. FMCG segment sales grew 8.5% YoY. Notebooks continued to weigh on business performance, and staple products have seen strong demand growth. Snacks and noodles have seen increased grammage in LUP, while biscuit LUPs have seen price cuts as a temporary measure. EBIT declined 17% YoY, and the EBIT margin contracted 70bp to 7.2% (in line).
- Agribusiness sales declined significantly by 31% YoY (est. 15%), hit by delayed call-offs by customers amid uncertainty due to the US tariffs. EBIT margin expanded by 360bp YoY to 11.2% (est. 7.5%).
- The paper business continued to struggle due to low-priced supplies into global markets (including India), subdued realizations, and elevated wood prices. But performance improved vs. 1QFY26. Revenue grew 5% YoY, while EBIT margin contracted 290bp YoY to 8.2% (est. 7.5%).
- ITC's core business growth has been steady, with healthy cigarette volume growth. Consistent focus on new launches, stable taxes, and a variety of other initiatives led to 7% cigarette growth in FY25, and the momentum continued in 1HFY26. Cigarette EBIT margin is likely to improve from 4QFY26. FMCG performance was below par in FY25, but with demand experiencing a recovery, we expect improving trends from 2HFY26. The paper business is also bottoming out for growth and margin. **We reiterate our BUY rating on ITC with our SoTP-based TP of INR515 (implying 27x Sep'27E P/E).**

Cigarette volume up ~6%; FMCG eyes strong growth

- Consolidated performance (ex-hotel business):** ITC's 2QFY26 net revenue declined 2% YoY at INR195b (est. INR216.8b); ex-agribusiness, the sales grew ~8% YoY. Gross margin improved 240bp YoY to 58.3% (est. 55%); the base was hurt by high food inflation and the rise of certain input costs (leaf, wood, etc.). EBITDA margin improved 170bp YoY to 34.3% (est. 31.8%). EBITDA dipped 1% YoY to INR66.9b (est. INR69b). PBT/APAT grew 1%/3%.
- Cigarette volume rises ~6%, with 4% EBIT growth:** Consol. gross cigarette sales grew 6% YoY to INR94.1b (est. INR95.4b). Standalone gross cigarette sales grew 6.7% YoY to INR87.2b. Cigarette volume is likely to have grown 6% (est. 6%). EBIT grew by 4.2% YoY to INR54.6b (est. INR55.3b). Cigarette EBIT margin contracted 100bp YoY to 58% (est. 58%). Consumption of high-cost leaf tobacco inventory weighed on margins. Procurement prices moderated in the current crop cycle.

- **FMCG – Others:** Consolidated FMCG-Others sales grew 8.5% YoY to INR60.6b (est. INR60b). Standalone FMCG-Others sales grew 6.9% YoY to INR59.6b, while ex-notebook growth was 8%. Growth was driven by categories such as staples, dairy, premium personal wash & agarbattis. The standalone EBITDA margin compressed 60bp YoY while improving 50bp QoQ to 10%. Consolidated EBIT declined 1% YoY to INR4.4b (est. INR4b) in 2QFY26. EBIT margin contracted 70bp to 7.2% (est. 6.9%).
- **Agribusiness** sales declined significantly by 31% YoY to INR40b (est. INR67.2b). EBIT grew by 2% YoY to INR4.5b. EBIT margin expanded by 360bp YoY to 11.2% (est. 7.5%).
- **The paperboards** business sales grew 5% YoY to INR22.2b (est. INR22b). EBIT was down 23% YoY to INR1.8b and EBIT margin dipped 290bp YoY to 8.2% (est. 7.5%).
- **FoodTech Business**, a key growth area in ITC Next's strategy, combines ITC's food science, FMCG brands, and culinary expertise to rapidly build a capital-efficient, tech-enabled full-stack platform with ~60 cloud kitchens in five cities currently. GMV crossed INR900m in 1HFY26 (FY25 GMV appx. INR1,050m).
- In 1HFY26, ITC's revenue/EBITDA/APAT grew 9%/3%/4%.

Valuation and view

- There are no material changes to our EPS estimates for FY26-28.
- ITC's core business of cigarettes saw steady performance. With stable taxes on cigarettes, we anticipate stable growth in this business. We model a 6% revenue CAGR in FY25-28E.
- We expect supportive macroeconomic factors to act as a catalyst for boosting consumption sentiment. In line with that, we expect FMCG performance to improve in the coming quarters. We model 9% revenue CAGR during FY25-28E.
- If ITC sustains mid-single-digit volume growth in the cigarette business and the FMCG business sees a recovery in 2HFY26, we expect a valuation re-rating. **We reiterate our BUY rating on ITC with our SoTP-based TP of INR515 (implying 27x Sep'27E P/E).**

Y/E March	Consol. Quarterly Performance (Reported)										(INR b)	
	FY25					FY26					FY25	Var.
	1Q	2Q	3Q*	4Q*	1Q*	2Q*	3QE	4QE	FY25	FY26E		
Est. cigarette vol. gr. (%)	3.0	3.5	6.0	5.0	6.0	6.0	6.0	6.0	4.4	6.0	6.0	-10.1%
Net Sales	184.6	207.4	187.9	187.7	214.9	195.0	208.2	208.7	767.5	826.8	216.9	
YoY change (%)	7.5	16.7	4.3	4.7	16.5	-6.0	10.8	11.2	8.3	7.7	4.6	
Gross Profit	111.7	115.9	108.3	110.3	112.6	113.6	119.1	115.2	446.2	460.5	119.3	
Margin (%)	60.5	55.9	57.6	58.8	52.4	58.3	57.2	55.2	58.1	55.7	55.0	
EBITDA	67.5	67.6	63.6	65.2	68.2	66.9	69.6	70.9	263.9	275.9	69.0	-3.0%
Growth (%)	1.2	4.8	-2.2	-1.6	1.0	-1.0	7.9	7.2	0.5	4.5	2.1	
Margins (%)	36.6	32.6	33.9	34.7	31.7	34.3	33.0	33.5	34.4	33.4	31.8	
Depreciation	5.0	5.2	4.2	4.1	4.2	4.3	4.5	4.6	18.5	17.7	4.4	
Interest	0.1	0.2	0.1	0.1	0.2	0.2	0.1	0.0	0.5	0.5	0.1	
Other Income	6.9	6.2	6.0	6.4	6.8	5.8	6.6	8.0	25.5	27.3	6.8	
PBT	69.3	68.4	65.3	67.4	70.6	68.2	71.5	74.3	270.4	284.9	71.2	-4.2%
Tax	17.6	17.9	17.3	16.8	17.8	17.9	17.8	18.2	69.6	71.7	18.0	
Rate (%)	25.4	26.2	26.4	24.9	25.3	26.3	25.2	24.8	25.7	25.2	25.2	
Adj PAT	50.9	49.9	47.3	50.7	52.4	50.6	53.2	54.7	198.9	210.9	52.7	-4.0%
YoY change (%)	-0.2	2.0	-11.4	-0.9	3.0	1.3	10.3	5.7	-2.8	6.0	5.6	
Reported PAT	50.9	49.9	47.3	50.7	52.4	51.3	52.9	54.3	199.9	210.9	52.7	-2.8%

E: MOSL estimate; *Excluding the hotel business data, therefore not comparable YoY

Estimate change	
TP change	
Rating change	

Bloomberg	NTPC IN
Equity Shares (m)	9697
M.Cap.(INRb)/(USDb)	3346.8 / 37.7
52-Week Range (INR)	417 / 293
1, 6, 12 Rel. Per (%)	-4/-9/-22
12M Avg Val (INR M)	4578

Financials & Valuations (INR b)

Y/E March	FY25	FY26E	FY27E
Sales	2,023	2,177	2,341
EBITDA	602	687	777
Adj. PAT	218	269	302
Adj. EPS (INR)	23	28	31
EPS Gr. (%)	8	23	12
BV/Sh.(INR)	198	216	237
Ratios			
Net D:E	1.3	1.2	1.1
RoE (%)	11.9	13.4	13.7
RoCE (%)	7.5	8.2	8.7
Payout (%)	41.9	34.8	33.0
Valuations			
P/E (x)	15.3	12.5	11.1
P/BV (x)	1.7	1.6	1.5
EV/EBITDA (x)	9.8	8.7	7.6
Div. Yield (%)	2.7	2.8	3.0
FCF Yield (%)	3.9	3.5	10.0

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	51.1	51.1	51.1
DII	29.1	29.0	26.6
FII	16.4	16.1	18.6
Others	3.4	3.8	3.7

FII Includes depository receipts

CMP: INR345

TP: INR372 (+8%)

Neutral

Weak power demand weighs on 2Q performance

Adjusted PAT in 2QFY26 was 4% above our estimate, mainly supported by higher-than-estimated other income. EBITDA missed our estimate as weak power demand led to soft generation trends. Management highlighted its vision to take group capacity to 244GW by 2037. Medium-term capacity addition targets were guided at 9.8/9.6/10.5 GW in FY26/27/28. We maintain a cautious view on execution, especially at NGEL. Further, we believe valuations for NGEL (15% of our SOTP) have little room for re-rating and may continue to face pressure. We reiterate our Neutral stance on NTPC with a TP of INR372.

Decline in power generation weighs on earnings performance

2QFY26 performance:

- NTPC reported standalone revenue of INR392b in 2QFY26, 13% below our estimate of INR453b (-3% YoY), owing to subdued demand.
- EBITDA came in 15% below our est. at INR100b (+4% YoY, -3% QoQ).
- Reported PAT of INR46.5b (flat YoY, -3% QoQ) beat our estimates by 7%, mainly on account of higher-than-expected other income. Adj. PAT came in at INR45b (+8% YoY, +2% QoQ).
- NTPC Green reported consolidated revenue of INR6.1b (up 22% YoY) and EBITDA of INR5.3b (up 26% YoY) in 2QFY26. APAT rose 131% YoY to INR0.9b.

Operational and other highlights:

- NTPC Group's total installed capacity now stands at 83.9GW (Standalone: 60.7GW).
- The company's gross power generation fell 6% YoY to 83Bus in 2Q.
- NTPC group added a capacity of 4,403MW in 1HFY26. Of this, 1,732MW was added on a standalone basis, 1,506MW through NGEL and its JVs and balance 1,165MW through other JVs and subsidiaries. An additional 956 MW was commissioned in Oct'25.
- Plant availability for coal plants stood at 84.4% in 2QFY26 (2QFY25: 84.93%).
- Coal plant PLF declined 627bp YoY to 66.01% in 2QFY26, primarily due to grid restrictions impacting generation.
- Hydro plant PLF improved to 104.6% (vs. 97.4% in 2QFY25), while gas plant PLF remained flat YoY at 6.8%.
- Average tariff was INR4.90/unit in 1HFY26 vs. INR4.67 in 1HFY25.
- Total electricity generation stood at 214BUs, down 6BUs YoY due to subdued demand.
- Pumped Storage Project: Commissioned first two units (250 MW each); two additional units expected within FY26.
- Coal Stock: Maintained 13.4 MMT (15 days' requirement) with 85% station availability.
- **Financial Highlights**
- Cost of borrowing fell to 6.11% from 6.63% last year through refinancing and loan restructuring.
- Receivables improved to 28 days from 33 days in 1HFY25.
- Capex: Group capex stood at INR232b (+32% YoY); standalone capex was INR141b (flat YoY), and NGEL incurred INR66b.

- Regulated equity: Standalone regulated equity at INR945b (+6% YoY); consolidated at INR1,160b (+10% YoY).
- **Corporate Developments**
- Executed business transfer agreements for hiving off the coal mining business to NTPC Mining (NML) at an estimated value of INR105b; Chatti and Badam mines already transferred, and the remaining mines expected to be transferred in FY26.
- **Dividend**
- Declared an interim dividend of INR2.75/share for FY26.

Valuation and view

Our TP of INR372 for NTPC is based on:

- Value of INR207 for the standalone, coal, and other businesses at Dec'27E P/B of 2x.
- Value of INR19 for other subsidiaries and INR59 for JV/associates at Dec'27E P/B of 2.0x.
- The stake in NGEL is valued at a 25% discount to the current market price.

Y/E March	Standalone performance										(INR b)				
	FY25					FY26E				FY25	FY26E	FY26E 2QE	Var. %	YoY %	QoQ %
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE							
Net Sales	444	403	414	439	426	392	451	520	1,700	1,788	453	-14%	-3%	-8%	
YoY Change (%)	13.5	-1.3	4.8	3.2	-4.2	-2.9	9.0	18.4	5.0	5.1	12				
EBITDA	124	97	120	113	103	100	130	156	454	489	118	-15%	4%	-3%	
Margin (%)	28.0	24.0	28.9	25.6	24.2	25.6	28.8	30.1	26.7	27.4	26				
Depreciation	37	36	37	40	39	40	39	38	151	156	39	3%	10%	3%	
Interest	26	31	22	31	28	27	30	31	111	116	28	-6%	-14%	-6%	
Other Income	6	9	10	19	8	15	8	4	44	35	8	91%	66%	100%	
PBT incl. Regulatory items	62	61	66	81	63	63	69	91	269	285	59				
Extra-Ord inc/(exp)	-	-	-	-	-	-	-	-	-	-	-				
PBT	62	61	66	81	63	63	69	91	269	285	59	6%	4%	1%	
Tax	17	14	19	23	15	16	17	26	73	74	16	5%	17%	11%	
Rate (%)	26.9	23.2	28.9	28.7	23.7	26.1	25.1	28.2	27.1	26.0	26.3				
Reported PAT	45	46	47	58	48	47	51	65	196	211	44	7%	0%	-3%	
Adj PAT	42	42	46	50	44	45	51	65	180	206	44	4%	8%	2%	
YoY Change (%)	13.9	28.9	6.0	0.4	5.2	7.5	11.3	31.0	-16.2	14.5	4				
Margin (%)	9.4	10.4	11.2	11.4	10.4	11.5	11.4	12.6	10.6	11.5	10				

NTPC: SoTP valuation

Segment	Regulated Equity (Dec-27E)	P/B	Value/Sh. (INR)
Standalone + Coal + Others	10,04,554	2.0	207
Other subsidiaries	92,799	2.0	19
JV & Associates	2,85,635	2.0	59
NGEL Stake*			61
Cash and equivalents			26
Target price			372
CMP			345
Upside/(Downside)			8%

*At 25% Discount

Source: MOFSL

Hyundai Motor

Estimate change	↓
TP change	↓
Rating change	↔

Bloomberg	HYUNDAI IN
Equity Shares (m)	813
M.Cap.(INRb)/(USDb)	1961.2 / 22.1
52-Week Range (INR)	2890 / 1542
1, 6, 12 Rel. Per (%)	-12/35/25
12M Avg Val (INR M)	2170

Financials & valuations (INR b)

Y/E MARCH	2026E	2027E	2028E
Sales	715	831	974
EBITDA	95	113	134
Adj. PAT	60	71	86
EPS (INR)	74	88	106
EPS Gr. (%)	6	19	21
BV/Sh. (INR)	254	319	397
Ratios			
RoE (%)	32.4	30.6	29.5
RoCE (%)	29.2	27.4	26.3
RoIC (%)	26.3	22.5	20.6
Valuations			
P/E (x)	32.8	27.6	22.8
P/BV (x)	9.5	7.6	6.1
EV/EBITDA (x)	20.1	17.0	14.3
Div. Yield (%)	0.8	1.0	1.1

Shareholding pattern (%)

As On	Sep-25	Jun-25
Promoter	82.5	82.5
DII	7.7	7.8
FII	7.4	7.1
Others	2.4	2.7

FII Includes depository receipts

CMP: INR2,414 **TP: INR2,801 (+16%)** **Buy**

Improved mix drives earnings beat

New product launches and exports to drive healthy growth

- Hyundai India's (HMIL) 2Q earnings at INR15.7b came in ahead of our estimate of INR14.8b, aided by better-than-expected margins. EBITDA margins at 13.9% were ahead of our estimate of 13.5% owing to improved product and export mix.
- HMI targets to launch 26 products by FY30, of which eight would be launched over FY26-27E. Considering its launch pipeline, we now factor in a 6% volume CAGR over FY25-28E, which is largely back-ended. This is likely to be boosted by 20% volume CAGR in exports. We also believe that higher-than-expected operating costs for the new Pune plant will impact earnings for the near to medium term. Overall, HMIL is expected to deliver 15% earnings CAGR over FY25-28E. We believe HMIL is well positioned to benefit from the premiumization trend in India, given its mix in favor of SUVs. Reiterate **BUY** with a TP of INR2,801, valued at 29x Sep'27E EPS.

Earnings ahead of estimates led by better-than-expected margins

- 2Q earnings at INR15.7b beat our estimate of INR14.8b, supported by better-than-expected margins.
- Revenue improved marginally YoY to INR175b (in line) despite a marginal decline in volumes. While domestic sales declined ~7% YoY to 140k units, exports grew strongly by ~22% to 51.4k units. Avg ASP was up 1.7% YoY due to an improved mix.
- Gross margins improved 240bp YoY (+60bp QoQ) to 29.9%, above our estimate, led by an improved mix (SUV mix at 71% of domestic volumes, exports up at 27% from 22% YoY). The benefit of an improved mix was partially offset by higher-than-expected other expenses.
- Led by improved gross margins, EBITDA margin expanded 110bp YoY (+60bp QoQ) to 13.9%, ahead of our estimate of 13.5%.
- EBITDA grew 10% YoY and was ahead of our estimate by 4%.
- While other income was higher than our estimate, depreciation came in below estimate, which in turn boosted PAT.
- PAT grew 14.3% YoY to INR15.7b (vs. est. of INR14.8b).
- For 1HFY26, CFO came in at ~INR23b and capex at ~INR26b. Consequently, it reported FCF loss of INR3b.
- In 1HFY26, revenue fell 2.1% to INR346b, whereas EBITDA/PAT grew 1.5%/2.7% YoY to INR45b/INR29b. In 2HFY26, we expect revenue/EBITDA/PAT to grow 9%/11.5%/10% YoY to INR377b/INR49b/INR30.4b.

Highlights from the management commentary

- From Navratri to Diwali, retail sales grew 23% for HMIL. Hatchback sales grew 16%, sedans grew 47% and SUVs grew 21%. Within SUVs, Venue and Exter outperformed with 28% growth. However, Venue growth was limited due to its upcoming new variant launch scheduled for 4th Nov.

- HMIL expects to grow in line with the industry in the domestic market in 2H, aided by the launch of new Venue and future product interventions.
- Exports are likely to exceed its initial growth guidance of 7-8% in FY26.
- The Pune plant commenced operations in Oct. Costs (employee expense, overheads and depreciation) are likely to rise by ~20% in the near term until the plant ramps up and operating leverage benefits kick-in. While this will impact profitability in the near term, operating efficiency and cost control measures are expected to offset this impact partially.

Valuation and view

- Considering its launch pipeline, we now factor in a 6% volume CAGR over FY25-28E, which is largely back-ended. This is likely to be boosted by 20% volume CAGR in exports. We now believe that higher-than-anticipated operating costs for the new Pune plant would impact earnings in the near and medium term. Overall, HMIL is expected to deliver 15% earnings CAGR over FY25-28E. We believe HMIL remains well-positioned to benefit from the premiumization trend in India, given its mix in favor of SUVs. **Reiterate BUY with a TP of INR2,801, valued at 29x Sep'27E EPS.**

Cons Quarterly Performance (INR b)										
Y/E March	FY25					FY26E			FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Financial Performance										
Volumes ('000 units)	192.1	191.9	186.4	191.6	180.4	190.9	202.3	207.3	762.1	780.9
Change (%)	4.7	-8.5	-2.4	-1.1	-6.1	-0.5	8.5	8.2		2.5
ASP (INR '000/car)	903.1	899.3	893.1	936.1	909.8	914.6	915.4	923.9	908.0	916.2
Change (%)	-0.4	1.1	1.1	2.6	0.7	1.7	2.5	-1.3		0.9
Net operating revenues	173.4	172.6	166.5	179.4	164.1	174.6	185.1	191.5	692	715
Change (%)	4.3	-7.5	-1.3	1.5	-5.4	1.2	11.2	6.8		3.4
RM Cost (% of sales)	71.9	72.5	73.1	71.2	70.7	70.1	70.1	70.1	72.2	70.2
Staff Cost (% of sales)	3.2	3.2	3.6	3.4	3.8	3.5	3.9	3.7	3.3	3.7
Other Cost (% of sales)	11.5	11.5	12.0	11.3	12.2	12.4	13.2	12.9	11.5	12.7
EBITDA	23.4	22.1	18.8	25.3	21.9	24.3	23.8	25.4	89.5	95.3
EBITDA Margins (%)	13.5	12.8	11.3	14.1	13.3	13.9	12.8	13.3	12.9	13.3
Depreciation	5.3	5.2	5.3	5.3	5.3	5.2	6.1	6.7	21.1	23.3
EBIT	18.1	16.9	13.5	20.0	16.6	19.1	17.7	18.7	68.5	72.0
EBIT Margins (%)	10.4	9.8	8.1	11.2	10.1	10.9	9.5	9.7	9.9	10.1
Interest	0.3	0.3	0.3	0.4	0.2	0.2	0.3	0.3	1.3	0.9
Non-Operating Income	2.2	1.9	2.4	2.1	2.1	2.3	2.5	2.7	8.7	9.6
PBT	20.0	18.5	15.6	21.8	18.5	21.3	19.9	21.1	75.9	80.7
Effective Tax Rate (%)	25.6	25.6	25.7	25.8	25.9	26.0	25.9	25.8	25.7	25.9
Adjusted PAT	14.9	13.8	11.6	16.1	13.7	15.7	14.7	15.6	762.1	59.8
Change (%)	12.1	-15.5	-18.6	-3.7	-8.1	14.3	27.1	-3.1		6.0

Estimate change	
TP change	
Rating change	

Bloomberg	CIPLA IN
Equity Shares (m)	808
M.Cap.(INRb)/(USDb)	1244 / 14
52-Week Range (INR)	1673 / 1307
1, 6, 12 Rel. Per (%)	-3/-7/2
12M Avg Val (INR M)	2638

Financials & Valuations (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Sales	289.1	310.9	343.9
EBITDA	68.9	71.5	80.5
Adj. PAT	49.5	49.9	55.5
EBIT Margin (%)	19.8	18.8	19.1
Cons. Adj. EPS (INR)	61.3	61.8	68.7
EPS Gr. (%)	-2.3	0.9	11.1
BV/Sh. (INR)	443.7	499.6	562.3
Ratios			
Net D:E	-0.1	-0.2	-0.2
RoE (%)	13.8	12.4	12.2
RoCE (%)	14.9	13.3	13.0
Payout (%)	9.8	9.7	8.7
Valuations			
P/E (x)	25.1	24.9	22.4
EV/EBITDA (x)	17.2	16.3	14.0
Div. Yield (%)	0.3	0.3	0.3
FCF Yield (%)	3.2	2.2	3.7
EV/Sales (x)	4.1	3.7	3.3

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	29.1	29.1	30.9
DII	30.2	29.2	24.1
FII	24.8	25.4	29.0
Others	15.9	16.3	16.1

FII Includes depository receipts

CMP: INR1,540 **TP: INR1,500 (-3%)** **Neutral**
Pace of earnings growth on a downtrend
Efforts underway to navigate the g-Revlimid cliff

- Cipla's 2QFY26 financial performance was slightly better than our expectations. This was fueled by higher-than-expected sales from the North America (NA) segment and higher other income. Cipla stepped up R&D expenses to INR5.4b in this quarter vs INR3.9b/INR4.4b YoY/QoQ.
- Cipla showed better traction in certain products in NA, offsetting the impact of reduced business from g-Revlimid and driving higher sales QoQ to USD233m.
- The company's comprehensive approach in India, with a focus on Prescription (Rx) and trade generics as well as consumer health, was partly offset by weakness in acute therapy sales for the quarter. Agreement with Eli Lilly to distribute/promote Terzepatide would provide further growth prospects in the Rx segment.
- Cipla had weak 4% YoY growth in CC terms in the African private market segment. Even the tender segment, as well as OTC, had modest YoY growth for the quarter. Having said this, the secondary sales in the Rx segment outperformed the industry in 2QFY26.
- We cut our earnings estimates for FY26/FY27/FY28 by 1%/6%/6%, factoring in 1) higher R&D expenses over the near-to-medium term, 2) a limited scope of NA business growth in FY27 due to a higher base of g-Revlimid in FY26, and 3) the moderation in acute therapy growth in the Domestic Formulation (DF) segment.
- We value Cipla at 24x 12M forward earnings to arrive at our TP of INR1,500. Considering a modest 3% earnings CAGR over FY25-28 and current valuation adequately factoring this upside, **we reiterate our Neutral rating on Cipla.**

Operating deleverage drags profitability on a YoY basis

- Cipla's 2QFY26 revenue increased 7.6% YoY to INR75.9b.
- DF sales (41% of sales) grew 6.7% YoY to INR31.4b. SAGA sales (16% of sales) grew 10% YoY (6% in CC terms) to INR11.8b.
- EM sales (13% of sales) grew 20% YoY to INR9.7b. API sales (2% of sales) declined 7.5% YoY to INR1.5b.
- The US sales (27% of sales) dipped 2.7% YoY to INR20.3b (USD233m, down 1.7% in CC terms). We estimate g-Revlimid sales to be USD40-45m for 2Q.
- Gross margin contracted 50bp YoY to 67% (our est: 66.7%).
- EBITDA margin dipped 180bp YoY to 25%, due to higher R&D expense (up 160bp as a % of sales). **Assuming a 65-70% EBITDA margin for g-Revlimid, we estimate ex-gRevlimid EBITDA to be INR16.2b (22.5%) for 2QFY26.**
- EBITDA was stable YoY to INR18.9bn (above our est. INR18.3bn).
- PAT grew 3.7% YoY to INR13.5b (our est: INR13.1b).
- R&D spending for the quarter is INR5.3b (7.1% of sales).
- The net cash available as of Sep'25 was INR99b.

Key highlights from the management commentary

- Cipla revised its EBITDA margin guidance from 23.5-24.5% earlier to 22.75-24.0%. This is due to higher R&D spending towards potential opportunities.
- Cipla's current MD-Global CEO, Umang Vora, has expressed his intention not to seek reappointment as the MD & Global CEO upon completion of his current term on 31st Mar'26.
- Mr. Achin Gupta, Global Chief Operating Officer, has been elevated and appointed as the MD & Global Chief Executive Officer of the Company with effect from 1st Apr'26 for a term of five years up to 31st Mar'31.
- G-Revlmid sales have been lower in 2Q vs. 1QFY26 and are expected to trend further lower in the coming quarters.
- Despite lower sales of g-Revlmid, the overall NA sales grew QoQ, driven by market share gain in albuterol, lanreotide, and other potential products.
- Given the deal with Eli Lilly to distribute and promote Terzapotide in India, Cipla would evaluate the Semaglutide opportunity post regulatory approval for the Indian market.

Y/E March	Quarterly Performance (Consolidated)								(INR b)			
	FY25				FY26				FY25	FY26	Est.	% Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		2QE		
Net Revenues	66.9	70.5	70.7	67.3	69.6	75.9	73.4	70.3	275.5	289.1	73.3	3.5
YoY Change (%)	5.8	5.6	7.1	9.2	3.9	7.6	3.8	4.4	6.9	5.0	4.0	
Total Expenditure	49.8	51.7	50.8	51.9	51.8	56.9	57.4	54.1	204.2	220.2	55.1	
EBITDA	17.2	18.9	19.9	15.4	17.8	18.9	16.0	16.2	71.3	68.9	18.3	3.8
YoY Change (%)	14.9	8.8	13.8	16.9	3.6	0.5	-19.5	5.1	13.3	-3.4	-3.2	
Margins (%)	25.6	26.7	28.1	22.8	25.6	25.0	21.8	23.0	25.9	23.8	24.9	
Depreciation	2.5	2.7	2.8	3.1	2.5	3.0	3.1	3.0	11.1	11.6	3.2	
EBIT	14.7	16.1	17.1	12.3	15.3	16.0	12.9	13.2	60.2	57.3	15.1	
YoY Change (%)	17.1	8.5	12.9	19.6	3.8	-1.0	-24.7	7.1	14.0	-4.9	-6.5	
Margins (%)	21.9	22.9	24.2	18.3	21.9	21.1	17.5	18.7	21.9	19.8	20.6	
Interest	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.6	0.5	0.1	
Other Income	1.6	1.9	1.5	2.9	2.6	2.7	2.3	2.4	7.9	10.0	2.3	
Profit before Tax	16.1	17.9	18.5	15.0	17.7	18.5	15.1	15.5	67.5	66.7	17.2	
One-time (expense)/income	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	
PBT after EO expense	16.1	17.9	19.2	15.0	17.7	18.5	15.1	15.5	68.2	66.7	17.2	7.6
Tax	4.4	4.8	3.3	2.8	4.8	5.0	3.8	3.9	15.3	17.5	4.1	
Rate (%)	27.0	27.0	18.0	18.6	27.0	27.0	25.0	25.5	22.7	26.2	24.0	
Minority Interest	0.0	0.0	0.1	0.0	-0.1	0.0	-0.1	-0.1	0.2	-0.2	0.0	
Reported PAT	11.8	13.0	15.7	12.2	13.0	13.5	11.4	11.7	52.7	49.5	13.1	3.2
Adj PAT	11.8	13.0	13.6	12.2	13.0	13.5	11.4	11.7	50.7	49.5	13.1	3.2
YoY Change (%)	18.3	10.9	14.0	40.6	10.2	3.7	-16.8	-4.6	19.6	-2.3	0.6	

E: MOFSL Estimates;

Estimate change	↑
TP change	↑
Rating change	↔

Bloomberg	CBK IN
Equity Shares (m)	9071
M.Cap.(INRb)/(USDb)	1205.4 / 13.6
52-Week Range (INR)	134 / 79
1, 6, 12 Rel. Per (%)	2/30/22
12M Avg Val (INR M)	2786

Financials & Valuations (INR b)

Y/E March	FY25	FY26E	FY27E
NII	370.7	383.6	443.8
OP	313.9	362.7	373.5
NP	170.3	194.1	207.6
NIM (%)	2.4	2.2	2.4
EPS (INR)	18.8	21.4	22.9
EPS Gr. (%)	17.0	14.0	6.9
BV/Sh. (INR)	106	120	133
ABV/Sh. (INR)	99	113	126
RoA (%)	1.1	1.1	1.1
RoE (%)	19.9	19.5	18.6

Valuations

P/E (x)	7.1	6.2	5.8
P/BV (x)	1.3	1.1	1.0
P/ABV (x)	1.3	1.2	1.1

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	62.9	62.9	62.9
DII	12.2	11.4	11.7
FII	11.9	11.4	11.3
Others	12.9	14.3	14.2

CMP: INR133

TP: INR153 (+15%)

Buy

Steady quarter; other income drives earnings beat

NIMs decline 5bp QoQ

- CBK reported 2QFY26 standalone PAT of INR47.7b (12% beat), up 19% YoY/flat QoQ, aided by a healthy beat in other income.
- NII declined by 2% YoY to INR91.4b (up 1.5% QoQ, in line). NIMs declined by a modest 5bp QoQ to 2.50%.
- Loan book grew 15% YoY/5% QoQ to INR11.3t, while deposits grew 13.4% YoY/4% QoQ to INR15.3t. CASA deposits grew 11% YoY/8% QoQ. As a result, CASA ratio improved 113bp QoQ to 30.7%.
- Slippages moderated to INR20.31b (INR21.29b in 1QFY26). Accordingly, GNPA/NNPA ratios improved by 34bp/9bp QoQ to 2.35%/0.54%. PCR stood at 77.4%.
- We increase our earnings estimates by ~3%, factoring in better other income. **We estimate CBK to deliver FY27E RoA/RoE of 1.08%/18.6%.** Reiterate **BUY** with a revised TP of INR153 (based on 1.1x FY27E ABV+ INR11 for subs).

Business growth steady; asset quality improves

- 2Q PAT rose 19% YoY to INR47.7b (12% beat), led by healthy fee income. NII declined by 2% YoY to INR91.4b (up 1.5% QoQ, in line). NIMs declined by a modest 5bp QoQ to 2.50%.
- Other income was up 42% YoY/flat QoQ at INR70.5b (14% beat). Treasury income stood at INR12.2b vs. INR16.2b in 1QFY26. Total revenue thus grew 13% YoY (7% beat).
- Operating expenses grew 14% YoY/1.2% QoQ to INR76.1b (broadly in line). Thus, C/I ratio stood at 47%. PPoP increased 12% YoY to INR 85.9b (11% beat). Provisions stood at INR23.5b (+4.6% YoY, 16% higher than est.).
- Loan book grew by a healthy 15% YoY/5.3% QoQ, led by robust growth in retail segment at 29% YoY/6.7% QoQ. Within retail, housing grew 15% YoY/5% QoQ. Deposits grew 13.4% YoY/4% QoQ, led by growth in CASA deposits at 11% YoY/8% QoQ. As a result, CASA ratio improved 113bp QoQ to 30.7%. CD ratio rose to 74%.
- Slippages moderated to INR20.31b (INR21.29b in 1QFY26). Accordingly, GNPA/NNPA ratios improved by 34bp/9bp QoQ to 2.35%/0.54%. PCR stood at 77.4%.
- Reported credit cost stood at 0.68% vs. the bank's guidance of 0.9% for FY26. SMA book moderated to 0.65% in 2QFY26 from 0.8% in 1QFY26.

Highlights from the management commentary

- The stake sale of Canara Robeco and Canara HSBC Life resulted in a gain of INR20b for CBK (INR19.35b after expenses), which will be recorded in P&L in 3Q.
- Margins will remain stable at ~2.5% for one more quarter and will improve afterwards if there are no further cuts.

- ~INR3.8b has been provided for in standard provisioning related to one account in SMA-1 (state government drinking water project) and another account, which is out of SMA book.
- 2Q slippages: Agriculture at INR7.5b, Retail at INR3.5b, and MSME at INR9b.

Valuation and view

CBK reported a healthy quarter, with the earnings beat driven by healthy fee income, in-line NII, and contained opex. Margins are expected to remain stable in 3QFY26 and improve thereafter. Loan growth was steady and driven by robust growth in the retail segment. Deposit growth was healthy, aided by growth in CASA deposits. Asset quality improved as slippages declined, leading to a controlled credit cost for the bank. CBK maintains healthy provisions for the SMA book. It will record the stake sale gain of INR19.35b in P&L in 3Q, which will boost other income. We increase our earnings estimates by ~3% for FY27. **We estimate CBK to deliver FY27E RoA/RoE of 1.08%/18.6%. Reiterate BUY with a revised TP of INR153 (based on 1.1x FY27E ABV+ INR11 for subs).**

Quarterly Performance

									(INR b)			
	FY25				FY26E				FY25	FY26E	FY26E	V/s our
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
Net Interest Income	91.7	93.2	91.5	94.4	90.1	91.4	96.6	105.6	370.7	383.6	89.7	2
% Change (Y-o-Y)	5.8	4.6	-2.9	-1.4	-1.7	-1.9	5.6	11.8	1.4	3.5	-3.7	
Other Income	53.2	49.8	58.0	63.5	70.6	70.5	80.6	70.2	224.5	291.9	62.0	14
Total Income	144.9	143.0	149.5	157.9	160.7	162.0	177.2	175.7	595.2	675.5	151.7	7
Operating Expenses	68.7	66.4	71.1	75.1	75.2	76.1	78.8	82.8	281.3	312.8	74.2	2
Operating Profit	76.2	76.5	78.4	82.8	85.5	85.9	98.3	93.0	313.9	362.7	77.5	11
% Change (Y-o-Y)	0.2	0.5	15.2	12.1	12.3	12.2	25.5	12.2	6.7	15.5	1.2	
Other Provisions	22.8	22.5	24.0	18.3	23.5	23.5	35.5	21.9	87.6	104.5	20.3	16
Profit before Tax	53.3	54.0	54.4	64.5	62.0	62.3	62.8	71.0	226.3	258.2	57.1	9
Tax	14.3	13.9	13.3	14.5	14.5	14.6	16.0	18.9	56.0	64.0	14.6	0
Net Profit	39.1	40.1	41.0	50.0	47.5	47.7	46.8	52.1	170.3	194.1	42.6	12
% Change (Y-o-Y)	10.5	11.3	12.3	33.1	21.7	18.9	13.9	4.2	17.0	14.0	6.0	
Operating Parameters												
Deposit (INR b)	13,352	13,473	13,695	14,569	14,677	15,279	15,520	15,909	14,569	15,909	15,133	
Loan (INR b)	9,464	9,840	10,237	10,492	10,736	11,301	11,369	11,782	10,492	11,782	10,953	
Deposit Growth (%)	12.0	9.3	8.4	11.0	9.9	13.4	13.3	9.2	11.0	9.2	12.3	
Loan Growth (%)	10.7	10.3	11.2	12.6	13.4	14.8	11.1	12.3	12.6	12.3	11.3	
Asset Quality												
Gross NPA (%)	4.1	3.7	3.3	2.9	2.7	2.5	2.3	2.2	2.9	2.2	2.6	
Net NPA (%)	1.2	1.0	0.9	0.7	0.6	0.6	0.5	0.5	0.7	0.5	0.6	
PCR (%)	71.0	74.1	74.1	76.7	77.1	77.4	77.8	78.4	76.6	78.4	77.0	

E: MOFSL Estimates

Union Bank of India

Estimate change	
TP change	
Rating change	

Bloomberg	UNBK IN
Equity Shares (m)	7634
M.Cap.(INRb)/(USDb)	1115.4 / 12.6
52-Week Range (INR)	159 / 101
1, 6, 12 Rel. Per (%)	2/7/20
12M Avg Val (INR M)	1628

Financials & Valuation (INR b)

Y/E March	FY25	FY26E	FY27E
NII	372.1	364.8	412.5
OP	310.9	278.7	313.9
NP	179.9	166.7	183.3
NIM (%)	2.7	2.5	2.6
EPS (INR)	23.6	21.8	24.0
EPS Gr. (%)	24.9	-7.3	9.9
BV/Sh. (INR)	144	160	180
ABV/Sh. (INR)	136	153	171
RoA (%)	1.2	1.1	1.1
RoE (%)	18.1	14.7	14.4

Valuations

P/E(X)	6.0	6.5	5.9
P/BV (X)	1.0	0.9	0.8
P/ABV (X)	1.0	0.9	0.8

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	74.8	74.8	74.8
DII	11.7	11.9	11.2
FII	7.9	7.7	6.9
Others	5.7	5.6	7.1

CMP: INR146
TP: INR155 (+6%)
Neutral

NII in line; business growth remains tepid

Margin contracts 9bp QoQ

- Union Bank of India (UNBK) reported 2QFY26 PAT of INR42.5b (down 10% YoY/ up 3% QoQ, 20% beat), backed by better other income (amid interest on tax refund), lower provisions, and lower tax rate.
- NII declined 2.6% YoY and 3.3% QoQ to INR88.1b (largely in line with MOFSLe). NIMs stood at 2.67% (down 9bp QoQ, vs our est of 2.67%).
- Loan book grew 5.7% YoY/0.2% QoQ to INR9.48t, while deposits grew 1.9% YoY/ declined 0.4% QoQ. CD ratio increased to 76.8% (up 51bp QoQ).
- Fresh slippages declined 8% QoQ to INR21.5b from INR23.5b in 1QFY26. GNPA/NNPA ratio improved 23bp/7bp QoQ to 3.29%/0.55%. PCR increased to 83.8%.
- **We increase our earnings estimate slightly by 3%/2.5% for FY26/FY27E earnings and estimate FY27E RoA/RoE at 1.1%/14.4%. We expect loans to post a 9% CAGR over FY25-27E. We reiterate our neutral rating on the stock with a revised TP of INR155 (0.9x FY27E ABV).**

Asset quality improves; IT refund drives earnings beat

- UNBK reported 2QFY26 PAT of INR42.5b (3.2% QoQ, 20% beat). NII declined 2.6% YoY/ 3.3% QoQ; NIMs contracted 9bp QoQ to 2.67%.
- Other income increased 11% QoQ (down 6% YoY) to INR49.9b (9% higher than MOFSLe), amid HIGHER fee income and interest refund on income tax.
- Opex grew 12% YoY/4.6% QoQ to INR69.9b (in line). C/I ratio increased 146bp QoQ to 50.7%. PPoP declined 16% YoY/1.4% QoQ to INR68b (5% beat on MOFSLe).
- Business growth was sub-par yet again, with advances standing flat QoQ (up 5.7% YoY) at INR9.48t. Of this, retail grew faster at 24% YoY/4% QoQ and MSME grew 4.7% YoY/2% QoQ, while large corporate and agri segments continued to decline 1.3% QoQ and 1.9% QoQ, respectively.
- Deposits grew 1.9% YoY/declined 0.4% QoQ to INR12.3t, led by a reduction in CA as well as bulk deposits. CASA grew 1.4% YoY/declined 0.3% QoQ. As a result, CASA ratio stood stable at 32.6%, while CD ratio increased to 76.8% (up 51bp QoQ).
- Deposits grew 1.3% YoY and declined 5.3% QoQ to INR12.4t, led by a reduction in CASA and bulk deposits. CASA ratio decreased 100bp QoQ to 32.5%, while CD ratio increased 350bp QoQ to 76.3%.
- Fresh slippages declined 8.3% QoQ to INR21.5b, while healthy recoveries and upgrades led to an improvement in the GNPA/NNPA ratio by 23bp QoQ/7bp QoQ to 3.29%/0.55%. PCR ratio increased to 83.8%.

Highlights from the management commentary

- The bank aims to achieve growth above the system level going forward and has already identified and addressed the root causes behind the slower deposit growth.
- The sequential contraction in NIMs has been narrowing, with stabilization expected from 3Q onwards and an improving trend likely from 4Q.
- PSLC sales are expected to resume by 4QFY26 or early FY27, at a similar quantum as in FY25.

Valuation and view

UNBK reported an earnings beat, led by healthy other income, lower tax rate, and lower provisions. However, business growth remained tepid, with muted QoQ trends in both advances and deposits, while CASA growth stood flat. NIMs were broadly in line with our expectations, as management has recently prioritized margins over growth, leading to a reduction in bulk deposits during 1HFY26. With business growth being sub-par for the past two quarters, the bank aims to revive momentum. Asset quality ratios continue to improve, led by controlled slippages and in-line provisions. **We increase our earnings estimate slightly by 3%/ 2.5% for FY26/FY27E earnings and estimate FY27E RoA/RoE at 1.1%/14.4%. We expect loans to post a 9% CAGR over FY25-27E. We reiterate our Neutral rating on the stock with a revised TP of INR155 (0.9x FY27E ABV).**

Quarterly Performance

								(INR b)		
	FY25				FY26E			FY25	FY26E	FY26E V/S our
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	2Q	Est
Net Interest Income	94.1	90.5	92.4	95.1	91.1	88.1	90.8	94.7	372.1	364.8
% Change (YoY)	6.5	-0.9	0.8	0.8	-3.2	-2.6	-1.7	-0.4	1.8	-2.0
Other Income	45.1	53.3	44.2	55.6	44.9	50.0	46.6	52.8	198.1	194.2
Total Income	139.2	143.8	136.6	150.7	136.0	138.1	137.4	147.5	570.3	559.0
Operating Expenses	61.4	62.6	61.7	73.7	66.9	69.9	68.4	75.1	259.4	280.3
Operating Profit	77.9	81.1	74.9	77.0	69.1	68.1	69.0	72.4	310.9	278.7
% Change (YoY)	8.4	12.4	2.9	17.9	-11.3	-16.0	-7.9	-6.0	10.2	-10.4
Provisions	27.6	17.1	16.0	15.4	16.6	14.0	16.1	15.3	76.1	62.1
Profit before Tax	50.3	64.0	58.9	61.6	52.4	54.2	52.9	57.1	234.8	216.6
Tax	13.5	16.8	12.9	11.7	11.3	11.7	13.2	13.6	54.9	49.8
Net Profit	36.8	47.2	46.0	49.8	41.2	42.5	39.7	43.4	179.9	166.7
% Change (YoY)	13.7	34.4	28.2	50.6	11.9	-10.0	-13.9	-12.9	31.8	-7.3
Operating Parameters										
Deposit (INR b)	11,965	12,116	12,166	12,722	12,399	12,346	13,583	13,844	13,097	13,844
Loan (INR b)	8,787	8,971	9,202	9,535	9,461	9,483	10,012	10,269	9,535	10,269
Deposit Growth (%)	6.1	6.5	3.8	4.2	3.6	1.9	11.6	8.8	7.2	5.7
Loan Growth (%)	14.0	11.6	6.7	9.5	7.7	5.7	8.8	7.7	9.5	7.7
Asset Quality										
Gross NPA (%)	4.5	4.4	3.9	3.6	3.5	3.3	3.0	3.0	3.6	3.0
Net NPA (%)	0.9	1.0	0.8	0.6	0.6	0.6	0.5	0.5	0.6	0.5
PCR (%)	80.9	78.4	79.3	83.1	82.9	83.8	83.5	83.2	82.6	83.2
										82.5

Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	SWIGGY IN
Equity Shares (m)	2494
M.Cap.(INRb)/(USDb)	1044.7 / 11.8
52-Week Range (INR)	617 / 297
1, 6, 12 Rel. Per (%)	-5/24/-
12M Avg Val (INR M)	6784

Financials & Valuations (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
GOV	345.7	419.6	498.9
Net Sales	229.9	321.0	432.3
Change (%)	51.0	39.7	34.6
EBITDA	-31.9	-13.2	19.4
EBITDA margin (%)	-13.9	-4.1	4.5
Adj. PAT	-39.4	-20.0	8.7
PAT margin (%)	-17.1	-6.2	2.0
RoE (%)	-45.54	-30.89	13.60
RoCE (%)	-41.96	-30.99	5.51
EPS	-17.22	-8.75	3.80
EV/ Sales	4.0	2.9	2.1
Price/ Book	13.5	16.3	13.8

Shareholding Pattern (%)

As On	Sep-25	Jun-25
Promoter	0.0	0.0
DII	16.0	13.5
FII	19.1	15.1
Others	64.9	71.4

FII includes depository receipts

CMP: INR419
TP: INR550 (+31%)
Buy

Preparing for battle, again

Capex moderation aids margins, but competitive risks loom ahead

- Swiggy delivered a revenue of INR55.6b in 2QFY26 (up 12.1% QoQ) vs. our estimate of INR54.6b. The food delivery (FD) business's GOV grew 18.7% YoY, whereas the contribution margin (CM) remained stable at 7.3%. FD's adj. EBITDA as a % of GOV margin improved 40bp QoQ to 2.8% vs. our est. of 2.7%.
- Instamart's GOV was INR70.2b (up 107% YoY) vs. our estimate of INR 69.7b. The contribution margin expanded 200bp QoQ to -2.6%. Adjusted EBITDA as a % of GOV was -12.1% (-15.8% in 1Q), above our estimate of -13.8%.
- Overall, Swiggy posted a net loss of INR11b, marking an increase of 75% YoY.
- For 1HFY26, revenue/adj. EBITDA loss grew 54%/118% YoY. For 2HFY26, we expect revenue to grow **48%**, while the adjusted EBITDA loss is expected to **decline 15% YoY**. The combination of steady FD growth, rising Instamart AOV, and easing fixed-cost drag enhances the visibility of positive unit economics. We value the FD business at 30x FY27E adjusted EBITDA and QC using DCF. **We reiterate our BUY rating on Swiggy with a TP of INR550, implying a potential upside of 31%.**

Our view: Competition to pick up, but decent operating leverage as new dark stores ramp up

- **Cash burn reduces in Qcommerce, breakeven expected by 1QFY27:** Both CM and adj. EBITDA for the quick commerce business improved QoQ (CM improved 200bp, and adj. EBITDA margin expanded 370bp). This, coupled with lower capex, reduced the absolute cash burn in Instamart by 50% QoQ.
- **Competitive intensity high, again:** Contrary to last quarter, when most players alluded to reducing competitive intensity, both Eternal and Swiggy now expect heightened competition going forward. We believe this period will be similar to the one we saw last year (2HFY25) in terms of marketing/branding costs. However, one key difference is that the dark store investment pace for most players (especially Swiggy) will be far lower than last year, which saw heightened capex as well as opex (in partner stores). Hence, there is still room for margins to expand. We expect Instamart to reach contribution breakeven by 1QFY27 (in line with company guidance).
- **FD growth in line, but QoQ growth indicates some market share loss:** Swiggy's GOV grew by 5.6% QoQ, a tad slower than Eternal, indicating some market share loss. The company has managed to increase marketing expenses in response to Eternal as both players fight in a slowing FD market. Adj. EBITDA margin, however, improved sequentially, and we expect linear improvement (5% of GOV in the next three years).
- **INR100b QIP fundraise to shore up defenses:** Swiggy plans to raise INR100bn. Its current cash balance is INR46b, and its current burn rate, albeit reducing, gives it a runway of 6-7 quarters, in our opinion. It also expects to net INR25b from its Rapido stake sale. Thus, the fundraise is to shore up its defenses in an intense Qcommerce battle amongst the top 3 players as well as new entrants.

Valuation and view

- We believe Swiggy is entering a phase of profitability, supported by operating discipline and improving network efficiency. The combination of steady FD growth, rising Instamart AOV, and easing fixed-cost drag enhances the visibility of positive unit economics.
- Steady improvements in AOV, dark store throughput, and take rates could lead to a material re-rating in profitability, prompting a more constructive stance on the stock.
- We value the FD business at 30x FY27E adjusted EBITDA and QC using DCF. We have brought forward our profitability assumptions for Instamart. **We reiterate our BUY rating with a TP of INR550, implying a potential upside of 31%.**

In-line FD GOV growth and beat on Instamart's adj. EBITDA margin

- Swiggy reported a 2QFY26 net revenue of INR55.6b (+12.1% /54.4% QoQ /YoY) vs. our estimate of INR 54b.
- FD GOV was INR85.4b (up 5.6%/18.7% QoQ/YoY) vs. our estimate of INR86.5b.
- Instamart GOV came in at INR70.2b (up 107% YoY) vs. our estimate of INR 69.7b. Dark store rollouts with 40 new active Dark stores in 2Q. Half of the dark stores were megapods.
- For food delivery, adjusted EBITDA as a % of GOV margin was up 40bp QoQ at 2.8% vs. our estimate of 2.7%.
- Instamart's adjusted EBITDA as a % of GOV was -12.1% (-15.8% in 1Q) vs. our estimate of -13.8%.
- Consol. Adj. EBITDA came in at negative INR6.9b.
- Instamart reported a contribution margin of -2.6% (-4.6% in 1Q) vs. our estimate of -3.3%. This was aided by higher advertising, optimization of customer incentives, increased capacity utilization, and operating leverage.
- Swiggy reported a net loss of INR11b (est. INR11.2b), an increase of 75% YoY.
- Swiggy to consider a fundraise of INR100b through the QIP route.

Key highlights from the management commentary

- **FD:** General softness in discretionary consumption was offset by benign food and fuel inflation and supportive income-tax cuts, which aided spending.
- 10-minute delivery through Swiggy Bolt is now live across 700+ cities, contributing over 10% of total orders.
- The quarter witnessed heightened competitive intensity with lower subscription fees and reduced minimum order values. Swiggy responded by further subsidizing Swiggy One deliveries, balanced by a higher platform fee.
- Growth remains the overarching priority, even as the company continues to progress toward a steady-state margin of 5% of GOV.
- The resilient GOV performance was driven by a growing MTU base, enabled by better execution—particularly in Tier-2 cities—and improved consumer propositions, which also helped expand GOV per MTU.
- 'Bolt' now contributes over 10-12% of total orders. It has a minimal impact on AOV and is not dilutive at the platform level. Its economics are close to the platform average, despite no incremental monetization.
- **Instamart:** Its GOV stood at INR70.2b, up 107% YoY and ~15% QoQ. The company added 40 new dark stores during the quarter, half of which were megapods. It aims to meet or exceed industry growth.

- Sufficient capacity has been built in the dark-store network, capable of handling up to 2x the current business levels.
- AOV rose ~40% YoY to INR 697, led by expansion in non-grocery categories and higher-value basket behavior. Management sees further headroom for AOV expansion as penetration in non-grocery remains low.
- Non-grocery categories contributed 26.2% of GOV (vs. 8.7% YoY), driven by Electronics, Small Appliances, Home & Kitchen, and Toys — each doubling in share over the past two quarters. Pharmacy adoption has also grown faster than other segments.
- Swiggy would consider a fundraise of INR100b through the QIP route. This fundraise aims to bolster growth capital and strategic reserves.
- The company acknowledged that an eventual shift to a partial inventory-led model is possible. Domestic investor shareholding now stands at 43%.

Valuation and view

- We believe Swiggy is entering a phase of profitability, supported by operating discipline and improving network efficiency. The combination of steady FD growth, rising Instamart AOV, and easing fixed-cost drag enhances the visibility of positive unit economics.
- Steady improvements in AOV, dark store throughput, and take rates could lead to a material re-rating in profitability, prompting a more constructive stance on the stock.
- We value the FD business at 30x FY27E adjusted EBITDA and QC using DCF. We have brought forward our profitability assumptions for Instamart. **We reiterate our BUY rating with a TP of INR550, implying a potential upside of 31%.**

Y/E march	Consolidated - Quarterly Earnings Model								(INR m)			
	FY25				FY26E							
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	FY25	FY26	Estimate	Var.
Revenue (net of delivery)	32,222	36,015	39,931	44,100	49,620	55,610	60,337	64,268	1,52,268	2,29,855	54,639	1.8
YoY Change (%)	34.8	30.3	31.0	44.8	54.0	54.4	51.1	45.7	35.4	51.0	51.7	270bp
Inventory of traded goods	11,954	13,874	15,650	18,538	20,640	23,420	26,281	28,248	60,015	98,589	23,207	0.9
Employee Expenses	5,892	6,073	6,568	6,956	6,860	6,900	7,016	7,518	25,489	28,294	6,832	1.0
Delivery expenses	10,460	10,949	11,269	11,614	13,130	14,260	18,262	18,954	44,292	64,606	17,292	-17.5
Gross Profit	3,916	5,119	6,444	6,992	8,990	11,030	8,779	9,548	22,472	38,347	7,309	50.9
Margins (%)	12.2	14.2	16.1	15.9	18.1	19.8	14.5	14.9	14.8	16.7	13	650bp
Advertisement and sales promotion	4,454	5,371	7,515	9,777	10,360	10,390	9,768	9,103	27,117	39,621	9,808	5.9
Others	4,905	5,290	6,185	6,833	8,160	8,620	6,519	7,317	23,213	30,616	7,947	8.5
EBITDA	-5,442	-5,542	-7,257	-9,618	-9,530	-7,980	-7,508	-6,872	-27,858	-31,890	-10,445	NA
Margins (%)	-16.9	-15.4	-18.2	-21.8	-19.2	-14.3	-12.4	-10.7	-18.3	-13.9	-19.1	480bp
Depreciation	1,217	1,309	1,540	2,057	2,880	3,040	2,112	2,249	6,123	10,281	1,912	59.0
Interest	198	231	256	322	410	480	200	200	1,006	1,290	200	140.0
Other Income	879	848	1,028	1,207	870	590	1,300	1,300	3,962	4,060	1,300	-54.6
PBT before EO expense	-5,978	-6,233	-8,024	-10,790	-11,950	-10,910	-8,520	-8,022	-31,025	-39,401	-11,258	NA
Tax	0	0	0	0	0	0	0	0	0	0	0	NA
Rate (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	NA	NA	0.0	0bp
Adj PAT	-5,978	-6,233	-8,024	-10,790	-11,950	-10,910	-8,520	-8,022	-31,025	-39,401	-11,258	NA
Extra-Ord expense	-132	-21	35	0	0	0	0	0	-118	0	0	
Minority Interest & P/L of Asso. Cos.	1	1	1	22	10	10	0	0	26	20	0	
Reported PAT	-6,111	-6,255	-7,991	-10,812	-11,960	-10,920	-8,520	-8,022	-31,169	-39,421	-11,258	-3.0
YoY Change (%)	NA	NA	NA	NA	NA	NA	NA	NA	33%	26%	NA	NA
Margins (%)	-19.0	-17.4	-20.0	-24.5	-24.1	-19.6	-14.1	-12.5	-20.5	-17.2	-20.6	NA



Aditya Birla Capital

Bloomberg	ABCAP IN
Equity Shares (m)	2612
M.Cap.(INRb)/(USDb)	853.8 / 9.6
52-Week Range (INR)	329 / 149
1, 6, 12 Rel. Per (%)	7/60/45
12M Avg Val (INR M)	1251

Financials & Valuations (INR b)

Y/E March	FY25	FY26E	FY27E
PBT Break-up			
NBFC	33.6	41.2	52.9
Housing	4.2	7.6	11.5
AMC	12.5	13.6	15.4
Life Insurance	1.6	1.8	2.0
Health Insurance	0.1	0.8	1.5
Other businesses	1.4	2.0	1.7
Consolidation adjustments	1.5	1.6	1.7
Consol PBT	54.8	68.5	86.8
Consol PAT Post MI and others	33.3	39.4	50.5
Growth (%)	-0.1	18.3	28.2
RoE (%)	11.6	12.3	14.2
Con PE	25.6	21.5	16.8
Cons. PBV	2.8	2.5	2.3

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	68.7	68.8	68.9
DII	12.8	12.1	8.5
FII	6.8	7.2	11.1
Others	11.7	12.0	11.6

FII Includes depository receipts

CMP: INR327

TP: INR380 (+16%)

Buy

Operating performance strengthens in both NBFC and HFC

Lending (HFC+NBFC) book grew ~29% YoY; asset quality improves

- Aditya Birla Capital's (ABCAP) 2QFY26 consolidated revenue grew 4% YoY to ~INR124.8b, and consolidated PAT (excl. one-off items in 2QFY25) grew ~3% YoY to ~INR8.55b.
- Overall lending book (NBFC and Housing) grew 29% YoY/7% QoQ to ~INR1.78t. Total AUM (AMC, Life insurance, and Health insurance) grew ~10% YoY to INR5.5t. Mutual fund quarterly average AUM grew 11% YoY to INR4.25t.
- Life insurance individual first year premium (FYP) grew ~19% YoY to INR18.8b in 1HFY26, and health insurance GWP grew ~31% YoY to INR28.4b in 1HFY26.

NBFC: AUM up ~22% YoY; NIM expands ~10bp QoQ

- NBFC Loan book grew ~22% YoY and 6% QoQ to ~INR1.4t. Disbursements grew ~14% YoY to ~INR220b. NIM rose ~10bp QoQ to 6.1%.
- The company reported a sequential improvement in asset quality, with GS2 + GS3 assets declining ~70bp QoQ to ~3%. Reduction in Stage 3 assets was also driven by an ARC sale of INR7.4b, of which ~INR5b consisted of unsecured business loans, while the balance was secured MSME loans.
- Management highlighted that asset quality remains robust, with consistent improvement across product segments. Bounce rates and forward flows are well contained. The company guided for FY26 credit costs in the range of 1.2-1.3%.
- The credit environment across the unsecured loans and Personal & Consumer (P&C) segment has stabilized, enabling the company to cautiously reaccelerate growth. Disbursements in the P&C segment grew 26% QoQ, supported by improved branch productivity and healthy traction in direct digital sourcing. With improving product mix from higher proportion of P&C loans, management guided for a gradual improvement in yields and NIMs in the subsequent quarters.
- PBT grew ~13% YoY and ~3% QoQ to INR9.6b. 2QFY26 RoA stood at ~2.2%

HFC: Robust growth in HFC AUM; asset quality improves

- HFC loan book grew 65% YoY to ~INR383b, and disbursements in 2QFY26 grew 44% YoY to ~INR58b.
- NIM declined ~15bp QoQ to ~4.02%. PBT grew ~87% YoY and 26% QoQ to INR1.9b RoA/RoE stood at ~1.8%/14%. Asset quality improved, with GS2+ GS3 declining ~25bp QoQ to ~1.1%. PCR rose ~5.2pp QoQ to ~57.6%.
- Management expects to sustain the current business momentum in HFC and has guided for a significant improvement in RoA to ~2-2.2% over the next 6-8 quarters. This improvement is expected to be driven by better operating leverage, partially offset by a decline in NIMs, while credit costs are expected to remain broadly stable.

Asset Management: QAAUM rose ~11% YoY

- Quarterly average MF AUM (QAAUM) rose 11% YoY to INR4.25t. Monthly average individual AUM grew 2% YoY to INR2.07t as of Sep'25.
- The equity mix stood at ~45.3% (PQ: ~44.6%). Equity QAAUM grew ~7% YoY to INR1.92t. Operating profit grew by 13% YoY to INR2.7b.

Life Insurance: Individual FYP grew ~19% YoY; 13M persistency at 86%

- Individual FYP grew 19% YoY to ~INR18.8b, while renewal premium grew 18% YoY in 1HFY26.
- Net VNB margin stood at ~11.6% in 2QFY26. 13M persistency stood at ~86% in Sep'25. Value of new business (VNB) grew 74% YoY to INR2.4b.
- Management has guided for a ~20-22% CAGR in individual FYP over the next three years, with a continued focus on expanding the VNB margin to >18%.

Health Insurance: GWP grew 31% YoY; market share stood at 13.6%

- GWP in the health insurance segment grew 31% YoY to ~INR28.4b in 1HFY26. The combined ratio stood at 112%.
- ABHI's market share among standalone health insurers stood at 13.6% in 2QFY26.

Highlights from the management commentary

- The company infused equity capital of INR2.5b into the housing subsidiary in 2Q, which takes the total infusion to INR5b for FY26.
- Management indicated that the sale of stage 3 assets was primarily undertaken to address cash flow mismatches under government guarantee schemes; however, the company intends to continue leveraging the CGTSME scheme going forward.
- The ABCD platform continued to receive a robust response, while Udyog Plus scaled well, contributing 32% of unsecured loan disbursements.

Valuation and view

- ABCAP's operational metrics continued to improve during the quarter. Loan growth remained healthy in both HFC and NBFC segments, accompanied by a further improvement in asset quality. NIMs have started improving in the NBFC business and management expects further improvement in NIM, aided by an increase in the share of unsecured loans.
- We expect a consolidated PAT CAGR of ~25% over FY25-28. The thrust on cross-selling, investments in digital, and leveraging 'One ABC' should drive healthy profitability, resulting in RoE of ~16% by FY28E. **Reiterate BUY with an SoTP (Sep'27E)-based TP of INR380.**

ABC: SOTP - Sep 2027

	Stake	Value (INR B)	Value (USD B)	INR per share	% To Total	Rationale
NBFC	100	518	6.1	200	52	1.8x PBV
HFC	100	128	1.5	49	13	1.7x PBV
AMC	45	156	1.8	60	16	28x Earnings
LI	51	139	1.6	54	14	1.3x EV
Health Ins	46	40	0.5	15	4	1.0x GWP
Others		5	0.1	2	1	
Target Value		987	11.6	380	100	

Quarterly Performance							(INR M)	
Y/E March	FY25			FY26E		FY25	FY26E	
	1Q	2Q	3Q	4Q	1Q	2Q		
ABFSL - NBFC arm								
Net Income	17,089	17,114	17,339	17,854	18,585	19,942	69,396	70,892
Opex	5,080	5,310	5,410	5,560	5,340	6,590	21,360	21,620
Cost to Income Ratio (%)	29.7	31.0	31.2	31.1	28.7	33.0	30.8	30.5
Operating Profits	12,009	11,804	11,929	12,294	13,245	13,352	48,036	49,272
Provisions	3,680	3,360	3,880	3,520	3,990	3,790	14,440	14,750
Profit Before Tax	8,329	8,444	8,049	8,774	9,255	9,562	33,596	34,522
Change YoY (%)	20.6	14.7	5.0	10.6	11.1	13.2	12.5	2.8
Consolidated Earnings								
Cons PBT Before JV Interest	12,437	16,057	11,840	14,413	16,826	-43,079	54,746	59,135
Growth YoY %	23.1	51.3	9.8	5.0	35.3	-368.3	18.7	8.0
Lending	9,177	9,482	9,147	9,985	10,796	11,502	37,791	39,410
NBFC	8,329	8,444	8,049	8,774	9,255	9,562	33,600	41,176
HFC	848	1,038	1,098	1,211	1,541	1,940	4,194	7,636
AMC	3,045	3,351	2,999	3,050	3,723	3,156	12,450	13,576
Life Insurance	215	443	432	495	386	669	1,580	1,817
Health Insurance	-540	-653	-835	2,089	-372	-676	60	800
Others*	540	3,434	97	-1,206	2,293	-57,730	2,865	3,532
Taxes	2,930	3,560	3,040	4,750	3,280	3,290	14,280	14,630
Tax rate %	23.6	22.2	25.7	33.0	19.5	-7.6	26.1	24.7
Profit After Tax	7,650	8,540	7,150	8,860	8,500	8,820	32,200	33,050
MI and Others	200	200	160	210	160	270	770	730
PAT post MI and other adjustments	7,450	8,340	6,990	8,650	8,340	8,550	31,430	32,320
Growth YoY %	15	18	-5	7	12	3	8	3
Gain on Sale of stake in Subs/associate (net of tax)	140	1,660	90	0	0	0	1,890	-20
Reported PAT	7,590	10,000	7,080	8,650	8,340	8,550	33,320	32,300
Growth YoY %	16.9	41.8	-3.7	6.5	9.9	-14.5	-0.1	-3.1
Details on lending business								
Loans (INR B)	1277	1379	1462	1574	1658	1779		
Change YoY (%)	27.2	26.6	26.9	26.9	29.9	28.9		
NBFC	1073	1147	1194	1264	1312	1396		
Change YoY (%)	24.9	22.7	21.1	19.6	22.3	21.7		
HFC	204	232	267	311	346	383		
Change YoY (%)	40.6	50.5	61.5	68.6	69.6	64.7		
Net Interest Margins								
NBFC	6.56	6.29	5.99	6.07	5.97	6.06		
HFC	4.24	4.22	4.06	4.07	4.16	4.02		
GNPA %								
NBFC	2.51	2.50	2.27	2.30	2.20	1.68		
HFC	1.60	1.30	0.99	0.66	0.62	0.61		
Details on Other business								
AMC Business								
QAAUM (INR B)	3,676	4,004	4,009	4,056	4,433	4,608		
Change YoY (%)	19.2	23.8	23.5	17.3	20.6	15.1		
Life Ins - 13th Mt persistency	88.0	88.0	87.0	88.0	87.0	86.0		

* Others includes Health Ins, PE, AB Money and inter group adjustment; Numbers may vary from actual reporting due to difference in reporting

Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	SAIL IN
Equity Shares (m)	4130
M.Cap.(INRb)/(USDb)	566 / 6.4
52-Week Range (INR)	143 / 99
1, 6, 12 Rel. Per (%)	-3/14/12
12M Avg Val (INR M)	2124
Free float (%)	35.0

Financials & Valuations (INR b)

Y/E MARCH	2026E	2027E	2028E
Sales	1,083	1,193	1,282
EBITDA	112	141	151
APAT	35	54	59
EBITDA Margin (%)	10	12	12
Cons. Adj. EPS (INR)	8	13	14
EPS Gr. (%)	158	57	8
BV/Sh. (INR)	149	160	171
Ratios			
Net D:E	0.5	0.5	0.5
RoE (%)	5.7	8.5	8.6
RoCE (%)	6.0	8.4	8.7
Payout (%)	15.0	20.0	20.0
Valuations			
P/E (x)	16.4	10.4	9.7
P/BV (x)	0.9	0.9	0.8
EV/EBITDA(x)	7.6	6.2	5.9
Div. Yield (%)	0.9	1.9	2.1
FCF Yield (%)	16.0	-0.2	2.1

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	65.0	65.0	65.0
DII	18.1	17.3	16.0
FII	3.8	3.7	2.8
Others	13.2	14.0	16.2

FII Includes depository receipts

CMP: INR137
TP: INR150 (+9%)
Neutral
Beat on estimates driven by better-than-expected volume and NSR; outlook strong

- SAIL reported revenue of INR267b (+16% YoY and +4% QoQ) in 2QFY26 against our estimate of INR244b. The beat was driven by healthy volume growth and a lower-than-expected decline in NSR.
- During the quarter, crude steel production stood at 4.9mt (+6% YoY and +3% QoQ), while sales volume was also 4.9mt (+20% YoY and +8% QoQ vs our est. 4.6mt). Strong offtake during 2QFY26 led to an inventory reduction to 1.9mt (vs opening stock of 2.7mt).
- ASP stood at INR54,387/t (-3% YoY and -4% QoQ) vs. our est. of INR52,590/t in 2QFY26. The decline in steel prices during 2Q was largely offset by higher sales of scrap (incl. defects) and by-product inventories (contributed INR11.4b in 2QFY26 vs INR8.69b in 1QFY26), leading to a better-than-expected NSR.
- EBITDA stood at INR25.3b (+98% YoY and -3% QoQ) against our est. of INR16.5b. EBITDA/t stood at INR5,149/t (vs. our est. of INR3,553/t), rising 66% YoY but declining 10% QoQ, driven by a decent NSR and lower operating cost. Adj. PAT came in at INR6.7b (vs. our est. INR1b), up 18% QoQ, compared to a net loss of INR3.8b in 2QFY25.
- In 1HFY26, sales volume stood at 9.5mt (+17% YoY) and revenue at INR525b (+12% YoY). EBITDA stood at INR51b (+47% YoY; INR5,416/t), driven by strong revenue and muted cost during 1HFY26. Adj. PAT stood at INR12.4b in 1HFY26, compared to the net loss of INR548m in 1HFY25.

Highlights from the management commentary

- Steel prices are expected to recover from late Nov'25 onwards, driven by a seasonal pickup in domestic demand, infra spending, and restocking activity.
- The company expects coking coal costs to rise USD6-8/t in 3QFY26.
- It has guided for 2HFY26 margins to expand over higher volumes, improved realizations, and lower input costs.
- The company has maintained its full-year capex guidance of over INR75b for FY26. For FY27, it has guided for higher capex of INR100b, mainly directed toward major expansion projects.
- The deleveraging measure will be supported by inventory liquidation, higher by-product monetization, and disciplined capex execution.

Valuation and view

- Despite muted NSR over weak seasonal prices, SAIL reported a strong 2QFY26 earnings, driven by healthy volumes and muted costs. The earnings outperformance during the quarter was primarily attributed to better-than-expected NSR.

- The company expects improved operational performance in 2HFY26, supported by higher volumes, efficiency gains, inventory liquidation, and stable raw material costs. We have increased our FY26 Revenue/EBITDA and APAT estimates by 3%/18% and 13% to incorporate the 2Q performance beat, while we largely maintain our FY27 estimates.
- SAIL plans to increase its capacity to 35mtpa. It is currently in the initial tendering phase, with any notable development likely to be visible only after FY27. Considering the limited room for production, we estimate a modest volume CAGR of 6% over FY26-28E. Therefore, any incremental earnings will be driven by healthy pricing and lower costs. **We reiterate our Neutral rating on the stock with a TP of INR150 (premised on 6.5x EV/EBITDA on Sep'27 estimate).**

Quarterly performance (INR b)

Y/E March	FY25				FY26				FY25	FY26	FY26	Vs Est
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Sales (m tons)	4.0	4.1	4.4	5.3	4.6	4.9	4.9	5.1	17.9	19.4	4.6	6.0
Change (YoY %)	3.4	(14.6)	16.6	16.9	13.5	19.8	9.5	(4.1)	4.9	8.7		
Realization (INR per ton)	59,845	56,191	55,282	55,002	56,590	54,387	55,387	56,666	56,431	55,753	52,590	3.4
Change (YoY %)	(4.7)	(3.5)	(10.0)	(4.4)	(5.4)	(3.2)	0.2	3.0	(5.6)	(1.2)		
Net Sales	240.0	230.4	244.9	293.2	257.5	267.0	268.7	289.5	1,008.4	1,082.7	243.6	9.6
Change (YoY %)	(1.5)	(17.6)	4.9	11.7	7.3	15.9	9.7	(1.2)	(1.1)	7.4		
Change (QoQ %)	(8.6)	(4.0)	6.3	19.7	(12.2)	3.7	0.6	7.7				
Total Expenditure	217.8	217.6	224.6	258.3	231.5	241.8	240.4	256.6	918.3	970.3		
EBITDA	22.2	12.8	20.3	34.8	26.0	25.3	28.3	32.9	90.1	112.4	16.5	53.6
Change (YoY %)	34.6	(40.0)	(5.3)	97.0	16.9	98.2	39.4	(5.5)	17.2	24.8		
Change (QoQ %)	25.5	(42.5)	59.1	71.6	(25.5)	(2.6)	11.9	16.4				
EBITDA per ton (INR)	5,536	3,111	4,582	6,536	5,704	5,149	5,831	6,444	5,042	5,790	3,553	44.9
Interest	6.9	7.6	6.8	6.6	5.9	4.8	5.5	5.8	27.9	22.2		
Depreciation	14.0	13.0	14.2	15.2	14.4	14.5	14.9	15.6	56.5	59.4		
Other Income	1.8	1.7	2.3	3.0	1.6	2.1	2.4	2.6	8.8	8.8		
Share of Asso/JVs	1.1	1.6	1.3	0.9	0.7	1.0	1.8	2.5	4.9	6.0		
PBT (before EO Inc.)	4.1	(4.6)	2.9	16.9	7.9	8.9	12.1	16.6	19.3	45.6		
EO Income(exp)	(3.1)	16.4	0.3	(0.3)	1.7	(3.4)	-	-	13.2	(1.6)		
PBT (after EO Inc.)	1.0	11.7	3.2	16.6	9.7	5.6	12.1	16.6	32.5	43.9		
Total Tax	0.2	2.8	1.8	4.1	2.2	1.4	3.0	4.4	8.8	11.0		
% Tax	16.6	23.5	56.1	24.5	23.1	24.7	25.0	26.2	27.1	25.0		
Reported PAT	0.8	9.0	1.4	12.5	7.4	4.2	9.1	12.2	23.7	32.9		
Adjusted PAT	3.2	(3.8)	1.1	12.8	5.7	6.7	9.1	12.2	13.4	34.6	1.0	NA
Change (YoY %)	52.9	(219.3)	(69.1)	609.1	75.7	(277.1)	698.7	(4.3)	24.3	158.3		
Change (QoQ %)	80.0	(216.9)	(129.9)	1,029.5	(55.4)	17.8	34.6	35.3				

Source: MOFSL, Company

Nippon Life India AMC

Estimate change	↔
TP change	↑
Rating change	↔

Bloomberg	NAM IN
Equity Shares (m)	637
M.Cap.(INRb)/(USDb)	546.2 / 6.2
52-Week Range (INR)	987 / 456
1, 6, 12 Rel. Per (%)	-7/31/21
12M Avg Val (INR M)	738

Financials & Valuations (INR b)

Y/E Mar	FY26E	FY27E	FY28E
AAUM	6,595	7,906	9,485
MF Yield (bp)	39.0	37.5	36.0
Rev from Ops	26.1	30.0	34.6
Core PAT	12.5	14.7	17.2
PAT	15.0	17.6	20.2
PAT (bp as AAUM)	23	22	21
Core EPS	19.8	23.4	27.3
EPS	23.9	27.9	32.0
EPS Grw. (%)	17	17	14
BVPS	68	69	71
RoE (%)	35	41	46
Div. Payout (%)	95	95	95

Valuations

Mcap/AUM (%)	8.3	6.9	5.8
P/E (x)	36.5	31.2	27.2
P/BV (x)	12.8	12.5	12.3
Div. Yield (%)	2.6	3.0	3.5

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	72.1	72.3	72.5
DII	13.0	13.5	13.5
FII	7.6	7.6	7.7
Others	7.3	6.7	6.3

FII Includes depository receipts

CMP: INR858

TP: INR1,060 (+24%)

Buy

Revenue in line, beat on EBITDA

- Nippon Life India AMC's (NAM) operating revenue grew 15%/9% YoY/QoQ to INR6.6b (in line) in 2QFY26. Yields came in at 40.1bp vs. 41.6bp in 2QFY25 and 39.6bp in 1QFY26. For 1HFY26, revenue grew 18% to INR12.6b.
- Total opex grew 16% YoY to INR2.3b (in line) in 2QFY26. As a result, EBITDA rose 15% YoY to INR4.3b (5% beat) for the quarter. This led to an EBITDA margin of 65.3% vs. 65.5% in 2QFY25.
- NAM's PAT stood at INR3.4b in 2QFY26 (in-line), down 4%/13% YoY/QoQ. PAT margin stood at 52.3% in 2QFY26 vs 63% in 2QFY25 and 65.2% in 1QFY26. For 1HFY26, PAT grew 7% to INR7.4b.
- Overall yields are expected to decline ~1-2bp annually, primarily due to the telescopic pricing effect. During the quarter, NAM revised commissions for one additional scheme, taking the total number to four, now accounting for nearly 60% of overall equity AUM.
- **We broadly retain our earnings estimates, with higher expected yields offsetting the increase in expenses. We reiterate our BUY rating on the stock with a TP of INR1,060, based on 35x Sep'27E EPS.**

Market share across categories continues to expand

- Overall MF QAAUM grew 20% YoY/7% QoQ to INR6.6t. The Equity /ETF/ Index/Debt funds grew 17%/24%/34%/38% YoY in 2QFY26.
- NAM's market share for QAAUM rose 22bp YoY to ~8.5%, with equity market share rising 17bp YoY to ~7.1%. ETF market share continues to surge, rising 160bp YoY to 19.8%, with NAM maintaining a dominant position in this space at 50% of overall industry folios.
- The share of Equity/ETF/Debt/Liquid in the overall QAAUM stood at ~47.7%/27.9%/9.7%/11.4% in 2QFY26 vs. 49.2%/27.0%/8.4%/12.4% in 2QFY25.
- SIP flows were robust during the quarter at INR107.2b compared to INR90.3b in 2QFY25, reflecting a monthly SIP inflow of INR35.7b (+19% YoY). The SIP book grew to INR1.6t (+11% YoY).
- Operating expenses rose 16% YoY to INR2.3b, with opex as a % of AUM at 13.9% vs 14.3% in 2QFY25 and 14.3% in 1QFY26. Employee costs rose 15% YoY to INR1.2b. ESOP costs for the quarter stood at INR90m, of which INR60m pertained to the new scheme. ESOP costs are estimated at ~INR420m-430m/INR260m for FY26/FY27.
- Other expenses grew 21% YoY/11% QoQ to INR855m. The sequential rise was on account of branding expenses, technology investments, and maintenance costs related to new office establishments.
- Other income came in at INR366m (down 70%/75% YoY/QoQ).
- Under the distribution mix, the retail share improved to 54% in 2QFY26 (vs. 50% in 1QFY26), led by a strong retail investor base. Management expects these levels to be sustained, while the corporate/HNI share was 35%/11%.
- On the product front, NAM launched three new ETF products: Nippon India Nifty One Day Rate Liquidity ETF, Nippon India Nifty India Manufacturing ETF, and Nippon India Nifty India Manufacturing Index Fund.

- NAM's market share in the industry ETF folio stood at ~50%, while its ETF trading volume share on NSE and BSE was 49%.
- Cumulative AIF commitments reached INR 87.2b as of Sep'25, reflecting a 30% YoY increase; during 2QFY26, NAM raised INR 6.2b across various asset classes. The upcoming product pipeline includes the Nippon India Credit Opportunity AIF Scheme and the Performing Credit Fund.
- On the offshore front, AUM declined to INR161b from INR172b in 2QFY25 and INR166b in 1QFY26 due to geopolitical uncertainties and mark-to-market (MTM) impacts.
- On the GIFT CITY side, NAM operates two feeder funds — Nippon India Large Cap Fund GIFT and Nippon India Nifty 50 Bees GIFT Fund — with combined AUM doubling QoQ to USD31b. The upcoming pipeline includes the Nippon India SHARP Equity Fund and Nippon India Digital Innovation Fund 2B.
- Digital transactions increased 15% YoY in 1HFY26 to 7.8m, contributing 75% of new purchases; notably, 43 new digital purchases/SIPs were initiated every minute during 1HFY26.

Key takeaways from the management commentary

- With respect to the SIF initiative, the team is already in place, and fund launches are in progress. Management highlighted strong inherent demand from the HNI segment and remains highly optimistic about this product category.
- On the offshore front, AUM trended lower due to geopolitical uncertainties and mark-to-market (MTM) impacts. However, management expects a gradual uptick going forward.
- On the debt side, the fixed-income category has started witnessing positive inflows across both short- and long-duration products. With a favorable long-term view on interest rates, NAM expects this momentum to be sustained.

Valuation and view


- NAM, being amongst the fastest-growing AMCs, continues to expand its market share across segments, especially in the passive segment, supported by robust flows, sustained investor stickiness, and new product launches. While yields are expected to decline at a relatively moderate pace, strong net flows are likely to cushion the impact on overall yields.
- **We have broadly maintained our earnings estimates, with higher expected yields offsetting the increase in expenses. We reiterate our BUY rating on the stock with a TP of INR1,060, based on 35x Sep'27E EPS.**

Quarterly Performance													(INR m)	
Y/E March	FY25				FY26				FY25	FY26E	2QFY26E	Act v/s Est. (%)	YoY	QoQ
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE						
Revenue from Operations	5,050	5,713	5,879	5,665	6,066	6,581	6,681	6,754	22,307	26,082	6,332	3.9	15.2	8.5
Change YoY (%)	42.6	43.7	38.9	21.0	20.1	15.2	13.6	19.2	35.8	16.9	11			
Fees & Commission	179	192	187	159	186	198	200	207	718	791	190.0	4.2	2.9	6.2
Employee Expenses	1,051	1,069	1,065	1,105	1,226	1,233	1,278	1,323	4,290	5,060	1,261.4	-2.3	15.3	0.5
Other expenses	655	708	770	750	772	855	843	816	2,883	3,286	790.0	8.2	20.8	10.7
Total Operating Expenses	1,886	1,969	2,022	2,014	2,185	2,286	2,321	2,346	7,891	9,138	2,241	2.0	16.1	4.6
Change YoY (%)	24	26	23	13	16	16	15	17	21.5	15.8	14			
EBITDA	3,164	3,744	3,857	3,652	3,881	4,295	4,360	4,407	14,416	16,944	4,090	5.0	14.7	10.7
EBITDA Margin	62.7	65.5	65.6	64.5	64.0	65.3	65.3	65.3	64.6	65.0	64.6	-67 bps	-26bps	128bps
Other Income	1,308	1,208	154	230	1,460	366	775	776	2,900	3,376	600	-39.0	-69.7	-74.9
Depreciation	68	74	77	86	84	88	90	92	306	355	86	2.6	18.7	4.5
Finance Cost	16	17	17	18	18	18	18	18	67	72	18	0.0	8.4	0.0
PBT	4,388	4,861	3,917	3,778	5,239	4,555	5,027	5,072	16,943	19,893	4,586	-0.7	-6.3	-13.1
Tax Provisions	1,066	1,261	965	795	1,282	1,113	1,228	1,231	4,086	4,854	1,122	-0.9		
Net Profit	3,322	3,600	2,953	2,983	3,957	3,443	3,799	3,841	12,857	15,039	3,464	-0.6	-4.4	-13.0
Change YoY (%)	41.1	47.4	4.0	-12.9	19.1	-4.4	28.7	28.8	16.2	17.0	-3.8			
Core PAT	2,331	2,705	2,836	2,801	2,854	3,166	3,213	3,254	10,674	12,487	3,011	5.2	17.0	10.9
Change YoY (%)	59.0	47.9	42.5	8.5	22.4	17.0	13.3	16.2	36	17	11.3			
Key Operating Parameters (%)														
Revenue / AUM (bps)	41.8	41.6	41.3	40.7	39.6	40.1	39.6	38.9	41.3	39.6	38.7	-140 bps	-151bps	50bps
Opex / AUM (bps)	15.6	14.3	14.2	14.5	14.3	13.9	13.8	13.5	14.6	13.9	13.7	-23 bps	-42bps	-34bps
PAT / AUM (bps)	27.5	26.2	20.7	21.4	25.8	21.0	22.5	22.1	23.8	22.8	21.2	20 bps	-525bps	-486bps
Cost to Operating Income Ratio	37.3	34.5	34.4	35.5	36.0	34.7	34.7	34.7	35.4	35.0	35.4	67 bps	26bps	-128bps
EBITDA Margin	62.7	65.5	65.6	64.5	64.0	65.3	65.3	65.3	64.6	65.0	64.6	-67 bps	-26bps	128bps
Tax Rate	24.3	25.9	24.6	21.0	24.5	24.4	24.4	24.3	24.1	24.4	24.5	5 bps	-151bps	-5bps
PAT Margin	65.8	63.0	50.2	52.7	65.2	52.3	56.9	56.9	57.6	57.7	54.7	240 bps	-1070bps	-1292bps
Core PAT Margin	46.2	47.4	48.2	49.4	47.1	48.1	48.1	48.2	47.9	47.9	47.6	-56 bps	75bps	106bps
Opex Mix (%)														
Fees & Commission	9.5	9.8	9.3	7.9	8.5	8.7	8.6	8.8	9.1	8.7	8.5	-18 bps	-111bps	13bps
Employee Expenses	55.8	54.3	52.7	54.9	56.1	53.9	55.1	56.4	54.4	55.4	56.3	234 bps	-35bps	-220bps
Others	34.7	36.0	38.1	37.2	35.3	37.4	36.3	34.8	36.5	36.0	35.2	-216 bps	146bps	207bps
Key Parameters														
QAUM (INR b)	4,838	5,492	5,700	5,572	6,127	6,565	6,749	6,937	5,400	6,595	6,544	0.3	19.5	7.1



United Breweries

Estimate change



TP change

Rating change

Bloomberg	UBBL IN
Equity Shares (m)	264
M.Cap.(INRb)/(USDb)	473.1 / 5.3
52-Week Range (INR)	2300 / 1738
1, 6, 12 Rel. Per (%)	-6/-24/-14
12M Avg Val (INR M)	408

Financials & Valuations (INR b)

Y/E March	FY26E	FY27E	FY28E
Net Sales	95.4	108.1	121.4
Sales Gr. (%)	7.1	13.3	12.3
EBITDA	8.2	11.5	14.1
Margin (%)	8.6	10.6	11.6
Adj. PAT	4.3	7.1	9.2
Adj. EPS (INR)	16.4	26.9	34.8
EPS Gr. (%)	-7.2	64.0	29.6
BV/Sh. (INR)	173.7	188.1	206.7
Ratios			
RoE (%)	9.7	14.9	17.6
RoCE (%)	10.4	15.1	17.8
Valuations			
P/E (x)	109.2	66.6	51.4
P/BV (x)	10.3	9.5	8.7
EV/EBITDA (x)	55.3	40.9	32.0

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	70.8	70.8	70.8
DII	17.8	17.5	17.8
FII	6.3	6.7	6.3
Others	5.1	4.9	5.1

FII includes depository receipts

CMP: INR1,789

TP: INR1,750 (-2%)

Neutral

Disappointing performance; margin volatility persists

- United Breweries (UBBL) reported a 3% YoY revenue decline in 2QFY26 (vs. our est. of +3%), after clocking 16% growth in 1QFY26. We were already building up muted growth due to weak seasonal demand and the extended monsoon, but it was weaker than expected. Volumes dipped 3% YoY (est. of +3%; +11% in 1QFY26), while the premium portfolio clocked a 17% growth, led by strong traction in Heineken Silver, which grew 34% YoY. UBBL experienced a double-digit volume decline in Jul and Aug'25. However, demand revived in Sep'25 with 4-5% volume growth; the positive trend continued in Oct.
- Management highlighted that roughly one-third of the business delivered robust growth, another one-third was affected by adverse weather conditions, while the remaining one-third faced headwinds from affordability pressures and elevated excise duties in select states.
- Regionally, the West and South markets grew 16% and 4%, while the North and East dipped 18% and 6%, respectively. The overall volume dip was mainly led by softness in Odisha, Karnataka, Telangana, West Bengal, and Rajasthan, partially offset by recovery in Andhra Pradesh, Assam, and Maharashtra.
- Gross margin contracted 100bp YoY to 42.8% (vs. est. 44%) due to temporary pressures from interstate transfers and an adverse state mix. EBITDA margin fell sharply by 440bp YoY to 6.3% (vs. est. 9.8%), marking a 10-quarter low. The margin compression was largely driven by volume deleverage, higher brand investments, and short-term cost headwinds (flood-related), rather than structural weakness. Management reiterated its medium-term aspiration of achieving double-digit EBITDA margins. We forecast EBITDA margins of 10.5% for FY27 and 11.5% for FY28 (pre-pandemic margin at more than 15%).
- UBBL remains focused on volume-led growth and further market share gains in the premium segment. We expect a ~12% revenue CAGR over FY26-28, led by high single-digit volume growth and a steady recovery in margins, which have been under pressure for the past five years. Despite volatile margin history, we model EBITDA margin expansion given high growth for the premium portfolio and the scope of cost rationalization. Given rich valuations and lingering regulatory headwinds, we maintain our Neutral stance on the stock with a TP of INR1,750 (55x Sep'27E EPS).

Weak revenue delivery; multi-quarter low margin

- Decline in revenue:** UBBL's standalone net sales declined by 3% YoY to INR20.5b (est. INR21.8b) after clocking 16% growth in 1QFY26. Volume declined by 3% (est. +3%), while the premium segment sustained robust growth and clocked 17% YoY growth.
- Regional performance:** The West and South regions posted volume growth of 16% and 4%, while the North and East regions reported volume declines of 18% and 6%, respectively. The volume growth seen in Maharashtra, Andhra Pradesh, and Assam drove regional performance.

- **Big miss on margins:** Gross margin contracted 100bp YoY to 42.8% (est. 44%, 42.5% in 1QFY26). Employee expenses grew 6% YoY, and other expenses rose 7% YoY. EBITDA margin contracted 440bp YoY to 6.3% (est. 9.8%, 10.8% in 1QFY26). After delivering an improved margin trajectory, there was a sharp contraction in margin in 2Q.
- **Decline in profitability:** EBITDA declined 43% YoY to INR1.3b (est. INR2.1b). Interest cost rose ~570% YoY to 147m (est. INR50m). APAT declined 65% YoY to INR0.5b (est. INR1.2b).
- In 1HFY26, net sales grew 7%, while EBITDA and APAT declined 14% and 25%, respectively.

Highlights from the management commentary

- During 2QFY26, there was an unusually heavy and prolonged monsoon, which hit beer consumption across multiple key markets. Despite the weather-related challenges, UBBL outperformed the broader beer industry, showcasing resilience and effective execution of its commercial strategy.
- The company plans to step up capital expenditure to high single digits as a percentage of sales (vs. mid-single digits historically).
- Maharashtra delivered strong double-digit growth led by improved execution, capacity upgrades, and distributor redesign, while Karnataka, Odisha, West Bengal, and Telangana faced sharp declines due to high taxation, adverse weather, and affordability issues. Meghalaya saw demand recovery post excise cuts, and Uttar Pradesh remained a key growth market despite can shortages, supported by premium brand traction and upcoming brewery expansion.
- Management remains confident that the Indian beer category can deliver a 5–6% annual growth rate in a normalized environment.

Valuation and view

- We cut our PAT estimates by ~20% for FY26 and 10% for FY27, factoring in the miss on EBITDA in 2Q and adjusting the margin for FY27.
- UBBL continues to face multiple headwinds, including prolonged monsoon-led disruptions, high excise duties, and affordability pressures in key markets such as Karnataka, Telangana, and Odisha, which have weighed on category growth. Management is focusing on portfolio premiumization, cost discipline, and proactive engagement with state authorities to drive recovery.
- UBBL remains focused on volume-led growth and further market share gains in the premium segment. We expect a ~12% revenue CAGR over FY25-28, led by high single-digit volume growth and a steady recovery in margins, which have been under pressure for the past five years. However, given the rich valuations and lingering regulatory headwinds, **we reiterate our Neutral rating** on the stock with a TP of INR1,750 (premised on 55x Sep'27E EPS).

Standalone Quarterly Performance											(INR m)	
Y/E March	FY25				FY26E				FY25	FY26E	FY26	Variance
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	
Volume growth (%)	5	5	8	5	11	-3	2	8	6	7	3	
Net Sales	24,730	21,147	19,984	23,214	28,624	20,511	21,183	25,091	89,074	95,409	21,781	-5.8%
YoY Change (%)	8.8	12.0	9.6	8.9	15.7	-3.0	6.0	8.1	9.7	7.1	3.0	
Gross Profit	10,642	9,272	8,619	9,772	12,176	8,779	9,151	10,730	38,305	40,835	9,584	-8.4%
Margin (%)	43.0	43.8	43.1	42.1	42.5	42.8	43.2	42.8	43.0	42.8	44.0	
EBITDA	2,847	2,268	1,411	1,862	3,105	1,301	1,652	2,149	8,390	8,208	2,135	-39.0%
YoY Change (%)	27.8	22.9	-3.0	31.2	9.1	-42.6	17.1	15.4	20.5	-2.2	-5.9	
Margins (%)	11.5	10.7	7.1	8.0	10.8	6.3	7.8	8.6	9.4	8.6	9.8	
Depreciation	577	571	613	567	628	640	625	624	2,327	2,517	610	
Interest	16	22	32	59	112	147	100	92	129	450	50	
Other Income	73	105	101	79	110	150	165	111	357	536	125	
PBT before EO expense	2,327	1,781	867	1,316	2,475	665	1,092	1,544	6,291	5,776	1,600	
Tax	595	458	227	342	638	196	251	360	1,622	1,444	400	
Rate (%)	25.5	25.7	26.2	26.0	25.8	29.4	23.0	23.3	26.9	25.0	25.0	
Reported PAT	1,733	1,322	383	974	1,837	469	841	1,184	4,412	4,332	1,200	-60.9%
Adj PAT	1,733	1,322	640	974	1,837	469	841	1,184	4,669	4,332	1,200	-60.9%
YoY Change (%)	27.3	22.9	-24.5	20.5	6.0	-64.5	31.4	21.6	13.6	-7.2	-9.3	
Margins (%)	7.0	6.3	3.2	4.2	6.4	2.3	4.0	4.7	5.2	4.5	5.5	

E: MOFSL Estimates



Radico Khaitan

Estimate change	
TP change	
Rating change	

Bloomberg	RDCK IN
Equity Shares (m)	134
M.Cap.(INRb)/(USDb)	423.6 / 4.8
52-Week Range (INR)	3423 / 1846
1, 6, 12 Rel. Per (%)	4/20/35
12M Avg Val (INR M)	716

Financials & Valuations (INR b)

Y/E March	2026E	2027E	2028E
Sales	61.8	71.1	80.8
Sales Gr. (%)	27	15	14
EBITDA	9.5	11.4	13.4
Margin (%)	15.3	16.0	16.6
PAT	5.6	7.1	8.8
EPS (INR)	41.9	53.3	65.5
EPS Gr. (%)	62	27	23
BV/Sh.(INR)	235	277	330
Ratios			
RoE (%)	17.9	19.2	19.9
RoCE (%)	18.2	20.6	22.9
Payout (%)	20.0	20.0	20.0
Valuations			
P/E (x)	75.0	58.9	48.0
P/BV (x)	13.4	11.3	9.5
EV/EBITDA (x)	44.7	37.0	31.0

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	40.2	40.2	40.2
DII	25.5	26.0	24.7
FII	18.0	17.8	18.6
Others	16.3	16.0	16.5

FII includes depository receipts

CMP: INR3,164

TP: INR3,600 (+14%)

BUY

Solid performance backed by robust underlying volumes

- Radico Khaitan reported another quarter of strong operating performance, as its 2QFY26 revenue grew 34% YoY (est. 25%) and total volume grew 38% (beat). The Prestige & Above (P&A) segment clocked volume growth of 22% and value growth of 24%. Regular segment posted 83% value growth and 79% volume growth, aided by a low base and route-to-market changes in Andhra Pradesh (Oct'24). The market share in AP jumped to 30% in 1HFY26 from 10% in 1HFY25. Non-IMFL delivered revenue growth of 27% YoY, led by higher bulk alcohol sales YoY.
- Management indicated that the overall share of Radico in the Alcobev space has increased by ~200bp, primarily driven by its premiumization drive and broad-based growth across geographies. Luxury segment contributes ~10% of company sales. Radico remains on track to achieve its FY26 revenue target of INR5b from this segment.
- Gross margin was flat YoY at 43.6% (est. 43.2%), led by stable RM prices. EBITDA margin expanded 130bp YoY to 15.9% (est. 15.3%), led by operating leverage. Radico has maintained its margin expansion guidance of 125-150bp annually for the next three years, aiming to reach high-teen margins. We model EBITDA margins of 16%/16.5% for FY27/FY28.
- Radico has delivered robust returns (~30%) since our initiation in May'25 ([IC report](#)), where we highlighted its strong growth trajectory in the P&A segment and its strategic expansion into premium and luxury portfolios, which continue to exhibit strong industry volume growth. With continued focus on premiumization and broad-based geographic expansion, Radico has delivered industry-leading growth. We believe the rich valuations are well justified by its strong performance delivery. We reiterate a BUY rating with a TP of INR3,600 (based on 60x Sep'27E EPS).

Robust volume growth; beat across parameters

- Strong volume growth of 38%:** Standalone net sales rose 34% YoY to INR15b (est. INR14b) in 2QFY26. Total volume grew 38%, with P&A volume up 22% YoY (41% in 1QFY26) to 3.9m cases (in line). Regular volume rose 79% YoY to 5m cases. Volume growth was aided by a low base, resolution of state-specific issues, and route-to-market changes in AP. Royalty cases were down by 46% YoY to 0.4m cases. Non-IMFL revenue grew 27%, led by higher bulk alcohol sales YoY.
- EBITDA up 46% YoY:** Gross margin was flat YoY at 43.6% given relatively stable raw material costs and a higher proportion of Regular volumes. Management remains optimistic about the stability of ENA and grain prices in FY26. Employee costs rose 14%, S&D was up 46%, and other expenses increased 21% YoY. EBITDA margin was up 130bp YoY at 15.9%.
- Strong growth in profitability:** EBITDA/PBT/APAT grew 46%/67%/69% YoY in 2Q. For 1HFY26, revenue/EBITDA/APAT grew 33%/50%/76% YoY.
- The board has approved the amalgamation of its wholly owned subsidiary and step-down subsidiaries. These subsidiaries were formed to acquire the land for the Sitapur greenfield project. As the project is now complete, the amalgamation will streamline the corporate structure and bring the land holdings directly under the company.

Highlights from the management commentary

- Luxury segment contributes ~10% of company sales. Management is confident of achieving INR5b sales from the luxury portfolio in FY26 (vs. INR3.4b in FY25).
- In the next three years, Radico expects Magic Moments to achieve volume of 10m cases vs. 7m in FY25.
- The industry saw a decline of 25% in Maharashtra and Radico declined by ~20%.
- The company has maintained its margin expansion guidance of 125-150bp annually for the next three years, aiming to reach high-teen margins.
- Radico remains on track to be debt free by FY27.

Valuation and view

- We raised our EPS estimates by 3% for FY26/FY27 on strong volume growth and beat in EBITDA margin.
- Radico's debt is likely to decline steadily, supported by healthy free cash flow generation. The company has reduced net debt by INR1.4b since Mar'25 and is on track to be debt free by FY27.
- Radico remains focused on accelerating the premium and luxury growth while driving greater efficiency across operations with disciplined capital allocation.
- The valuation gap with UNSP has narrowed significantly, reflecting market recognition of Radico's brand strength and execution. Despite past margin pressures, the company's ability to sustain premium-led volume growth makes it a compelling long-term story.
- Radico is currently trading at 59x/48x FY27E/FY28E EPS, with RoE/RoIC of ~19%/20% in FY27E. We believe a ~35% EPS CAGR provides adequate support for sustaining rich valuations. We value the company at 60x P/E on Sep'27E EPS to derive a TP of INR3,600.

Radico Khaitan (Standalone)											(INR m)
Y/E March	FY25					FY26E		FY25	FY26E	FY26E	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		2QE	(%)
IMFL volume growth %	-4.1	-2.4	15.5	27.5	37.5	37.7	21.5	20.0	9.2	28.1	26.7
P&A volume growth (%)	14.2	12.7	18.0	16.4	40.7	21.6	23.0	29.9	15.5	28.1	22.0
Regular volume growth (%)	-14.0	-11.9	13.5	78.1	51.8	79.4	40.0	13.8	13.3	40.9	45.0
Total revenues	11,365	11,163	12,942	13,041	15,060	14,939	16,075	15,755	48,512	61,830	13,939 7%
YoY change (%)	19.1	20.7	11.5	20.9	32.5	33.8	24.2	20.8	17.8	27.5	24.9
Gross Profit	4,720	4,870	5,568	5,669	6,477	6,520	7,025	6,918	20,773	26,940	6,022 8%
Margin (%)	41.5	43.6	43.0	43.5	43.0	43.6	43.7	43.9	42.8	43.6	43.2
EBITDA	1,490	1,632	1,840	1,776	2,322	2,376	2,443	2,319	6,737	9,460	2,126 12%
Margins (%)	13.1	14.6	14.2	13.6	15.4	15.9	15.2	14.7	13.9	15.3	15.3
EBITDA growth (%)	24.7	34.6	28.8	45.0	55.8	45.6	32.8	30.6	33.1	40.4	30.3
Depreciation	329	357	356	360	363	374	375	384	1,401	1,495	365
Interest	185	167	195	215	159	163	155	126	738	603	155
Other income	37	11	11	14	47	24	25	30	49	125	30
PBT	1,014	1,118	1,299	1,215	1,846	1,863	1,938	1,839	4,646	7,487	1,636 14%
Tax	251	297	339	308	443	474	487	476	1,194	1,879	411
Rate (%)	24.7	26.5	26.1	25.3	24.0	25.4	25.1	25.9	25.7	25.1	25.1
Extraordinary inc/(Exp)	0	0	0	0	-70	0	0	0	0	-70	0
Reported PAT	763	822	960	907	1,473	1,390	1,452	1,363	3,452	5,678	1,225 13%
Adj.PAT	763	822	960	907	1,403	1,390	1,452	1,363	3,452	5,608	1,225 13%
YoY change (%)	20.7	32.8	30.0	59.7	83.9	69.1	51.3	50.2	35.0	62.5	49.1

E: MOFSL Estimate

LIC Housing Finance

Estimate change	
TP change	
Rating change	

Bloomberg	LICHF IN
Equity Shares (m)	550
M.Cap.(INRb)/(USDb)	313.8 / 3.5
52-Week Range (INR)	658 / 484
1, 6, 12 Rel. Per (%)	-4/-11/-16
12M Avg Val (INR M)	965

Financials & Valuations (INR b)

Y/E March	FY25	FY26E	FY27E
NII	81.3	82.4	89.2
PPP	71.4	74.8	80.3
PAT	54.3	54.7	56.9
EPS (INR)	98.6	99.3	103.3
EPS Gr. (%)	13.9	0.7	4.0
BV/Sh (INR)	659	737	819
Ratios			
NIM (%)	2.8	2.6	2.7
C/I ratio (%)	16.2	14.8	14.9
RoAA (%)	1.8	1.7	1.7
RoE (%)	16.0	14.2	13.3
Payout (%)	10.1	10.8	10.4
Valuations			
P/E (x)	5.8	5.7	5.5
P/BV (x)	0.9	0.8	0.7
Div. Yield (%)	1.8	1.9	1.9

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	45.2	45.2	45.2
DII	22.2	22.2	20.5
FII	20.2	20.3	22.0
Others	12.5	12.3	12.3

FII Includes depository receipts

CMP: INR570 TP: INR630 (+10%) Neutral

Profitability taking precedence over loan growth

Disbursement weak and BT-OUT elevated; Asset quality continues to improve

- LIC Housing Finance's (LICHF) 2QFY26 PAT grew ~2% YoY to ~INR13.5b (in line). NII in 2QFY26 rose ~3% YoY to ~INR20.4b (in line). Fee and other income grew 74% YoY to INR1.4b.
- Opex declined ~3% YoY to INR3b (~12% lower than est.) and the cost-income ratio declined ~120bp YoY to ~13.9% (PY: ~15.1% and PQ: ~13.4%). PPoP grew ~8% YoY to ~INR18.7b (in line).
- Reported yields declined ~20bp QoQ to 9.4%, while CoB declined ~8bp QoQ to ~7.4%. This resulted in spreads declining ~12bp QoQ to ~1.98%. NIM in 2QFY26 declined ~6bp QoQ to ~2.62%.
- The muted loan growth was driven by both a weakness in disbursements as well as higher repayments (from elevated BT-OUTs). Banks (particularly PSU banks) continue to remain aggressive in both the IHL (individual home loans) and non-IHL segments. Management shared that it will prioritize NIM (and profitability) over aggressive loan growth. The company continued to guide for NIM of ~2.6-2.8% in FY26, and we estimate NIM of 2.6%/2.7% in FY26/FY27.
- LICHF plans to review its organizational structure and distribution channels to improve loan growth. It plans to expand its direct sourcing through lead generation and improve the share of its subsidiary-sourced business. We model loan growth/disbursements CAGR of 7%/ 8% for FY25-FY28.
- The company reported a minor improvement in asset quality, which is expected to improve further, with 2-3 large accounts (ticket size > INR2b) in their final stages of resolution and expected to be resolved in 2HFY26. The increase in Stage 3 PCR during the quarter was attributed to the creation of management overlays on a few long outstanding stressed assets.
- We estimate a CAGR of ~7%/4% in advances/PAT over FY25-28 and RoA/RoE of 1.7%/13% by FY28. LICHF is planning to engage with a consultant to evaluate areas for process improvement and reorganization. However, these changes are often long-drawn with no real certainty of a turnaround. Meanwhile, as shared by the company, it will continue to prioritize NIM (and profitability), which will keep the loan growth in mid-to-high single digits over the medium term. With no near-term catalyst, we reiterate our Neutral rating on the stock with a TP of INR630 (based on 0.7x Sep'27E P/BV).

Weak disbursements and higher repayments lead to subdued growth

- Loan disbursements in IHL grew ~3% YoY, while non-IHL disbursements rose 23% YoY. Non-housing commercial disbursements declined ~19% YoY. Builder/project loan disbursements declined ~73% YoY.

- Loan growth was sluggish, driven by both weak disbursements and higher repayments. Total disbursements declined ~1% YoY to ~INR163b. Overall loan book grew ~6% YoY and ~1% QoQ to INR3.12t. Home loans grew ~7% YoY, while the developer loan book grew ~17% YoY. Repayments stood at 18.2% (PQ and PY both at 14.6%).
- Management expects a better disbursement momentum in 3Q and 4QFY26, especially with a strong pipeline in the construction finance segment.

Marginal improvement in asset quality

- GS3/NS3 declined ~10bp each QoQ to ~2.5%/1.2%, respectively. Stage 3 PCR improved ~230bp QoQ to ~53% (PQ: ~51%). Stage 1 PCR declined to ~17bp (PQ: ~18bp), and Stage 2 PCR rose ~15bp QoQ to ~3.9% (PQ: 3.7%).
- Stage 2 + 3 assets (30+ dpd) declined ~30bp QoQ to 5.9% (vs. ~6.2% in Jun'25). ECL/EAD remained stable QoQ at ~1.63%. Management shared that most of the Stage 3 loans are legacy stressed accounts. About 2-3 large corporate loans (Ticket size >INR2b) are expected to be resolved in 2HFY26, which will further improve the asset quality.
- Credit costs stood at ~INR1.7b (~25% higher than MOFSLe) and translated into annualized credit costs of 22bp (PY: ~11bp and PQ: 25bp). Despite credit costs of 22-25bp in 1HFY26, the management expects FY26 credit costs to be contained between 15bp and 20bp. We model credit costs of ~18bp/25bp in FY26/FY27.

Highlights from the management commentary

- The company's ~43% of borrowings are repo-linked and benefit directly from lower market rates, while ~53% are fixed-rate NCDs that will reprice gradually.
- The construction finance segment witnessed a slowdown due to home loan-like interest rates offered by banks. However, the company has a strong pipeline in this segment, which is expected to support overall disbursements in 2H.

Valuation and view

- LICHF reported a tepid quarter, marked by muted loan growth and weak disbursements. NIM continued to remain under pressure due to the realization of the full impact of the ~25bp PLR cut taken in Apr'25. Management indicated that NIMs have bottomed out and are now expected to see improvement in subsequent quarters.
- We believe that the declining interest rate environment, coupled with aggression from banks (in the home loan as well as construction finance segments), will weigh on LICHF's loan growth and its consequent trade-off with margins.
- LICHF's valuation of ~0.7x FY27E P/BV reflects the inability of the franchise to deliver stronger loan growth. **We estimate a CAGR of ~7%/4% in advances/PAT over FY25-28E and RoA/RoE of 1.7%/13% by FY28. We reiterate our Neutral rating on the stock with a TP of INR630 (based on 0.7x Sep'27E BV).**
- **Key risks:** a) an elongated period of weak loan growth due to high competitive intensity and b) volatility in the NIM profile.

Quarterly Performance (INR M)													
Y/E March	FY25					FY26				FY25	FY26	2QFY26E	Act. v/s est. (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q					
Interest Income	67,391	68,534	69,516	71,173	71,131	70,335	70,898	71,488	2,76,615	2,83,852	70,348	0	
Interest Expenses	47,501	48,796	49,515	49,508	50,473	49,951	50,251	50,818	1,95,320	2,01,493	50,422	-1	
Net Interest Income	19,891	19,739	20,001	21,664	20,658	20,385	20,648	20,670	81,295	82,360	19,926	2	
YoY Growth (%)	-10.0	-6.3	-4.6	-3.2	3.9	3.3	3.2	-4.6	-6.0	1.3	0.9		
Fees and other income	446	784	1,057	1,661	1,201	1,362	1,480	1,349	3,948	5,392	1,375	-1	
Net Income	20,337	20,522	21,059	23,326	21,859	21,747	22,128	22,019	85,243	87,751	21,300	2	
YoY Growth (%)	-9.7	-4.9	-1.9	2.0	7.5	6.0	5.1	-5.6	-3.6	2.9	3.8		
Operating Expenses	2,621	3,105	3,564	4,536	2,938	3,018	3,279	3,711	13,826	12,946	3,416	-12	
Operating Profit	17,715	17,417	17,495	18,790	18,920	18,729	18,849	18,308	71,416	74,806	17,885	5	
YoY Growth (%)	-11.9	-8.3	-7.2	-1.3	6.8	7.5	7.7	-2.6	-7.2	4.7	2.7		
Provisions and Cont.	1,431	773	-440	1,094	1,929	1,682	1,345	648	2,858	5,604	1,350	25	
Profit before Tax	16,285	16,644	17,934	17,696	16,992	17,047	17,504	17,660	68,558	69,202	16,535	3	
Tax Provisions	3,282	3,355	3,615	4,016	3,392	3,508	3,623	4,008	14,268	14,532	3,307	6	
Net Profit	13,002	13,289	14,320	13,680	13,599	13,539	13,880	13,651	54,290	54,669	13,228	2	
YoY Growth (%)	-2	12	23	25	5	2	-3	0	14	1	6		
Key Operating Parameters (%)													
Yield on loans (Cal)	9.37	9.40	9.37	9.38	9.22	9.06	9.01	8.89	9.5	9.1			
Cost of funds (Cal)	7.50	7.64	7.62	7.43	7.46	7.35	7.28	7.21	7.5	7.3			
Spreads (Cal)	1.87	1.76	1.75	1.95	1.76	1.70	1.73	1.68	2.0	1.9			
Margins (Cal)	2.76	2.71	2.69	2.86	2.68	2.62	2.62	2.57	2.7	2.6			
Credit Cost (Cal)	0.20	0.11	-0.06	0.14	0.25	0.22	0.17	0.08	0.1	0.2			
Cost to Income Ratio	12.9	15.1	16.9	19.4	13.4	13.9	14.8	16.9	16.2	14.8			
Tax Rate	20.2	20.2	20.2	22.7	20.0	20.6	20.7	22.7	20.8	21.0			
Balance Sheet Parameters													
Loans (INR B)	2,887	2,946	2,991	3,077	3,096	3,118	3,178	3,253	3028	3198			
Change YoY (%)	4.4	6.0	6.4	7.3	7.2	5.8	6.2	5.7	7.9	5.6			
Indiv. Disb. (INR B)	124	151	145	183	130	159	167	183	602	639			
Change YoY (%)	16.9	6.0	-2.1	9.3	4.6	5.7	15.1	0.0	6.9	6.0			
Borrowings (INR B)	2,537	2,574	2,626	2,706	2,709	2,725	2,796	2,841	2706	2841			
Change YoY (%)	5.1	5.7	7.1	7.0	6.8	5.8	6.5	5.0	7.2	5.0			
Loans/Borrowings (%)	113.8	114.4	113.9	113.7	114.3	114.4	113.6	114.5	111.9	112.6			
Asset Quality Parameters													
GS 3 (INR B)	95.3	90.1	82.3	76.0	81.1	78.3			76.0	71.2			
Gross Stage 3 (% on Assets)	3.30	3.06	2.75	2.47	2.62	2.51			2.5	2.2			
NS 3 (INR B)	48.0	45.7	43.2	37.1	39.9	36.7			37.1	60.7			
Net Stage 3 (% on Assets)	1.69	1.58	1.47	1.22	1.31	1.20			1.2	1.9			
PCR (%)	49.6	49.3	47.5	51.2	50.8	53.1			51.2	14.8			
ECL (%)	1.96	1.85	1.66	1.59	1.63	1.63							
Loan Mix (%)													
Home loans	85.3	85.2	85.1	85.0	84.8	84.7							
LAP	12.7	12.9	13.2	13.3	13.6	13.7							
Non Individual loans	2.0	1.9	1.7	1.7	1.6	1.6							
Borrowing Mix (%)													
Banks	34.0	34.0	33.0	32.0	31.0	35.0							
NCD	54.0	54.0	54.0	55.0	55.0	53.0							
Sub Debt	1.0	1.0	1.0	1.0	0.0	0.0							
Deposits	3.0	3.0	3.0	3.0	4.0	4.0							
NHB	4.0	4.0	5.0	4.0	5.0	4.0							
CP	4.0	4.0	4.0	5.0	5.0	4.0							

E: MOFSL Estimates

Metro Brands

BSE SENSEX	S&P CNX
84,404	25,878



Bloomberg	METROBRA IN
Equity Shares (m)	272
M.Cap.(INRb)/(USDb)	309.5 / 3.5
52-Week Range (INR)	1340 / 890
1, 6, 12 Rel. Per (%)	-17/0/-10
12M Avg Val (INR M)	123

Financials & Valuations (INR b)

Y/E March	FY26E	FY27E	FY28E
Sales	28.0	32.4	36.9
EBITDA	8.5	10.0	11.5
Adj. PAT	4.0	4.8	5.6
EBITDA Margin (%)	30.4	30.8	31.3
Adj. EPS (INR)	14.9	17.8	20.9
EPS Gr. (%)	6.9	19.1	17.7
BV/Sh. (INR)	74.1	85.9	99.7
Ratios			
Net D:E	0.3	0.2	0.1
RoE (%)	22.1	22.8	23.1
RoCE (%)	15.2	15.3	15.4
Payout (%)	35.8	34.8	34.8
Valuations			
P/E (x)	76.2	64.0	54.4
EV/EBITDA (x)	37.8	32.0	27.5
EV/Sales (X)	11.5	9.9	8.6
Div. Yield (%)	0.5	0.5	0.6

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	71.9	71.9	72.0
DII	7.4	7.5	7.0
FII	3.9	3.7	3.4
Others	16.9	17.0	17.7

FII includes depository receipts

CMP: INR1,136 TP: INR1,400 (+23%)

Buy

Doubling down on the S&A portfolio through MetroActiv

- Metro Brands (MBL) has delivered double-digit growth on average over the past four quarters, continuing its outperformance over the listed footwear peers.
- The company also ramped up store additions in 2Q, along with scaling up the recent partnerships with Clarks (presence in 200 MBOs) and Foot Locker (opened four EBOs) to sustain the double-digit growth trajectory.
- MBL is now doubling down on scaling up its presence in the fast-growing sports & athleisure (S&A) segment through the launch of a new in-house format, **MetroActiv**, focused on providing sports performance products from leading global brands under one roof.
- We view this as a positive portfolio evolution, expanding MBL's TAM and positioning the brand to participate more meaningfully in the fast-growing S&A segment in tier 1 and tier 2 towns in India.
- Given the strong runway for growth in the Metro, Mochi, and Walkway formats, along with significant growth opportunities in FILA/Foot Locker/Clarks, we build in a revenue/EBITDA/PAT CAGR of 14%/15%/14% over FY25-28E.
- We reiterate our BUY rating on MBL with a TP of INR1,400, premised on ~70x Dec'27 P/E.**

Launched MetroActiv to tap into the performance S&A segment

- MBL launches a new banner, **MetroActiv**, a multi-brand retail format focused on the sports performance segment, marking a deeper push into the fast-growing S&A segment.
- MetroActiv brings together leading global performance brands such as Nike, Adidas, Puma, Skechers, Asics, etc., across footwear, apparel, and accessories under the same roof.
- MetroActiv will be rolled out in Indore, Dehradun, and Jodhpur in the first phase, with stores spanning ~3-6k sqft, larger than Metro/Mochi formats (~1.5k sqft) but below Foot Locker scale (~6-8k sqft).
- The company aims to deliver superior retail expansion through a trained team of performance advisors, 'Pacers', to provide fitness expertise and product guidance.
- Further, the company would collaborate with local running clubs, fitness groups, and sports enthusiasts to drive discovery and engagement.
- MBL will also launch the e-commerce platform metroactiv.com to complement the physical stores and will integrate wellness tools such as calorie counter, nutrition tracker, and BMI calculator, with a view to providing a holistic active lifestyle ecosystem.
- We view this as a positive portfolio evolution, expanding MBL's TAM and positioning the brand to participate more meaningfully in the fast-growing S&A segment.

- **CEO Nissan Joseph** highlighted MetroActiv as the natural evolution of Metro's strategy, positioning it at the intersection of fitness, fashion, and functionality. The initiative aims to democratize performance retail and build a broader lifestyle movement centered on active living in India.

Doubling down on S&A with multiple banners spanning price points

- S&A remains the strongest structural growth driver in Indian footwear, compounding at ~19% over FY16–25 vs. ~12% for the industry, supported by fitness adoption, lifestyle usage, premiumization, and higher ASPs driving superior margins.
- MBL is addressing its historical whitespace in the S&A portfolio through the acquisition of strategic licenses for FILA and Foot Locker (high-end sneakers).
- Execution is now gaining momentum after BIS-led delays, with MBL adopting a calibrated rollout strategy, testing formats and store sizes to refine the right playbook. MBL opened four Foot Locker stores in 2Q and plans to scale FILA EBOs from 2HFY26.
- With the launch of MetroActiv, MBL will have an in-house banner catering to the sports performance segment, while Foot Locker will attract sneaker heads through its exclusive ranges.
- Initially, MetroActiv would primarily target Tier 1 and Tier 2 cities (vs. focusing on metros in the case of Foot Locker). The selling price is likely to be in the INR3-8k range (vs. 6k+ starting price points in the case of Foot Locker).
- While the target customer is different, we believe MetroActiv could serve as a strategic test bed to evaluate the potential of the Foot Locker format beyond top metros, enabling Metro to strengthen its footprint in S&A through a controlled, in-house play.

Valuation and view

- Concerns around Fila's liquidation and BIS-related challenges are now well behind the company, and MBL's strategic focus is on ramping up Foot Locker and FILA, as well as scaling up the recent addition, Clarks.
- We remain positive on MBL's long-term outlook, given a) its superior store economics, with industry-leading store productivity and strong cost controls, and b) a long runway for growth, largely funded through internal accruals.
- Given the strong runway for growth in the Metro, Mochi, and Walkway formats, along with significant growth opportunities in FILA/Foot Locker/Clarks, we build in revenue/EBITDA/PAT CAGR of 14%/15%/14% over FY25-28E.
- **We reiterate our BUY rating on MBL with a TP of INR1,400, premised on ~70x Dec'27 P/E.** Consistent double-digit growth and ramp-up of newer formats, such as FILA, Foot Locker, MetroActiv, and Clarks, remain the key re-rating triggers for the stock.

Exhibit 1: We ascribe a TP of INR1,400 to MBL based on 70x Dec'27E EPS

	Dec'27
(INR/share)	
EPS (INR)	20.1
Target P/E (x)	70
Target Price	1,400
CMP	1,127
Upside (%)	24.3%



Bandhan Bank

Estimate change

TP change

Rating change


Bloomberg	BANDHAN IN
Equity Shares (m)	1611
M.Cap.(INRb)/(USDb)	277.5 / 3.1
52-Week Range (INR)	192 / 128
1, 6, 12 Rel. Per (%)	0/-4/-10
12M Avg Val (INR M)	1373

Financials & Valuations (INR b)

Y/E March	FY25	FY26E	FY27E
NII	114.9	110.1	128.0
OP	73.9	60.2	72.0
NP	27.5	15.8	29.4
NIM (%)	6.7	5.8	5.9
EPS (INR)	17.0	9.8	18.2
EPS Gr. (%)	22.8	-42.5	86.0
BV/Sh. (INR)	151	155	167
ABV/Sh. (INR)	144	147	158
Ratios			
RoA (%)	1.5	0.8	1.3
RoE (%)	12.0	6.4	11.3
Valuations			
P/E(X)	10.0	17.4	9.3
P/BV (X)	1.1	1.1	1.0
P/ABV (X)	1.2	1.2	1.1

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	40.3	40.9	40.0
DII	17.9	16.6	16.4
FII	23.4	24.3	26.7
Others	18.4	18.2	16.9

FII Includes depository receipts

CMP: INR172
TP: INR175 (+2%)
Neutral
Weak performance; margins contract by sharp 55bp QoQ
MFI slippages remain elevated

- Bandhan Bank (BANDHAN) reported 2QFY26 PAT at INR1.12b (down 70% QoQ, 64% miss), supported by a sharp contraction in NIMs, lower other income, and elevated provisions.
- NII declined 12% YoY/6% QoQ to INR25.9b (in line). Margins contracted 55bp QoQ to 5.8% (vs MOFSLe of 5.98%) as the bank has cut 200bp of MCLR and passed on the full 75bp of repo rate.
- Other income declined 8% YoY/25% QoQ to INR5.5b (26% miss), Opex grew 8% YoY/1% QoQ to INR18.2b (broadly in line). C/I ratio, thus, increased 610bp QoQ to 58.2%.
- Net advances grew 6.8% YoY (up 4.7% QoQ), while deposits grew 10.9% YoY (up 2.2% QoQ). The CASA mix, thus, improved slightly sequentially to 28%. The CD ratio stood at 85% vs 83% in 1QFY26.
- The GNPA/NNPA ratio increased 6bp/1bp QoQ to 5.02%/1.37%. Fresh slippages stood elevated at INR15.9b (vs INR15.5b in 1QFY26). PCR stood flat at 73.7%.
- **We cut our earnings estimates by 34%/17% for FY26/FY27 and expect FY27E RoA/RoE of 1.28%/11.3%. Reiterate Neutral with a TP of INR175 (1.1x FY27E ABV).**

MFI declines to 37%; asset quality continues to remain under pressure

- BANDHAN reported 2QFY26 PAT at INR1.12b (down 88% YoY, down 70% QoQ, 64% miss), due to a sharp contraction in NIMs, lower other income, and elevated provisions.
- NII declined 12% YoY/ 6% QoQ to INR25.9b (in line). Margins contracted 55bp QoQ to 5.8%.
- Other income declined 8% YoY/25% QoQ to INR5.5b (26% miss). As a result, total revenue declined 12% YoY/10% QoQ to INR31.4b (5% miss).
- Opex grew 8% YoY/1% QoQ to INR18.2b (in line). PPoP, thus, declined 29% YoY (down 21% QoQ) to INR13.1b (7% miss). Provisions came in 15% higher than our estimates at INR11.5b (up 90% YoY, flat QoQ).
- Gross advances grew 7% YoY/5% QoQ. EEB book declined 13% YoY (down 2% QoQ), whereas the non-micro credit book rose 24% YoY (9% QoQ). Mix of EEB moderated to 37%.
- Deposit grew 10.9% YoY (up 2.2% QoQ). The CASA mix improved sequentially to 28%.
- GNPA/NNPA ratio increased 6bp/1bp QoQ to 5.02%/1.37%. Fresh slippages stood elevated at INR15.9b (up 43% YoY, 2.6% QoQ). PCR stood flat at 73.7%. SMA book increased 100bp QoQ to 4.8%. EEB (MFI) slippages are likely to continue for the next 2-3 months, and the full guardrail is taking longer than expected.

Highlights from the management commentary

- As the bank is moving toward a secured book, NIM is expected to reach 6% in two years.
- With the upcoming Bihar elections, collections remain normal and in line with expectations; proactive measures are in place, customer concerns are minimal, and no major disruptions have been observed, with ongoing regular customer meetings.
- The bank expects credit costs for EEB to remain at around 2.5-3% by the end of FY27, and expects bank-level credit costs to remain at 1.5% for FY28.
- Secured mix is expected to improve 3-4% over the next 3 to 4 years. The bank is expecting growth to rebound in EEB.

Valuation and view

BANDHAN reported a weak quarter with an all-around miss, driven by higher-than-expected provisions, lower other income, and a sharp 55bp QoQ moderation in margins due to a 200bp MCLR cut and the full pass-through of the 75bp repo rate cut. Loan growth was 7% YoY as the MFI book continues to decline, with the segment mix also reducing to 37%. Asset quality continues to deteriorate, and slippages remain elevated. With reduced SA funding costs and moderation in TD rates upon renewal, NIMs are expected to expand, especially from 4Q onwards, aided by the bank's shift toward a secured book. However, MFI slippages are expected to continue for the next 2-3 months, and the full guardrail is taking longer than expected. **We cut our earnings estimates by 34%/17% for FY26/FY27 and expect FY27E RoA/RoE of 1.28%/11.3%. Reiterate Neutral with a TP of INR175 (1.1x FY27E ABV).**

Y/E March	(INR b)												
	FY25					FY26E				FY25	FY26E	FY26E	V/S our
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE					
Net Interest Income	30.1	29.5	28.3	27.6	27.6	25.9	27.3	29.3	114.9	110.1	25.7	1%	
% Change (YoY)	20.7	20.7	12.1	-3.9	-8.2	-12.2	-3.5	6.4	11.3	-4.2	-12.9		
Other Income	5.3	5.9	11.0	7.0	7.3	5.5	6.6	8.0	29.7	27.3	7.3	-26%	
Total Income	35.3	35.4	39.3	34.6	34.8	31.3	33.9	37.3	144.6	137.4	33.0	-5%	
Operating Expenses	15.9	16.9	19.0	18.8	18.1	18.2	19.7	21.2	70.7	77.2	18.9	-3%	
Operating Profit	19.4	18.6	20.2	15.7	16.7	13.1	14.2	16.2	73.9	60.2	14.1	-7%	
% Change (YoY)	24.2	17.2	22.1	-14.5	-14.0	-29.4	-29.7	2.9	11.2	-18.6	-23.7		
Provisions	5.2	6.1	13.8	12.6	11.5	11.5	9.4	6.9	37.7	39.3	10.0	15%	
Profit Before Tax	14.2	12.5	6.5	3.1	5.2	1.6	4.8	9.3	36.2	20.8	4.1	-62%	
Tax	3.5	3.1	2.2	-0.1	1.5	0.5	1.1	2.0	8.8	5.0	1.0	-56%	
Net Profit	10.6	9.4	4.3	3.2	3.7	1.1	3.7	7.3	27.5	15.8	3.1	-64%	
% Change (YoY)	47.5	30.0	-41.8	482.0	-65.0	-88.1	-13.6	128.4	22.8	-42.5	-67.3		
Operating Parameters													
Deposits (INR b)	1,332	1,425	1,410	1,512	1,547	1,581	1,639	1,716	1,512	1,716	1,584	0%	
Loans (INR b)	1,216	1,261	1,274	1,320	1,285	1,346	1,408	1,495	1,320	1,495	1,320	2%	
Deposit Growth (%)	22.8	27.2	20.1	11.8	16.1	10.9	16.2	13.5	11.8	13.5	11.1		
Loan Growth (%)	23.8	23.6	15.6	9.0	5.7	6.8	10.5	13.3	9.0	13.3	4.7		
Asset Quality													
Gross NPA (%)	4.2	4.7	4.7	4.7	5.0	5.0	4.9	4.7	4.7	4.7	5.0		
Net NPA (%)	1.2	1.3	1.3	1.3	1.4	1.4	1.3	1.3	1.3	1.3	1.4		
PCR (%)	73.7	73.5	73.5	73.7	73.7	73.7	73.8	73.6	73.7	73.6	73.3		

E: MOFSL Estimates



Brigade Enterprises

Estimate change	
TP change	
Rating change	

Bloomberg	BRGD IN
Equity Shares (m)	244
M.Cap.(INRb)/(USDb)	254 / 2.9
52-Week Range (INR)	1341 / 813
1, 6, 12 Rel. Per (%)	11/-/20
12M Avg Val (INR M)	415

Financials & Valuations (INR b)

Y/E Mar	FY26E	FY27E	FY28E
Sales	49.4	60.8	86.4
EBITDA	17.7	22.5	30.2
EBITDA (%)	35.9	37.1	35.0
PAT	9.3	13.2	19.1
EPS (INR)	38.1	54.0	78.1
EPS Gr. (%)	35.9	41.7	44.6
BV/Sh. (INR)	266.9	318.9	395.0
Ratios			
Net D/E	0.2	0.0	(0.1)
RoE (%)	15.3	18.4	21.9
RoCE (%)	11.4	13.6	16.6
Payout (%)	5.2	3.7	2.6
Valuations			
P/E (x)	27	19	13
P/BV (x)	3.9	3.3	2.6
EV/EBITDA (x)	15.0	11.3	8.0
Div Yield (%)	0.2	0.2	0.2

Shareholding Pattern (%)

As of	Sep-25	Jun-25	Sep-24
Promoter	41.1	41.1	41.4
DII	23.3	23.5	24.0
FII	18.7	19.3	18.5
Others	16.9	16.1	16.1

CMP: INR1,039

TP:INR1,494 (+44%)

Buy

Healthy operating performance as launches intensify

Residential launch pipeline of 11msf provides near-term growth visibility

- In 2QFY26, Brigade Enterprises (BRGD) reported a 12% YoY presales growth (in line), reaching INR20.3b. The company recorded volumes of 1.9msf (+13% YoY; 9% above our expectations). In 1HFY26, presales rose 8% YoY to INR32b, while volumes were flat at 2.9msf.
- Consolidated collections rose 3% YoY to INR20b (in line).
- BRGD launched two residential and one plotted projects, with a TDA of 2.02msf in 2QFY26 across Bengaluru. Overall in 1HFY26, it launched three residential and one plotted projects, with a TDA of 3.11msf across Bengaluru and Chennai.
- BRGD plans to launch ~11msf in the next four quarters across Bangalore, Chennai, Hyderabad, and Mysuru.
- In 1HFY26, Brigade Group acquired a prime land parcel on Velachery Road, Chennai, for premium residential development with a total potential of 0.8msf, resulting in a GDV of INR16b. BRGD acquired this land for INR4.4b.
- The company's gross debt stood at INR42.9b, while net debt was INR17.7b. Its net debt to equity stood at 0.22x by the end of 2QFY26 (vs. 0.34x in 1QFY26); the cost of debt declined to 8.05% during the quarter.
- Leasing:** Leasing revenue grew 16% YoY to INR3.4b while EBITDA stood at INR1.9b with a margin of 56%. In 1HFY26, leasing revenue grew at 15% YoY to INR6.4b, while EBITDA stood at INR3.6b with a margin of 56%.
- Portfolio occupancy stood at 92% with an overall leasing of 8.67msf out of 9.38msf.
- It launched two commercial projects with a TDA of 0.72msf across Bengaluru and Chennai. Overall, in 1HFY26, it launched four commercial projects with a TDA of 1.26msf across Bengaluru, Gujarat, and Chennai.
- Around 4.21msf of area will be launched in the next four quarters.
- Hospitality:** Brigade Hotel Ventures Limited (BHVL) reported revenue of INR1.4b, which rose 16% YoY, while EBITDA stood at INR420m.
- BHVL currently has 1,604 keys. Nine hotels with a total of 1,700 keys are under the planning stage, of which six hotels with 940 keys are in agreement with Marriott International.

P&L performance

- In 2QFY26, BRGD's revenue increased 29% YoY to INR13.8b (14% above our estimate). In 1HFY26, its revenue grew 24% YoY to INR26.6b.
- EBITDA stood at INR3.3b, up 12% YoY (24% below estimates). EBITDA margin came in at 23.7%. In 1HFY26, EBITDA increased 11% YoY to INR6.5b with margins at 24.5%.
- BRGD's adj. PAT jumped 37% YoY to INR1.6b (32% below estimates), clocking a margin of 12%. In 1HFY26, PAT increased 54% YoY to INR3.1b with margins at 11.7%.

Valuation and view

- BRGD reported 12% booking growth on a YoY basis, while bookings were up 82% sequentially due to an increase in launches this quarter. It has a strong residential launch pipeline of ~11msf, which should enable it to sustain the growth traction going forward.
- Management intends to keep assessing growth opportunities in the residential segment and expects to spend more on business development over the next two years. This will provide growth visibility in the residential segment and lead to a further re-rating.
- **We reiterate our BUY rating with a revised TP of INR1,494 (vs. INR1,470), implying a 44% potential upside.**

Quarterly Performance

Y/E March	(INR m)											
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	FY25	FY26E	FY26E	Var
Gross Sales	10,777	10,722	14,639	14,604	12,811	13,834	13,020	9,727	50,742	49,393	12,088	14%
YoY Change (%)	64.8	-21.5	24.7	-14.2	18.9	29.0	-11.1	-33.4	3.6	-2.7	12.7	
Total Expenditure	7,851	7,802	10,502	10,444	9,575	10,553	8,350	3,198	36,600	31,675	7,752	
EBITDA	2,926	2,919	4,137	4,160	3,237	3,281	4,670	6,530	14,142	17,717	4,336	-24%
Margins (%)	27.1	27.2	28.3	28.5	25.3	23.7	35.9	67.1	27.9	35.9	35.9	-1216bps
Depreciation	679	689	763	756	756	765	834	810	2,888	3,165	774	
Interest	1,519	1,226	1,143	1,066	1,056	1,023	1,268	1,463	4,955	4,809	1,177	
Other Income	357	660	657	719	517	465	662	868	2,393	2,513	615	
PBT before EO expense	1,084	1,664	2,888	3,057	1,941	1,958	3,231	5,126	8,693	12,256	3,000	-35%
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0	
PBT	1,084	1,664	2,888	3,057	1,941	1,958	3,231	5,126	8,693	12,256	3,000	-35%
Tax	279	513	533	563	359	253	702	1,772	1,888	3,085	651	
Rate (%)	25.7	30.8	18.5	18.4	18.5	12.9	21.7	34.6	21.6	13.9	21.7	
MI & P/L of Asso. Cos.	-32	-39	-7	25	84	80	-40	-275	-53	-150	-37	
Reported PAT	837	1,190	2,362	2,468	1,499	1,625	2,569	3,629	6,858	9,322	2,385	-32%
Adj PAT	837	1,190	2,362	2,468	1,499	1,625	2,569	3,629	6,858	9,322	2,385	-32%
YoY Change (%)	117.3	-10.9	221.5	19.8	79.0	36.6	8.7	47.0	51.9	35.9	100.4	
Margins (%)	7.8	11.1	16.1	16.9	11.7	11.7	19.7	37.3	13.5	18.9	19.7	

E: MOFSL Estimates

Operational Performance

Pre Sales (msf)	1.2	1.7	2.2	2.0	1.0	1.9	2.6	5.1	7.0	10.6	1.7	9%
Booking Value (INRb)	10.9	18.2	24.9	24.5	11.2	20.3	27.7	45.8	78.5	105.0	20	-1%
Avg rate/sf (INR)	9,442	10,838	11,364	12,083	11,768	10,705	10,705	10,705	11132	9946	11768	-9%
Collections (INRb)	16.1	19.4	17.8	19.3	17.3	20.0	27.4	39.1	72.5	103.8	20	-1%

Source: Company, MOFSL Estimates

Navin Fluorine International

Estimate change	
TP change	
Rating change	

Bloomberg	NFIL IN
Equity Shares (m)	51
M.Cap.(INRb)/(USDb)	256.6 / 2.9
52-Week Range (INR)	5444 / 3180
1, 6, 12 Rel. Per (%)	3/4/44
12M Avg Val (INR M)	745

Financials & Valuations (INR b)

Y/E March	FY26E	FY27E	FY28E
Sales	31.7	37.9	44.4
EBITDA	9.5	11.1	12.8
PAT	5.5	6.6	7.7
EPS (INR)	108.2	129.8	149.4
EPS Gr. (%)	86.0	19.9	15.1
BV/Sh.(INR)	745.3	848.4	967.1
Ratios			
Net D:E	0.2	0.2	0.2
RoE (%)	17.2	16.3	16.5
RoCE (%)	14.2	14.2	14.4
Payout (%)	20.6	20.6	20.6
Valuations			
P/E (x)	46.0	38.3	33.3
P/BV (x)	6.7	5.9	5.1
EV/EBITDA (x)	27.7	23.9	20.7
Div. Yield (%)	0.4	0.5	0.6
FCF Yield (%)	0.2	0.2	0.7

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	27.1	28.0	28.4
DII	29.6	28.7	28.2
FII	22.2	21.6	18.2
Others	21.2	21.7	25.2

FII includes depository receipts

CMP: INR5,009

TP: INR5,400 (+8%)

Neutral

Strong performance across segments fuels growth momentum

Earnings beat estimates

- 2QFY26 was a strong quarter for Navin Fluorine International (NFIL), with revenue rising 46% YoY, supported by strong performance across all three business segments. Revenue in HPP/specialty chemicals/CDMO grew 38%/39%/97% YoY. EBITDA grew 2.3x YoY, driven by volume growth, operating efficiencies, pricing environment, and a favorable product mix
- We expect this momentum to sustain in 2HFY26, supported by the stable pricing environment of refrigerant gases, robust order book pipeline, and higher realizations and volumes in both domestic and international markets, leading to higher EBITDA margin.
- On the back of a robust 1HFY26, we increase our FY26/FY27/FY28 earnings estimates by 22%/15%/11% and reiterate our Neutral rating on the stock with a TP of INR5400 (40x Sep'27E EPS)

Operating leverage and better product mix drive earnings

- NFIL reported revenue of INR7.6b (est. in line), up 46% YoY, driven by growth across all three segments.
- Gross margin stood at 58.7% (up 200bp), while EBITDA margin stood at 32.5% compared to 20.7% in 2QFY25, driven by operational efficiencies, stable pricing environment, and a favorable product mix
- EBITDA stood at INR2.5b (est. INR1.7b), up 2.3x YoY, and PAT grew 2.5x YoY to INR1.5b in 1QFY26 (est INR892m).
- Revenue in the HPP segment grew 38% to INR4b, driven by higher volumes and improved realizations in both domestic and international markets, supported by the R32 plants running at optimal capacity.
- Revenue in the Specialty Chemicals segment grew 39% YoY to INR2.2b, driven by 81% growth in the international business. The CDMO business continued its growth trajectory in 2QFY26, with revenue growing 97% YoY to INR1.3b.
- India's revenue grew 2% YoY, while revenue from the International business grew 82% YoY.
- In 1HFY26 Revenue/EBITDA/Adj. PAT grew 42%/2.2x/2.4x to INR14.8b/INR4.5b/INR2.7b

Highlights from the management commentary

- **CDMO:** Following the successful delivery of late-stage pipeline molecules, management highlighted that the plant was audited by three leading global innovators. Further, the order book pipeline till FY27 remains strong, backed by robust purchase orders.
- **HPP:** The Board has approved capital expenditure of INR2.4b, adding 15,000 MTPA of R32 HFC capacity. This expansion is driven by strong global demand stemming from the transition to low-GWP gases and rising RAC and blend demand in both domestic and export markets. The project is expected to be completed by 3QFY27, with a peak revenue potential of INR6-8.25b.

- **Margin guidance:** Management remains optimistic about 2HFY26 and beyond, supported by a strong order book, deep customer relationships, and continued focus on R&D. Reflecting this confidence, the company has raised its EBITDA margin guidance to 28-30% (from 25% earlier) for FY26.

Valuation and view

- On the back of a robust 1HFY26, we believe the company is well-positioned to sustain its growth momentum in 2HFY26, led by robust order books, strategic customer relationships, ongoing R&D investment, new product launches, and repeat orders expected in CY26.
- The medium-term outlook is further supported by: 1) a strategic partnership with Chemours to foray into high-growth advanced materials, 2) planned investment toward increasing the R32 capacity and MPP debottlenecking for the specialty chemical plant at Dahej, and 3) strategic relations with global players.
- We expect a revenue/EBITDA/adj. PAT CAGR of 24%/34%/38% over FY25-28. The stock is trading at ~38x FY27E EPS of INR129.8 and ~24x FY27E EV/EBITDA. We value the company at 40 Sep'27E EPS to arrive at our TP of INR5,400, and **we reiterate our Neutral rating.**

Y/E March	Consolidated - Quarterly Snapshot (INR m)												
	FY25					FY26				FY25	FY26E	FY26	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		2QE	(%)		
Gross Sales	5,237	5,186	6,062	7,009	7,254	7,584	8,263	8,617	23,494	31,719	7,519	1%	
YoY Change (%)	6.6	9.9	21.2	16.4	38.5	46.3	36.3	22.9	13.8	35.0	0.5		
Gross Margin (%)	56.0%	56.8%	56.6%	54.2%	57.6%	58.7%	57.0%	57.9%	55.8%	57.8%	56.0%		
EBITDA	1,004	1,074	1,473	1,787	2,068	2,462	2,441	2,513	5,337	9,484	1,731	42%	
Margin (%)	19.2	20.7	24.3	25.5	28.5	32.5	29.5	29.2	22.7	29.9	23.0		
Depreciation	267	279	296	353	352	366	410	425	1,194	1,553	371		
Interest	156	139	202	283	304	303	290	250	779	1,147	291		
Other Income	103	112	105	118	139	182	150	144	437	615	123		
PBT before EO expense	683	768	1,080	1,270	1,551	1,975	1,891	1,983	3,801	7,400	1,192		
PBT	683	768	1,080	1,270	1,551	1,975	1,891	1,983	3,801	7,400	1,192		
Tax	171	179	244	320	379	491	477	510	915	1,858	300		
Rate (%)	25.0	23.4	22.6	25.2	24.5	24.9	25.2	25.7	24.1	25.1	25.2		
Reported PAT	512	588	836	950	1,172	1,484	1,414	1,472	2,886	5,542	892	66%	
Adj. PAT	512	588	836	950	1,172	1,484	1,414	1,472	2,886	5,542	892	66%	
YoY Change (%)	-16.8	-2.9	131.2	35.0	128.9	152.2	69.2	55.0	26.3	92.0	51.7		
Margin (%)	9.8	11.3	13.8	13.6	16.2	19.6	17.1	17.1	12.3	17.5	11.9		



Manappuram Finance

Estimate change	
TP change	
Rating change	

Bloomberg	MGFL IN
Equity Shares (m)	846
M.Cap.(INRb)/(USDb)	232.7 / 2.6
52-Week Range (INR)	298 / 148
1, 6, 12 Rel. Per (%)	-7/13/64
12M Avg Val (INR M)	2007

Financials & Valuations (INR b)

Y/E March	FY25	FY26E	FY27E
NII	62.2	55.0	64.9
PPP	36.3	27.2	34.7
PAT	12.0	10.6	19.8
EPS (INR)	14.2	11.3	19.2
EPS Gr. (%)	-45.2	-20.3	69.4
BV/Sh.(INR)	147	169	185
Ratios			
NIM (%)	15.0	12.2	12.5
C/I ratio (%)	44.2	52.9	48.8
RoA (%)	2.5	2.0	3.3
RoE (%)	10.0	7.5	11.3
Payout (%)	24.6	33.0	20.6
Valuations			
P/E (x)	19.3	24.3	14.3
P/BV (x)	1.9	1.6	1.5
Div. Yld. (%)	1.3	1.4	1.4

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	35.3	35.3	35.3
DII	9.2	8.6	11.0
FII	30.2	29.7	30.4
Others	25.4	26.4	23.4

FII Includes depository receipts

CMP: INR275

TP: INR305 (+11%)

Neutral

Gold loan growth strong but NIM compression continues

Gold tonnage growth weak; asset quality weakens in non-gold segments

- MGFL reported consol. PAT of INR2.2b in 2QFY26 (12% beat). NII declined ~16% YoY to ~INR13.8b (in line) and PPoP declined ~35% YoY to ~INR6.7b (in line). Operating expenses grew 6% YoY to ~INR7.4b (in line).
- Consol. credit costs declined QoQ to ~INR3.7b. Annualized credit costs for the quarter declined ~185bp QoQ to 3.3% (PQ: ~5.1%).
- Consol. total AUM rose ~4% QoQ and was flat YoY. Consol. Gold AUM grew ~9% QoQ and ~29% YoY to ~INR315b.
- Gold loan yields declined to ~19.7% (PQ: 20.5%). Standalone CoB declined ~12bp QoQ to ~9.1%, resulting in a ~70bp decline in spreads. Consol. NIM (calc.) declined ~45bp QoQ to ~12.4%
- Management shared that it will continue to focus more on gold loans, targeting higher-ticket size customers, while the non-gold businesses will resume their growth trajectory once they stabilize. The company guided for a 20-25% CAGR in gold loans over the medium term irrespective of any volatility in gold prices. This is in alignment with the management's strategy of deriving volume-led growth.
- MGFL continues to align the gold loan interest rates with its large peers, which has resulted in a sharp moderation in its gold loan yields. However, the impact will be partially mitigated by declining CoF, which fell by ~12bp in 2QFY26 and is expected to further trend downward in the coming quarters.
- Standalone (Gold +Vehicle + Onlending + MSME) GNPA/NNPA remained stable QoQ at 3.0%/2.6%. Stress was observed in the farm equipment and 2W segments, leading to higher delinquencies in Vehicle Finance business. However, management has ramped up the collection infrastructure and expects asset quality to stabilize and then improve in the subsequent quarters.
- We raise our FY26 EPS estimate by 8% to factor in higher gold loan growth, lower opex and credit costs and keep our FY27 estimates largely unchanged. Over FY25-28, we estimate a CAGR of 24%/16% in gold/consolidated AUM and ~29% in consolidated PAT, with consolidated RoA/RoE of ~3.7%/13% in FY28. **Reiterate our Neutral rating on the stock with a TP of INR305 (based on 1.6x Sep'27E consolidated BVPS).**

Strong gold loan growth of 29% YoY; co-lending to further boost growth

- Gold AUM grew ~9% QoQ and ~29% YoY to ~INR315b. Gold tonnage rose ~1% QoQ to ~57.2 tons. Within gold loans, LTV was stable QoQ at ~56% and the average ticket size (ATS) rose to INR83k (PQ: INR76k). Gold loan customer base was broadly stable at ~2.6m.

- Management highlighted that the RBI's recent initiatives have opened up opportunities for the company to pursue co-lending partnerships in gold loans. Additionally, the culture of availing gold loan is improving across the country, with borrowers now increasingly preferring organized lenders over unorganized lenders.

Asirvad MFI: AUM declines ~49% YoY; asset quality deteriorates

- MFI GNPA rose ~40bp QoQ to 4.8%, while NNPA rose ~60bp QoQ to ~2.0% and credit costs stood at ~INR2.5b (PQ: ~INR4.8b).
- Asirvad AUM declined ~49% YoY and ~8% QoQ to ~INR62b. Asirvad reported 2QFY26 loss of INR1.7b (vs. loss of INR2.7b in 1QFY26).
- Asirvad received ~INR5b equity infusion from MGFL to improve the resilience of its balance sheet.

Highlights from the management commentary

- The new CEO has prioritized certain facets of the business such as accelerating loan growth through branch expansion and co-lending. The company aims to increase efficiency while revamping non-gold business and subsidiaries, with strong collections and prudent risk management.
- Management shared that the Bain Capital transaction is in its final stages and it might get the RBI's approval within a month.

Valuation and view

- MGFL reported a soft quarter, with asset quality weakening across the non-gold business and profitability remaining under pressure from persistent NIM compression. The only bright spot was strong growth in the gold loan portfolio, even as this was tempered by significant yield compression. Asirvad MFI's net loss declined sequentially, driven mainly by lower credit costs; however, the MFI portfolio continues to exhibit a substantial run-down.
- MGFL trades at 1.5x FY27E P/BV, and we believe that there could be a near-term impact on profitability and consolidated AUM growth due to the lingering stress in the MFI, 2W and farm equipment segments. Gold loan is expected to exhibit healthy growth with an AUM CAGR of ~24% over FY25-28, but will be accompanied by a compression in yields. **Reiterate our Neutral rating on the stock with a TP of INR305 (based on 1.6x Sep'27E consolidated BVPS).**

MGFL - Quarterly Performance (Consolidated, INR m)

Y/E March	FY25					FY26E			FY25	FY26E	2Q	FY26E	Act v/s Est. %
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q					
Interest Income	23,861	25,411	25,163	23,062	22,357	22,512	22,332	22,349	97,997	89,550	22,088	22,088	2
Interest Expenses	8,483	9,057	9,253	8,616	8,553	8,756	8,651	8,550	35,747	34,510	8,630	8,630	1
Net Interest Income	15,378	16,354	15,909	14,446	13,804	13,756	13,681	13,799	62,250	55,040	13,458	13,458	2
YoY Growth (%)	19.4	20.75	9.5	-3.3	-10.2	-15.88	-14.0	-4.5	10.7	-11.6	-17.7	-17.7	
Other income	1,259	961	464	230	293	341	417	356	2,752	2,764	388	388	-12
Net Income	16,636	17,314	16,373	14,676	14,097	14,097	14,098	14,155	65,002	57,803	13,846	13,846	2
Operating Expenses	6,823	6,984	7,066	7,843	7,488	7,385	7,631	8,067	28,718	30,572	7,403	7,403	0
Operating Profits	9,814	10,331	9,307	6,833	6,609	6,712	6,466	6,087	36,285	27,232	6,443	6,443	4
YoY Growth (%)	22.4	19.2	-0.6	-26.8	-32.7	-35.0	-30.5	-10.9	2.6	-24.9	-37.6	-37.6	
Provisions	2,286	2,604	5,546	9,192	5,594	3,692	2,774	1,869	19,628	13,929	3,822	3,822	-3
PBT	7,528	7,727	3,761	-2,359	1,015	3,020	3,692	4,219	16,656	13,303	2,622	2,622	15
Tax Provisions	1,963	2,006	976	-327	-310	847	997	1,126	4,618	2,661	682	682	24
PAT	5,565	5,721	2,785	-2,032	1,325	2,173	2,695	3,092	12,039	10,642	1,940	1,940	12
YoY Growth (%)	12	2	-52	-136	-76	-62	-3	-252	-45	-12	-66	-66	
Key Ratios (%)													
Yield on loans	22.5	22.9	22.8	21.5	20.8	20.2	19.6	19.1	23.6	19.9			
Cost of funds (Cal)	9.4	9.4	9.8	9.5	9.4	9.3	9.2	9.1	10.4	9.4			
Spreads (Cal)	13.08	13.5	13.0	11.99	11.41	10.9	10.4	10.0	13.2	10.5			
NIMs (Cal)	14.50	14.8	14.4	13.47	12.85	12.37	12.0	11.8	15.0	12.2			
C/I ratio	41.0	40.3	43.2	53.4	53.1	52.4	54.1	57.0	44.2	52.9			
Credit Cost	2.10	2.3	4.9	8.43	5.12	3.3	2.4	1.6	4.7	3.1			
Tax Rate	26.1	26.0	26.0	13.9	-30.5	28.0	27.0	26.7	27.7	20.0			
Balance Sheet Parameters													
Consol. AUM (INR b)	449	457	442	430	443	459	466	485					
Change YoY (%)	21.2	17.4	9.5	2.3	-1.4	0.4	5.4	12.7					
Gold loans (INR b)	236	244	245	256	288	315	328	348					
Change YoY (%)	14.8	17.1	18.0	19.0	21.8	29.3	33.7	36.0					
Gold stock (tonnes)	60	60	57	56	57	57	0	0					
Gold loans/branch (INR m)	58	60	61	63	71	78	0	0					
Consol. Borrowings (INR b)	385	385	370	354	374	377	373	378					
Change YoY (%)	34.8	19.4	15.9	5.2	-2.8	-1.9	0.7	6.7					
Borrowings Mix (%)													
Debentures	12.3	12.1	11.3	10.6	10.1	9.0							
CPs	2.3	1.5	0.8	0.8	3.4	5.3							
WC/CC	20.5	19.1	20.6	20.5	21.1	19.2							
TL	54.3	47.7	53.5	52.7	51.3	47.3							
ECB	10.0	19.0	13.4	14.8	13.9	19.0							
Others	0.6	0.7	0.4	0.5	0.3	0.2							
Debt/Equity (x)	1.6												
Asset Quality Parameters (%)													
GNPL ratio (Standalone)	2.0	2.4	2.5	2.8	3.0	3.0							
NNPL ratio (Standalone)	1.7	2.1	2.3	2.5	2.6	2.6							
Return Ratios (%)													
RoA (Rep)	4.8	4.4	2.2	-1.6	1.1	1.7							
RoE (Rep)	16.7	18.6	8.9	-6.4	4.3	6.9							

E: MOSL estimates

Estimate change	↓
TP change	↓
Rating change	↔

Bloomberg	BATA IN
Equity Shares (m)	129
M.Cap.(INRb)/(USDb)	137.8 / 1.6
52-Week Range (INR)	1479 / 1025
1, 6, 12 Rel. Per (%)	-13/-18/-28
12M Avg Val (INR M)	291

Financials & Valuations (INR b)

Y/E March	FY26E	FY27E	FY28E
Sales	35.4	37.0	38.7
EBITDA	7.7	8.8	9.7
Adj. PAT	2.1	2.7	3.3
EBITDA Margin (%)	21.8	23.8	25.0
Adj. EPS (INR)	16.3	21.4	25.6
EPS Gr. (%)	-16.0	31.3	19.9
BV/Sh. (INR)	129.7	140.4	153.2
Ratios			
Net D:E	0.3	0.2	0.0
RoE (%)	12.9	15.8	17.5
RoCE (%)	10.1	11.8	12.8
RoIC (%)	11.5	14.4	16.6
Valuations			
P/E (x)	71.6	54.5	45.5
EV/EBITDA (x)	20.3	17.5	15.7
EV/Sales (X)	4.4	4.2	3.9
Div. Yield (%)	0.7	0.9	0.9

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	50.2	50.2	50.2
DII	29.4	29.4	27.1
FII	6.9	6.9	8.8
Others	13.6	13.6	13.9

FII includes depository receipts

CMP: INR1,072
TP: INR985 (-8%)
Neutral
Disappointing performance continues

- Bata India's (BATA) 2QFY26 revenue declined ~4% YoY, hurt by the deferment of purchases by channel partners and warehouse disruption.
- Reported EBITDA declined 17% YoY, driven by weaker sales, gross margin contraction (higher markdowns for pre-festive inventory clearance), and higher marketing spends.
- 1HFY26 revenue declined 2% YoY, while pre-Ind AS EBITDA declined 28% to INR1.3b, with margins contracting to 7.5% (vs. 10.2% YoY), despite accounting changes that would have otherwise raised reported profitability.
- The value segment (~40% mix) is showing early signs of recovery, with GST pass-through and sharper pricing. Meanwhile, the premium (~20% mix) segment remains resilient, led by Hush Puppies and comfort-tech lines, supporting ASP accretion and mix improvement.
- Post-COVID, BATA accelerated its initiatives across distribution (expanding stores by ~30% via franchise), enhancing brand relevance and product mix (improving youth connect through new concepts like Floatz, Power, Sneaker Studios), and driving premiumization. However, these efforts have yet to translate into meaningful growth or margin recovery, with profitability still lagging pre-COVID levels.
- We cut our FY26-28E EBITDA by 7-10% due to continued challenges both on growth and profitability. We model a revenue/EBITDA/adj. PAT CAGR of 4%/9%/10% over FY26-28E. **Reiterate Neutral with a revised TP of INR985.**

Muted demand and GST transition drag performance

- Revenue **declined 4% YoY** to INR 8.0b (~7% miss), due to the deferment of trade and consumer purchases following the GST rate rationalization announcement and a temporary disruption in a key warehouse in July.
- BATA added 30 new (17 net) franchise stores during the quarter, maintaining its focus on asset-light expansion.
- Management indicated that 2Q ended on a positive note, with signs of recovery in the festive season.
- Gross margin contracted **122bp YoY to 55.4% (160bp miss)**, owing to **higher markdowns** for pre-festive inventory clearance.
- Consequently, **gross profit declined 6% YoY (10% miss)**.
- Employee costs declined 2% YoY, while other expenses rose by a marginal 1% YoY.
- **EBITDA declined 17% YoY (31% miss)**, led by weaker sales, gross margin contraction, and higher marketing spends. EBITDA margin contracted **280bp to 18.1% (610bp miss)**.
- Pre-IND AS EBITDA for 1HFY26 stood at INR1.3b (down 28% YoY), with margins contracting to 7.5% (vs. 10.2% YoY) despite a change in accounting for one of the brands, which would have resulted in optically higher margins.
- Profitability was further impacted by a **VRS charge of INR83m**.

- Reported PAT declined sharply by 73% YoY to INR139m due to weaker EBITDA, higher D&A (+16% YoY), and finance cost (+6% YoY).
- Inventory days improved to 83 days in 1HFY26 (vs 89 in 1HFY25), supported by better inventory clearance. Core working capital remained broadly steady at ~60 days.
- OCF (post leases) declined to INR525m (vs. INR2.1b YoY) due to subdued profitability and adverse WC changes. FCF was modest at INR273m (vs. INR1.8b/INR3.1b in 1HFY25/FY25).
- 1HFY26 revenue/EBITDA declined 2%/4% YoY, while profitability was significantly impacted. Based on our estimates, the implied growth rate for revenue/EBITDA/PAT in 2HFY26 stands at 5%/13%/16%.

Key takeaways from the management commentary

- **Demand trends:** The GST transition led to deferred purchases by customers as well as channel partners, leading to a temporary volume dip. However, demand picked up during the festive season. Management noted that, excluding the transitory GST impact, revenue growth would have been flat YoY.
- **Outlook:** Demand rebounded sharply following GST implementation, supported by strong footfalls and channel orders, though this was partly spilled over into October. The festive uplift, coupled with GST-led normalization, resulted in the best exit run-rate in recent quarters. Recovery is expected to strengthen from 3Q, as cleaner inventory, faster turns, and store/channel productivity gains flow through.
- **The value segment**, which accounts for ~40% of the mix, is stabilizing after prolonged pressure. GST benefit pass-through and price re-indexing are aiding volume recovery, supported by cleaner assortments and stronger full-price sell-throughs, with early traction visible across lower-price SKUs.
- **The premium segment**, which accounts for ~20% of the mix, remained resilient, led by Hush Puppies' expansion and tech-driven comfort products like Power Easy Slide and Floats. This lifted ASPs, reinforcing premiumization focus and growing the lifestyle/comfort franchise.
- **Inventory cleanup** is nearly complete, with freshness improving ~7%, inventory declining 12% YoY, and turns rising to 2.5x. The adoption of zero-based merchandising has enabled sharper assortments and store refreshes.

Valuation and view

- Post-COVID, BATA accelerated its initiatives across distribution (expanding stores by ~30% via franchise), enhancing brand relevance and product mix (improving youth connect through new concepts like Floatz, Power, Sneaker Studios) and driving premiumization. However, these efforts have yet to translate into meaningful growth or margin recovery, with profitability still lagging pre-COVID levels.
- We cut our FY26-28E EBITDA by 7-10% due to continued challenges both on growth and profitability. We model a revenue/EBITDA/adj. PAT CAGR of 4%/9%/10% over FY26-28E.
- We reiterate our **Neutral rating with a revised TP of INR985 (earlier INR1,070), premised on 40x Dec'27 P/E.**
- With the recent GST cuts, we expect demand to pick up for organized players, especially in the value segment, which is expected to benefit BATA and prevent us from downgrading the stock to Sell.

Y/E March									(INR m)			
	FY25				FY26E			FY25	FY26E	FY26E	Est	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		2QE	Var (%)	
Revenue	9,446	8,371	9,188	7,882	9,419	8,013	9,602	8,379	34,888	35,413	8,624	-7.1
YoY Change (%)	-1.4	2.2	1.7	-1.2	-0.3	-4.3	4.5	6.3	0.3	1.5		
Gross Profit	5,182	4,740	5,163	4,634	5,038	4,439	5,425	4,841	19,644	19,743	4,916	-9.7
Gross margin%	54.9	56.6	56.2	58.8	53.5	55.4	56.5	57.8	56.3	55.8	57.0	-3
Total Expenditure	7,597	6,625	7,193	6,104	7,430	6,564	7,365	6,351	27,514	27,711	6,537	0.4
EBITDA	1,849	1,746	1,995	1,778	1,988	1,449	2,237	2,027	7,374	7,702	2,087	-30.6
EBITDA margin	19.6	20.9	21.7	22.6	21.1	18.1	23.3	24.2	21.1	21.8	24.2	-25
Change YoY (%)	-22.8	-3.9	9.4	-2.4	7.5	-17.0	12.1	14.0	-6.2	4.5		
Depreciation	872	902	902	1,037	1,061	1,050	1,072	1,104	3,713	4,286	1,072	-2.0
Interest	308	318	311	348	349	338	354	375	1,285	1,416	365	-7.4
Other Income	162	172	99	223	170	214	126	244	656	754	193	11.2
PBT before EO expense	832	698	881	617	748	276	937	793	3,032	2,754	843	-67.3
Extra-Ord expense	-1,340	0	108	0	48	83	0	0	-1,232	130		
PBT	2,171	698	773	617	701	193	937	793	4,264	2,624	843	-77.1
Tax	431	178	186	163	181	54	236	190	957	661	212	-74.6
Rate (%)	19.8	25.5	24.1	26.4	25.8	28.0	25.2	24.0	22.4	25.2	25.2	
Reported PAT	1,741	520	587	454	520	139	702	603	3,307	1,964	630	-78.0
Adj PAT	849	520	669	454	568	198	702	603	2,492	2,071	630	-68.5
YoY Change (%)	-21	-19	15	-29	-33	-62	5	33	-15	-17	0	
Margins (%)	9.0%	6.2%	7.3%	5.8%	6.0%	2.5%	7.3%	7.2%	7.1%	5.8%	0.0%	

E: MOFSL Estimates



Mahanagar Gas

Estimate change	
TP change	
Rating change	

Bloomberg	MAHGL IN
Equity Shares (m)	99
M.Cap.(INRb)/(USDb)	128 / 1.5
52-Week Range (INR)	1587 / 1075
1, 6, 12 Rel. Per (%)	-3/-9/-16
12M Avg Val (INR M)	814

Financials & Valuations (INR b)

Y/E March	FY26E	FY27E	FY28E
Sales	81.7	89.0	99.2
EBITDA	15.5	16.2	17.7
Adj. PAT	9.7	10.2	11.2
Adj. EPS (INR)	98.5	102.8	113.8
EPS Gr. (%)	-7.3	4.4	10.7
BV/Sh.(INR)	655.3	717.0	785.3

Ratios

Net D:E	-0.1	0.0	-0.1
RoE (%)	15.7	15.0	15.2
RoCE (%)	15.8	15.1	15.2
Payout (%)	40.0	40.0	40.0

Valuation

P/E (x)	13.0	12.4	11.2
P/BV (x)	1.9	1.8	1.6
EV/EBITDA (x)	7.9	7.6	6.9
Div. Yield (%)	3.1	3.2	3.6
FCF Yield (%)	2.5	1.9	3.1

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	32.5	32.5	32.5
DII	32.9	32.5	25.5
FII	23.6	25.5	34.2
Others	11.0	9.5	7.8

FII includes depository receipts

CMP: INR1,296 **TP: INR1,700 (+33%)** **Buy**

EBITDA margin below est.; medium-term outlook healthy

- Mahanagar Gas (MAHGL)'s 2QFY26 EBITDA margin of INR8/scm was below our est. of INR8.7/scm. Total volumes for MAHGL (ex-UEPL) were in line at 4.4mm scmd. On a sequential basis, EBITDA/scm (adjusted for one-off items in 1QFY26) declined INR1.6, as 1) gas costs grew INR1.4/scm QoQ to INR32.1/scm; 2) realization declined INR0.1/scm QoQ, and operating costs rose INR0.1/scm.
- Management guided a robust double-digit growth trajectory, with volumes likely to rise over 10% YoY and EBITDA margins sustaining at INR8-9/scm over the medium term. Incorporating the amalgamation of UEPL, we now forecast 11% CAGR in volumes over FY25-28 (vs. 9% earlier). However, we have marginally trimmed our EBITDA/scm estimates to INR9.2/8.7/8.7 for FY26/27/28, reflecting a more conservative margin outlook. Consequently, our EBITDA estimates for FY26-28 are lower by 2-3%, while PAT estimates have been revised down by 5-8%, factoring in higher depreciation post-amalgamation and a reduction in other income assumptions.
- We model MAHGL's volumes to clock an 11% CAGR over FY25-28 and estimate an EBITDA margin of INR8.7-9.2 per scm during the period. MAHGL currently trades at 11.2x FY28E SA P/E. We now value MAHGL at 15x Dec'27 P/E (15x FY27 P/E earlier), resulting in a TP of INR1,700. Reiterate BUY.

Focus remains on volume growth; plans to add 80 CNG stations in FY26

- Management guided a robust 10%+ YoY growth in volumes and a stable EBITDA/scm margin of INR8-9 in the medium term.
- **FY26 capex guidance:** MAHGL has guided for a consolidated capex of INR10.5-12b in FY26. Of this, INR9-10b will be deployed across MAHGL's three geographical areas (GAs), while INR1.5-2b will be incurred towards network expansion and infrastructure development in UEPL's GAs.
- **Gas sourcing split (MAHGL-ex UEPL):** MAHGL's total gas requirement is met through: 1) APM gas: ~1.6mm scmd, 2) New well gas: 0.35mm scmd, 3) HH-linked term contracts: 1.45mm scmd, 4) HPHT term contracts: 0.5mm scmd, and 5) IGX: 0.3-0.4mm scmd.
- **CNG stations:** For FY26, MAHGL targets commissioning around 80 new CNG stations, of which 17 have already been added.
- On the cost front, APM gas continues to offer the lowest landed cost at INR24-25/scm, while NWG HPHT gas is priced at INR32-37/scm and R-LNG at INR40-42/scm.

Miss on EBITDA/scm margin; stable volume growth

- MAHGL's total volumes stood at 4.6mm scmd (+3% QoQ).
- CNG/D-PNG volumes grew 2% QoQ, while I&C-PNG volumes grew 8% QoQ.
- EBITDA/scm came in at INR8 (vs. adjusted EBITDA/scm of INR9.6 in 1QFY26).
- On a QoQ basis, adj. EBITDA/scm margin declined by INR1.6, as 1) gas cost increased INR1.4/scm QoQ to INR32.1/scm; 2) realization declined INR0.1/scm QoQ, and operating cost increased INR0.1/scm QoQ.
- Reported EBITDA came in at INR3.4b (-18%/-33% YoY/QoQ).
- MAHGL's PAT stood at INR1.9b (-33%/-39% YoY/QoQ) for the quarter.

■ **UEPL was amalgamated with MAHGL during the quarter. Accordingly, the comparative financials for 1QFY26 and 2QFY25 have been restated to reflect the impact of the amalgamation, and other quarters are not comparable. Due to the unavailability of data, we assume UEPL's EBITDA/PAT of INR160m/INR50m for 2QFY26 (similar QoQ) and total volume of 0.21mmscmd (up 30% YoY). Comparison of MAHGL SA estimated numbers vs. actuals is as below:**

- EBITDA came in 8% below our estimate at INR3.2b, as EBITDA/scm stood 8% below our estimate of INR8/scm.
- APAT stood 21% below estimates at INR1.9b.
- Total volumes came in line with our estimate at 4.4mmscmd.

Valuation and view

- We expect an 11% CAGR in volume over FY25-28, driven by multiple initiatives implemented by the company. These initiatives include collaborating with OEMs to drive conversions of commercial CNG vehicles and providing guaranteed price discounts to new I/C-PNG customers.
- MAHGL currently trades at 11.2x FY28E SA P/E. We now value MAHGL at 15x Dec'27 P/E (15x FY27 P/E earlier), resulting in a TP of INR1,700/sh. **Reiterate BUY.**

Y/E March	Standalone - Quarterly Earnings Model (INR m)												
	FY25					FY26E				FY25	FY26E	FY26	Var. (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	2QE				
Net Sales	15,896	17,863	17,576	18,649	20,814	20,493	20,452	19,935	69,983	81,694	19,475	5%	
YoY Change (%)	3.4	13.7	12.0	19.0	30.9	14.7	16.4	6.9	12.1	16.7	13.8		
EBITDA	4,185	4,135	3,144	3,784	5,007	3,380	3,615	3,497	15,247	15,498	3,510	-4%	
EBITDA/SCM	11.9	11.1	8.3	10.0	12.4	8.0	8.4	8.1	10.3	9.2	8.7	-8%	
Margins (%)	26.3	23.1	17.9	20.3	24.1	16.5	17.7	17.5	21.8	19.0	18.0		
Depreciation	719	842	791	818	959	1,038	977	940	3,170	3,914	801		
Interest	31	31	34	39	45	50	38	18	135	151	34		
Other Income	402	468	463	464	319	289	403	554	1,796	1,565	528		
PBT	3,837	3,729	2,782	3,391	4,322	2,580	3,004	3,093	13,739	12,999	3,202	-19%	
Tax	992	861	529	869	1,127	646	756	743	3,250	3,272	806		
Rate (%)	25.8	23.1	19.0	25.6	26.1	25.1	25.2	24.0	23.7	25.2	25.2		
Reported PAT	2,845	2,868	2,254	2,522	3,196	1,934	2,248	2,350	10,489	9,727	2,396	-19%	
YoY Change (%)	-22.8	-15.3	-28.9	-4.8	12.3	-32.6	-0.3	-6.8	-18.6	-7.3	-15.3		
Margins (%)	17.9	16.1	12.8	13.5	15.4	9.4	11.0	11.8	15.0	11.9	12.3		
Sales Volumes (mmscmd)													
CNG	2.8	2.9	2.9	2.9	3.2	3.3	3.4	3.4	2.9	3.3	3.1	5%	
PNG - Domestic	0.5	0.5	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	5%	
PNG - Industrial/ Commercial	0.5	0.6	0.6	0.7	0.7	0.8	0.8	0.8	0.6	0.7	0.7	6%	
PNG - Total	1.1	1.2	1.2	1.3	1.3	1.3	1.3	1.4	1.2	1.3	1.3	5%	
Total Volumes	3.9	4.0	4.1	4.2	4.5	4.6	4.7	4.8	4.1	4.6	4.4	5%	

Transport Corporation of India

Estimate change	↔
TP change	↗
Rating change	↗

Bloomberg	TRPC IN
Equity Shares (m)	77
M.Cap.(INRb)/(USDb)	92.4 / 1
52-Week Range (INR)	1309 / 875
1, 6, 12 Rel. Per (%)	-3/9/6
12M Avg Val (INR M)	43

Financial Snapshot (INR b)

Y/E MARCH	2026E	2027E	2028E
Sales	51.2	59.2	67.8
EBITDA	5.6	6.6	7.6
Adj. PAT	4.7	5.2	5.9
EBITDA Margin (%)	11.0	11.2	11.2
Adj. EPS (INR)	61.5	66.9	76.2
EPS Gr. (%)	14.9	8.8	14.0
BV/Sh. (INR)	332.9	391.8	460.0
Ratios			
Net D:E	0.0	0.0	-0.1
ROE (%)	19.8	18.2	17.7
RoCE (%)	18.9	17.5	17.1
Payout (%)	13.0	12.0	10.5
Valuations			
P/E (x)	19.6	18.0	15.8
P/BV (x)	3.6	3.1	2.6
EV/EBITDA(x)	15.8	13.4	11.3
Div. Yield (%)	0.7	0.7	0.7
FCF Yield (%)	0.3	-0.4	1.3

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	68.7	68.7	68.8
DII	12.6	12.4	12.4
FII	3.2	3.2	3.0
Others	15.4	15.7	15.8

FII Includes depository receipts

CMP: INR1,205

TP: INR1,500 (+25%)

Buy

In-line performance; outlook remains bright

- Transport Corporation of India's (TRPC) revenue grew 7.5% YoY to ~INR12b in 2QFY26 (in line). Revenue growth experienced a slowdown across segments despite the company witnessing strong demand across auto, FMCG, and consumer durables.
- EBITDA margin came in at 10.5% in 2QFY26 (+10 bp YoY and -10 QoQ), against our estimate of 10.9%. EBITDA grew 8.2% YoY to INR1.26b (6% below our estimate), while APAT grew 5.8% YoY to ~INR1.12b (in line).
- Supply Chain revenue grew ~12% YoY, while the Freight and Seaways divisions reported ~7% and 2% YoY growth, respectively. EBIT margin for Freight/Supply Chain/Seaways divisions stood at 2.3%/5.6%/37.5%, respectively, in 2QFY26. EBIT margin contracted 40bp and 30bp YoY for the Freight and Supply Chain businesses, respectively, while it expanded 630bp on a YoY basis for the Seaways business.
- In 1HFY26, revenue grew 8%, whereas EBITDA and PAT grew 12% and 11%, respectively.
- TRPC delivered muted operational performance in 2QFY26. Supply Chain growth slowed down, while the Seaways division benefited from favorable market conditions. The Freight segment's growth was weak amid sectoral weakness, partially offset by festive season restocking. **We expect growth to be driven by higher margins in the Freight business, supported by an increased LTL mix, expansion of the supply chain and cold chain networks, favorable margins in the Seaways division, and greater adoption of multimodal logistics through new ships and rakes. We retain our estimates and reiterate our BUY rating with a TP of INR1,500 (based on 20x FY28E EPS).**

Supply Chain's growth slows down, while Seaways' margin remains elevated and Freight remains flattish

- Freight Division:** It reported ~7% YoY revenue growth, impacted by weakness in the infrastructure and capital goods sectors, though partly supported by festive season restocking. EBIT margin came in at 2.3%, declining 40bp YoY.
- Supply Chain Solutions (SCS):** Revenue growth slowed to ~12% YoY despite the onboarding of new contracts and expansion in scope with existing customers. EBIT margin stood at 5.6%, contracting 30bp YoY. SCS has emerged as the largest business segment and is expected to remain the key growth driver for the company.
- Seaways Division:** Revenue grew just ~2% YoY, aided by favorable freight rates and lower fuel costs. EBIT margin expanded significantly by ~630bp YoY to 37.5%, driven by operational leverage and lower depreciation as most vessels are depreciated.

Quarterly snapshot

Y/E March (INR m)	FY25								FY26E		INR m	
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	FY25	FY26E	FY26	Var. vs Est
Net Sales	10,451	11,208	11,471	11,788	11,393	12,049	13,408	14,324	44,918	51,173	12,361	(3)
YoY Change (%)	10.0	12.8	14.5	9.3	9.0	7.5	16.9	21.5	11.6	13.9	10.3	
EBITDA	1,038	1,171	1,185	1,217	1,210	1,267	1,502	1,642	4,611	5,620	1,347	(6)
Margins (%)	9.9	10.4	10.3	10.3	10.6	10.5	11.2	11.5	10.3	11.0	10.9	
YoY Change (%)	3.0	16.6	18.6	11.2	16.6	8.2	26.7	34.9	12.3	21.9	15.1	
Depreciation	290	291	305	292	288	305	365	408	1,178	1,366	340	
Interest	42	46	59	55	54	59	44	26	202	183	42	
Other Income	109	106	68	184	113	125	130	146	467	514	120	
PBT before EO expense	815	940	889	1,054	981	1,028	1,223	1,353	3,698	4,584	1,085	
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0	
PBT	815	940	889	1,054	981	1,028	1,223	1,353	3,698	4,584	1,085	
Tax	110	109	93	121	106	125	171	208	433	611	152	
Rate (%)	13.5	11.6	10.5	11.5	10.8	12.2	14.0	15.4	11.7	13.3	14.0	
Minority Interest	-6.0	-9.0	-12.0	-9.0	-7.0	-9.0	-7.6	-6.4	-36.0	-30.0	-7.0	
Profit/Loss of Asso. Cos	211	242	225	218	197	232	190	176	896	795	205	
Reported PAT	910	1,064	1,009	1,142	1,065	1,126	1,234	1,314	4,125	4,738	1,131	
Adj PAT	910	1,064	1,009	1,142	1,065	1,126	1,234	1,314	4,125	4,738	1,131	(0)
YoY Change (%)	10.6	22.3	27.1	9.3	17.0	5.8	22.3	15.0	16.8	14.9	6.3	
Margins (%)	8.7	9.5	8.8	9.7	9.3	9.3	9.2	9.2	9.2	9.3	9.2	



Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	QUESS IN
Equity Shares (m)	149
M.Cap.(INRb)/(USDb)	36.7 / 0.4
52-Week Range (INR)	379 / 232
1, 6, 12 Rel. Per (%)	-9/-32/-34
12M Avg Val (INR M)	238

Financials & Valuations (INR b)

Y/E Mar	FY26E	FY27E	FY28E
Sales	156.6	178.8	199.9
EBITDA Margin (%)	2.0	2.0	2.1
Adj. PAT	2.2	2.5	2.9
Adj. EPS (INR)	14.8	16.7	19.2
EPS Gr. (%)	(2.4)	12.9	14.7
BV/Sh. (INR)	83.0	71.4	61.6
Ratios			
RoE (%)	21.8	28.5	37.9
RoCE (%)	25.8	33.0	43.7
Payout (%)	108.1	95.7	83.4
Dividend Yield (%)	6.5	6.5	6.5
Valuations			
P/E (x)	16.6	14.7	12.8
P/BV (x)	3.0	3.4	4.0
EV/EBITDA (x)	10.6	9.3	8.0
EV/Sales (x)	0.2	0.2	0.2

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	56.9	57.0	56.6
DII	9.8	8.7	11.0
FII	14.1	14.6	15.8
Others	19.2	19.7	16.6

FII includes depository receipts

CMP: INR246

TP: INR280 (+14%)

Neutral

Not out of the woods yet

2H to mirror 1H performance; margins peak out

- Quess Corp's revenue was up 5% QoQ/3% YoY in 2QFY26, largely in line with our expectation of 6.3% QoQ growth. EBITDA margin was up 13bp YoY at 2%, in line with our estimate. Adj PAT rose 2% QoQ to INR520m. In 1HFY26, revenue/EBITDA/adj. PAT grew 2.6%/10.5%/4.5% YoY. In 2HFY26, we expect revenue/EBITDA/adj. PAT to grow 6.5%/31.0%/7.3% QoQ. Limited growth triggers in the core general staffing (GS) business and muted operating leverage amid a slower scale-up in professional staffing (PS) and overseas businesses keep us on the sidelines. We reiterate our **Neutral** rating with a TP of **INR280**, valuing the stock at **17x Jun'27E EPS**.

Our view: PS business growth a key monitorable

- GS recovery on expected lines:** We believe GS continues to stabilize after past one-offs like the NBFC ramp-down, aided by festive demand across Manufacturing, BFSI, and Consumer-Retail-Telecom (CRT) segments. Net additions of 21k reflect improving demand visibility, supported by macro tailwinds such as rate cuts, GST 2.0, and lower taxes. Management aims to sustain 10-15k net adds QoQ and guides that 2H will remain broadly similar to 1H, which we view as a steady but not accelerating growth trajectory.
- Margins were stable at 1.4%, with PAPM in the INR670-680 range. In our view, while execution and collections remain robust, the rising dependence on Tier-3/4 sourcing keeps the business operationally intensive, which could constrain both margin expansion and productivity gains.
- Professional segment remains resilient:** PS delivered 220bp margin improvement QoQ, supported by the rationalization of low-margin contracts and healthy GCC demand. Although one client issue impacted revenue (~INR300m), the margin mix improved. With 73% of headcount now tied to GCCs and a visible mandate pipeline, growth should remain steady. In our view, the early focus on GCCs and niche roles has helped insulate this segment from broader softness in IT hiring.
- However, the segment's scale (6-7% of revenue) remains modest relative to GS, and the near-term contribution from 'Origint', despite healthy traction, is unlikely to materially move the needle for overall profitability.
- Margins at peak levels; upside capped:** Quess delivered its highest-ever EBITDA (INR770m, 2% margin, up 10bp QoQ), led by a richer mix from PS and overseas operations (~50% of total EBITDA). However, the company has reiterated its target of exiting FY26 at a 2% margin, which is in line with what we have built into our numbers and suggests limited upside from these levels. We see little headroom for margin expansion in FY27 unless high-margin PS business scales meaningfully faster than GS.

Valuation and change in estimates

- We estimate revenue growth of 4.6%/14.2% in FY26/FY27, with stable EBITDA margins of ~ 2%.
- We believe growth triggers in the core GS business remain limited, as the segment is already operating with high sourcing intensity and limited pricing flexibility. The PS segment continues to perform well but remains too small to offset GS cyclical in the near term.
- Additionally, the company's dependence on Tier-3/4 sourcing and slower overseas scale-up could constrain operating leverage, keeping margin expansion muted. **We reiterate our Neutral rating** with a TP of INR280, valuing the stock at 17x Jun'27E EPS.

In-line revenue and margins; gross additions at 115k

- Revenue was up 5% QoQ/3% YoY, in line with our expectation of 6.3% QoQ.
- GS grew 3% YoY. PS grew 11% YoY. Overseas business was up 3% YoY.
- EBITDA margin was up 13bp YoY at 2%, in line with our expectations.
- Adj PAT was up 2% YoY at INR520m.
- Gross additions stood at ~115k employees in 2Q. Industrials, BFSI and Retail were among the top recruiting sectors.
- In GS, 72 new contracts were added, while 18 new were added in PS.

Key highlights from the management commentary

- Over the last 2-3 quarters, Queso focused on stabilizing after one-off events such as the NBFC ramp-down, with efforts in 1H directed toward recovering volumes in GS.
- Festive hiring momentum led to higher net additions, supported by seasonal demand in Manufacturing, BFSI, and CRT segments. The season benefitted from macro tailwinds such as repo rate reduction, lower tax rates, and GST 2.0. The company remains confident of repeating its 1H performance in 2H.
- Strong execution in collection efficiency continues, with dominance in the 'collect-and-pay' model. Cash conversion remains stable.
- CRT remains a mature segment with a healthy pipeline and sourcing funnel. While Telecom hiring is muted, Retail and E-commerce continue to grow.
- Manufacturing is growing faster than other sub-segments.
- PS remains a high-growth, high-margin business within the portfolio, maintaining margins at 12.2%. Margins are expected to remain stable at low double digits.
- Around 73% of headcount is tied to GCC projects across digital, telecom, and technology roles.
- Broad-based strength observed across the Middle East and Malaysia, with growth in both IT and non-IT verticals. The Philippines also delivered a strong quarter.

Consolidated - Quarterly

Y/E March	FY25					FY26E				FY25	FY26E	Est. 2QFY26
	1Q*	2Q*	3Q*	4Q*	1Q*	2Q	3QE	4QE				
Net Sales	35,869	37,048	40,191	36,564	36,514	38,316	40,061	41,691	1,49,672	1,56,582	38,828	
YoY Change (%)	-22.0	-22.0	-17.0	-25.5	1.8	3.4	-0.3	14.0	9%	5%	NA	
Total Expenditure	35,236	36,355	39,567	35,891	35,817	37,549	39,240	40,798	1,47,049	1,53,405	38,043	
EBITDA	632	693	625	674	697	767	820	892	2,623	3,177	785	
Margins (%)	1.8	1.9	1.6	1.8	1.9	2.0	2.0	2.1	1.8	2.0	2.0	
Depreciation	106	105	99	102	105	102	131	131	412	470	123	
EBIT	526	588	525	572	592	665	689	761	2,211	2,707	662	
Margins (%)	1.5	1.6	1.3	1.6	1.6	1.7	1.7	1.8	1.5	1.7	1.7	
Interest	106	97	92	91	99	131	110	110	386	470	125	
Other Income	64	14	49	109	47	40	42	42	236	172	37	
PBT before EO expense	483	505	482	591	541	575	621	693	2,061	2,410	574	
Recurring Tax	-6	-4	4	-35	12	57	62	69	-41	201	52	
Rate (%)	-1.3	-0.8	0.8	-5.9	2.3	9.9	10.0	10.0	-2.0	8.3	9.0	
MI & P/L of Asso. Cos.	-0.4	0.5	0	0	1	2	0	0	1	3	0	
Adjusted PAT	490	508	478	625	528	516	559	624	2,101	2,206	522	
Extraordinary items	-1	3	61	1,580	19	0	0	0	1,643	19	0	
Reported PAT	491	505	417	-955	509	516	559	624	458	2,188	522	
YoY Change (%)	2.6	-29.7	-34.8	-201.2	3.8	2.1	34.1	-165.4	-66%	378%	NA	
Margins (%)	1.4	1.4	1.0	-2.6	1.4	1.3	1.4	1.5	0.3	1.4	1.3	

*Note: FY25 figures are re-stated for Demerger.

Automobiles

CVs and 2Ws see revival in 2Q, PV demand remains weak

TVS outperforms in 2Ws, MM and Toyota in PVs, MM in CVs

- After a weak 1Q, 2Ws recovered to deliver a flat 1H performance, and CVs posted 8% growth in 2Q over a low base. However, PV volumes posted a 1.5% decline in 2Q.
- In the 2W segment, only scooters posted 4% YoY growth in 1H. On the other hand, motorcycle sales declined 2% YoY, while moped sales declined 7% YoY.
- In motorcycles, HMSI continues to outperform peers in the 125cc segment. Meanwhile, in the premium segment (150-250cc), TVS has been narrowing the gap with market leader BJAUT, with the difference now at just 70bp.
- In scooters, TVSL captured the highest share of 28.5% in 1H (+530bp YoY).
- In PVs, UV's contribution increased to 66% in 1H. However, the UV segment slowed down to just 1% growth in 1H. MM, Toyota, and Kia outperformed in the PV segment.
- In the CV segment, while MHCV goods grew 1%, all other segments (LCV goods and passenger segments of MHCV and LCV) grew 5% each in 1H.
- M&M continues to outperform in LCV goods, and its market share now stands at 50% (+180bp YoY). In MHCV goods, VECV stood out among the top three players, expanding its market share by 50bp to 18%.
- MSIL is our top pick among auto OEMs as its new launches and the current export momentum are expected to drive healthy earnings growth. We also like MM given the uptrend in tractors and healthy growth in UVs. We are positive on HMIL due to its healthy new launch pipeline and strong exports outlook. In 2Ws, we are positive on TVS Motors.

ICE 2Ws: Only scooters post positive growth in 1H

- Two-wheeler domestic (ICE) sales grew 7% YoY in 2QFY26 and 19% QoQ. However, for 1H, they marginally declined YoY due to a weak 1Q.
- In 1H, only scooters posted 4% YoY growth, while motorcycle sales declined 2% YoY and moped sales declined 7% YoY.
- Among major players, TVS gained 250bp share to 19%, while RE gained 110bp share YoY to 5.3%.
- On the other hand, all three 2W majors witnessed a decline in market share during 1H. HMSI lost ~200bp, while BJAUT and HMCL lost ~90bp each.

Segmental trends: Motorcycles down 2% but scooters up 4% in 1H

Motorcycle segment:

- Domestic motorcycle sales declined 2% YoY in 1H.
- Outperformers included RE (+27%) and TVSL (+9%).
- As a result, RE gained 190bp share to 8.3%, while TVSL gained 110bp share to 10.9%.
- On the other hand, both HMCL and BJAUT lost ~100bp share each in 1H.

100cc segment:

- While the 100cc segment posted 4.5% YoY growth in 2Q, it declined 4% YoY in 1H due to a weak 1Q.
- HMCL continued to strengthen its position in this segment, gaining 320bp share to reach 81% in 1H. The gain largely came from HMSI, which saw a sharp 280bp decline in its 100cc share to 4.6%.
- This was primarily due to the discontinuation of HMSI's Dream series models in this segment, along with weak demand for Livo (-38%) and Shine100 (-23%).
- For HMCL, Splendor volumes declined 1% YoY in 1H. While the HF series grew 2% and Passion recorded a 4% YoY increase.

125cc segment:

- The segment posted a 5.5% YoY decline in volumes in 1H.
- HMSI was the only player to post growth in this segment in 1H (+7% YoY).
- As a result, HMSI gained a 570bp share, reaching 50%.
- The largest share loss was witnessed by HMCL (-460bp to 15.3%), followed by BJAUT (-140bp to 23.1%).
- For HMCL, no material pick-up in volumes has been seen so far, despite the launch of its new Glamour X.

150-250cc segment:

- The 150-250cc segment also posted a 2% YoY decline in volumes for 1H.
- Among major players, TVS was the only player to post a strong 30% YoY growth in this segment.
- As a result, TVSL gained a 740bp share to reach ~30% in this segment, narrowing the gap with market leader BJAUT, which lost ~140bp share to 30.6%.
- Further, while HMSI lost a 200bp share to 19.4%, India Yamaha lost 330bp share to 16.6%.

>250cc segment:

- This segment has been a key growth driver for the industry in the recent past, posting a robust 24.5% YoY growth in 1H.
- Key outperformers in this segment were TVSL (+47%), RE (+27%), and HMSI (+24%). For RE, the key growth driver for 1H was Bullet 350, which posted an 84% YoY growth.

ICE scooters segment

- The ICE scooters' volumes posted 4% YoY growth for 1H.
- Apart from HMSI, which saw a 9% YoY decline in volumes, all other key players posted healthy growth for 1H.
- Overall, TVSL captured the largest share, reaching 28.5% in 1H (+530bp YoY).
- Further, while Suzuki gained about 110bp share to 17.2%, HMCL gained 50bp share to 5.5%.
- On the other hand, market leader HMSI saw a 640bp loss in share to 43.8%.
- For TVS, Jupiter remains the key growth driver, posting a 46% YoY growth.
- For HMCL, Destini 125 was the key growth driver, growing 57% YoY in 1H.

- For HMSI, its biggest underperformer was the Dio model, which saw a 21% YoY decline in 1H.
- For Suzuki Motorcycles, Burgman was one of its key growth drivers, posting 36% YoY growth (crossed 28k units in Sep'25).

PV update: UV mix now stands at 66% for 1H

- For 1HFY26, the PV industry posted 1% YoY decline in volumes.
- Key outperformers in the industry were MM (+14%), Toyota (+10%), and Kia (+3%).
- As a result, MM gained 200bp share to 14.5% in 1H, while Toyota gained 90bp share to 8.1%.
- On the other hand, MSIL lost 180bp share to 38.8%, while HMIL lost 110bp share to 13.3%, and TTMT lost 50bp share to 13.3%.

Car segment:

- The car segment's volumes declined 6% YoY in 1H.
- Within cars, the small car segment saw a significant decline in volumes: Alto (-34%), Spresso (-38%), Kwid (-38%), and Celerio (-49%).
- Even within compact cars, HMIL models like Grand i-10 (-21%) and i-20 (-26%) saw a sharp decline in volumes.
- Another notable trend in the mid-size car segment is that the VW Virtus now commands a 50% share of this sub-segment in 1H.
- Moreover, a key growth driver for MSIL in the car segment has been the new Dzire, which posted 38% YoY growth in 1H (clocking 20k units in Sept).
- Overall, MSIL has strengthened its position in cars, gaining a 70bp share in 1H to 66.2%.

UV segment:

- The UV segment posted just ~1% YoY growth in 1H.
- Outperformers included MM (+14%), Toyota (+13%), and Kia (+3%).
- On the other hand, MSIL (-8%), Hyundai (-7%), and TTMT (-3%) underperformed the segment in 1H.
- As a result, MM gained 260bp share to 22%, while Toyota gained 110bp share to 10.3%.
- Key growth drivers for MM in 1HFY26 were Thar Roxx (+71% YoY) and its new EVs (sold 23k units in 1HFY26). For MM, XUV700 (-5%) and XUV 3XO (-14%) seem to have peaked out.
- Moreover, while MSIL lost 210bp share to 23.5%, HMIL lost 110bp share to 14%.
- For MSIL, key underperformers included Brezza (-9%) and Grand Vitara (-33%), while Ertiga saw its first-ever 1% YoY volume decline in 1H. The company wholesaled 4,261 units of the newly launched Victoris for Sept and sold 3k units of the e-Vitara in the export market in Sept, and 6k units over Aug-Sep.
- For TTMT, underperformers included Punch (-28% YoY) and Safari (-23%). On the other hand, Nexon and Harrier volumes grew sharply by 24% each, with Harrier's volume growth supported by strong sales of Harrier EV.

- Creta was the only model to record volume growth for Hyundai in 1HFY26, growing 3% YoY. Key underperformers included Exter (-21%), Venue (-11%), and Alcazar (-7%).
- For Kia Motors, the Syros appears to have received a tepid response from customers, with Sept sales at just 465 units and 1H sales at 7.6k units.
- Another key highlight is the strong performance of Toyota's Urban Cruiser Hyryder, which grew 47% YoY to 45k units in 1H.

CV update – Domestic CVs up 4% YoY for 1H

- Domestic CVs posted a healthy recovery in 2Q, growing 8% YoY over a low base. Hence, despite a weak 1Q, 1H growth for domestic CVs stood at 4%.
- For 1H, the LCV goods, MHCV passenger, and LCV passenger segments each posted 5% YoY growth, while the MHCV goods segment saw a 1% YoY growth.
- Overall, MM gained 120bp share in domestic CVs, reaching 30%. On the other hand, TTMT lost 170bp share to 34%.

MHCV goods:

- As highlighted above, this segment posted just 1% YoY growth in 1H.
- Among the top three players, VECV outperformed with 4% YoY growth.
- As a result, its market share improved 50bp YoY to 18%.
- TTMT's market share remained stable at 49%, while for AL, it marginally declined to 30%.

LCV goods:

- This segment posted 5% YoY growth in 1H.
- Except TTMT (-3% YoY), all players posted growth in 1H.
- The biggest gainer in this segment is MM: +180bp YoY to 50%.
- On the other hand, TTMT lost a sizeable share of 240bp to 27%.

Bus segment:

- In the passenger segment, both MHCV and LCV segments posted a 5% YoY growth in 1HFY26.
- In the LCV passenger segment, Force Motors outperformed with a 15% YoY growth, thereby gaining a 440bp share to 51%.
- On the other hand, TTMT lost 160bp share to 24% in 1H.

Valuation and view

- Following the GST rationalization, demand has picked up across segments, especially for the festive season. A notable trend is that entry-level vehicles, both 2Ws and PVs, are seeing a marked pickup in demand. With a recovery in demand, we expect discounts to gradually reduce after the festive season.
- MSIL is our top pick among auto OEMs, as its new launches and the current export momentum are likely to drive healthy earnings growth. We also like MM, given the uptrend in tractors and healthy growth in UVs. We are positive on HMIL, driven by its healthy new launch pipeline. In 2Ws, we are positive on TVS Motors.

FOMC Oct'25: Fed eases, RBI set to follow

- The Fed cut rates by 25bp to 3.75-4.00%, as expected, and announced it will end Quantitative Tightening (QT) from 1st Dec'25 to ease money-market liquidity pressures. Inflation remains elevated but stable, giving the Fed some room to support a weakening labor market.
- With no new projections or dot plot, markets looked to Chair Powell's press conference. Powell sounded cautious, stressing that future rate cuts are not guaranteed and will depend on upcoming inflation and jobs data. Powell also pointed to uncertainty caused by the US government data delays and emphasized the need to balance growth and inflation risks.
- Market reaction was muted, as the decision was fully priced in. The US Treasury yields ticked up slightly, and the US dollar strengthened modestly after Powell's cautious remarks. In India and other EMs, investors took comfort from the global easing backdrop but were mindful that the Fed is signaling a pause rather than a rapid series of further cuts.
- At the same time, the Trump-Xi meeting in South Korea eased trade tensions and raised hopes of partial tariff rollbacks, boosting global risk sentiment and further supporting equities and EM currencies. Meanwhile, the BOJ kept policy unchanged but signaled readiness to normalize gradually, hinting at a possible rate hike in Dec'25.
- The Fed is likely to delay or skip another cut in Dec'25, given Powell's cautious tone and internal uncertainty. Further action will hinge on clearer data on inflation and labor markets.
- **Implications for India:** The Fed's 25bp rate cut reinforces the global shift toward monetary easing, reducing pressure on EM currencies and encouraging capital inflows into Indian bonds and equities. Softer global yields and improved liquidity conditions are expected to support the rupee and lift overall market sentiment. In India, real interest rates remain high, giving the RBI room to cut rates without risking price stability. Inflation is under control, but growth remains uneven. Further, the pending trade deal with the US continues to weigh on exports and investor confidence. Against this backdrop, the RBI is likely to focus on supporting growth. We expect the RBI to cut rates by 25bp in Dec'25, supported by benign inflation and a favorable global backdrop. A second cut in early 2026 is likely if growth remains below aspirational levels and inflation is contained.

■ Policy action

1. **The FOMC cut the policy rate by 25bp to the 3.75-4.00% range**, in line with expectations, while retaining its data-dependent guidance. Inflation remains sticky but stable, giving the Fed space to support a softening labor market. The policy statement noted that inflation remains above target but is trending lower, while labor market conditions have softened modestly with slower job gains and a gradual rise in unemployment.
2. **The Fed also announced that it will suspend its quantitative tightening (QT) program** and resume full reinvestment of maturing Treasuries beginning 1st Dec'25, to ease money-market liquidity strains.
3. The Fed acknowledged that overall economic activity continues to expand at a moderate pace, but risks to both employment and inflation are now seen as more balanced than earlier in the year.

■ Powell's message

1. In his post-meeting remarks, Chair Powell emphasized that the Fed's future policy moves will remain data-dependent, cautioning that another cut in December is not guaranteed.
2. He noted that the lack of key economic data due to the US government shutdown leaves the Fed operating with incomplete information and that there are differing views within the FOMC about the need for additional cuts.

■ **Market Reaction: Muted**

1. The market's reaction was largely muted, as the decision was widely priced in. US Treasury yields ticked up slightly, and the dollar strengthened modestly after Powell's cautious tone. EMs, including India, benefited from the global easing backdrop, with Indian equities gaining and foreign inflows improving on expectations of better liquidity, though investors remained mindful that the Fed is signaling a pause rather than a rapid easing cycle.
2. At the same time, the Trump–Xi meeting in South Korea eased trade tensions and raised hopes of partial tariff rollbacks, while the BOJ held rates steady but signaled readiness to normalize gradually, hinting at a possible December hike to counter a weak yen. These developments together boosted global risk sentiment and supported EM currencies.

■ **Outlook: Fed unlikely to cut rates in Dec'25**

1. The Fed is likely to delay or skip another cut in December, given Powell's cautious tone and internal uncertainty.
2. Further action will hinge on clearer data on inflation and labor markets.

■ **Implications for India**

1. The Fed's 25bp rate cut reinforces the global shift toward monetary easing, giving EMs more room to lower rates without triggering outflows. Softer global yields and improving liquidity conditions could support Indian bonds and reduce pressure on the rupee, allowing the RBI to shift focus toward domestic growth concerns.
2. In India, real interest rates remain high, giving the RBI room to lower policy rates without risking price instability. Inflation is well within target, while growth indicators are mixed. Overall, the outlook remains uncertain, as the pending trade deal with the US continues to weigh on export prospects and investment sentiment.
3. Against this backdrop, the RBI is likely to prioritize growth support through measured rate cuts. We expect the RBI to cut rates by 25bp in Dec'25. A second cut in early 2026 is likely if growth remains below aspirational levels and inflation is contained.

Exhibit 1: Real repo rate at 7-year high in India





Exhibit 2: Central bank balance sheet (% of GDP)



BSE SENSEX **S&P CNX**
84,404 25,878

Conference Call Details



Date: 31st October 2025

Time: 16:00 IST

Dial in details: +91 22 6280
1241 / +91 22 7115 8142

[Webcast link](#)

Financials & Valuations (INR b)

Y/E Mar	FY26E	FY27E	FY28E
Sales	101.9	103.9	110.5
EBITDA	30.6	31.3	31.9
EBITDA Margin (%)	30.0	30.1	28.9
PAT	43.0	42.8	44.7
EPS (INR)	17.4	17.3	18.1
EPS Gr. (%)	-1.5	-0.6	4.5
BV/Sh. (INR)	258.5	278.3	299.2
Ratios			
RoE (%)	44.7	44.9	43.0
RoCE (%)	3.0	2.8	2.6
Payout (%)	62.2	60.5	59.1
Valuations			
P/E (x)	0.4	0.4	0.4
P/BV (x)	0.0	-0.1	-0.1
EV/EBITDA (x)	9.7	8.9	8.7
Div yld (%)	5.5	5.2	5.0

CMP: INR777

Buy

Westpark launch and Dahlias incremental sales drive bookings

Robust pipeline

Residential performance

- In 2QFY26, DLF reported bookings of INR43b, up 6x YoY and down 62% QoQ (55% above our estimate). In 1HFY26, bookings were at INR157.6b, up 2x YoY.
- This impressive performance was fueled by healthy sales from its maiden launch 'The Westpark' in Mumbai in 2QFY26 which contributed ~53% of sales. ~37% of sales came from Dahlias in the quarter.
- Collections increased 13% YoY while it declined 4% QoQ to INR27b (40% below estimates). Consequently, OCF increased 12% YoY while it declined 15% QoQ to INR14b. Net cash stood at INR77b in the quarter vs. INR80b in 1QFY26.
- After the Westpark launch, the medium-term launch pipeline stands at INR602b. The company guided for launches worth INR172b+ in FY26, of which DLF has already achieved 80% in 1HFY26.

Rental performance (DCCDL)

- The overall occupancy in DCCDL's office portfolio was stable at 93% (98% - non-SEZ / 86% - SEZ / 97% Retail).
- Rental income increased 15% YoY to INR13.6b, driven by steady growth across the portfolio.
- Net debt increased to INR174b from INR173b in 1QFY26, with net debt to GAV of 0.20x. Cost of debt declined to 7.3% in the quarter from 7.67% in 1QFY26.

P&L highlights

- In 2QFY26, DLF's revenue came in at INR16.4b, down 17%/40% YoY/QoQ (33% below estimates). In 1HFY26, revenue came in at INR43.6b, up 31% YoY.
- EBITDA was down 44%/22% YoY/QoQ to INR2.8b (61% below estimates). EBITDA margin stood at 17.3%. In 1HFY26, EBITDA came in at INR6.5b, down 11% YoY.
- PAT stood at INR11.8b, -15%/+55% YoY/QoQ (8% above estimates) with margin at 72% due to one off reversal of impairment loss towards JV business and one time receipt of interest recognised under extra-ordinary item and other income respectively. In 1HFY26, PAT stood at INR19.4b, down 4% YoY with 45% margin.

Quarterly performance

Y/E March	FY25				FY26E				FY25	FY26E	FY26E	Variance (%/bp)	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q					
Gross Sales	13,624	19,750	15,287	31,276	27,167	16,430	24,993	33,277	79,937	1,01,867	24,451		-33
YoY Change (%)	-4.3	46.5	0.5	46.5	99.4	-16.8	63.5	6.4	24.4	27.4	23.8		
Total Expenditure	11,337	14,730	11,287	21,496	23,525	13,595	17,483	16,656	58,850	71,259	17,104		
EBITDA	2,286	5,020	4,000	9,780	3,642	2,836	7,510	16,621	21,086	30,608	7,347		-61
Margins (%)	16.8	25.4	26.2	31.3	13.4	17.3	30.0	49.9	26.4	30.0	30.0		-1279bps
Depreciation	373	377	387	369	345	295	390	559	1,507	1,589	382		
Interest	1,012	935	939	1,086	786	631	789	1,011	3,972	3,217	772		
Other Income	3,675	2,058	2,088	2,202	2,642	6,188	1,625	-3,833	10,022	6,621	1,589		
PBT before EO expense	4,576	5,766	4,761	10,527	5,153	8,097	7,955	11,218	25,630	32,423	7,782		4
Extra-Ord expense	0	0	3,024	0	0	-2,352	0	0	3,024	-2,352	0		
PBT	4,576	5,766	1,737	10,527	5,153	10,449	7,955	11,218	22,606	34,775	7,782		34
Tax	1,183	-4,668	-8,396	1,666	1,332	2,763	2,001	2,653	-10,214	8,749	933		
Rate (%)	25.9	-81.0	-483.3	15.8	25.8	26.4	25.2	23.6	-45.2	25.2	12.0		
MI & P/L of Asso. Cos.	3,054	3,378	6,183	4,108	3,806	4,116	4,172	4,911	16,723	17,004	4,082		
Reported PAT	6,447	13,812	16,316	12,969	7,627	11,801	10,125	13,477	49,544	43,030	10,931		8
Adj PAT	6,447	13,812	10,587	12,822	7,627	11,801	10,125	13,477	43,668	43,030	10,931		8
YoY Change (%)	22.5	122.1	61.5	39.4	18.3	-14.6	-4.4	5.1	60.3	-1.5	-20.9		
Margins (%)	47.3	69.9	69.3	41.0	28.1	71.8	40.5	40.5	54.6	42.2	44.7		2712bps

Operational Metrics

Residential (INRb)

Pre-sales	64	7	121	20	114	43	43	32	212	233	28		55
Collections	30	24	31	33	28	27	41	75	118	170	44		-40
Net Debt	-29	-28	-45	-68	-80	-77	0	-20	-68	-20	0		

Source: Company, MOFSL

We currently have a 'BUY' rating for DLF. However, estimates are under review and we will revise them after the earnings call

BSE SENSEX
84,404

S&P CNX
25,878

Conference Call Details


Date: 31st Oct 2025

Time: 4:00pm IST

Dial-in details:
[Diamond Pass Registration](#)

Financials & Valuations (INR b)

Y/E March	2026E	2027E	2028E
Sales	147.0	166.8	189.1
Sales Gr. (%)	11.8	13.5	13.4
EBITDA	34.2	38.7	44.0
EBITDA Margin (%)	23.3	23.2	23.3
Adj. PAT	24.5	28.1	32.1
Adj. EPS (INR)	24.1	27.7	31.6
EPS Gr. (%)	16.8	14.6	14.3
BV/Sh.(INR)	108.1	122.2	138.3
Ratios			
RoE (%)	23.6	24.0	24.3
RoCE (%)	22.0	22.5	22.8
Payout (%)	49.3	49.2	49.0
Valuations			
P/E (x)	61.9	54.0	47.2
P/BV (x)	13.8	12.2	10.8
EV/EBITDA (x)	43.5	37.8	33.3
Div. Yield (%)	0.8	0.9	1.0

CMP: INR1,487
Neutral

Steady performance with consistent volume growth

Consolidated performance

- **Consol. sales grew by 10% YoY to INR35.5b (est. INR35.2b).**
- Underlying volume growth (UVG) remained strong at 10.3% (est. 7%, 9.9% in 1QFY26). UVG was 10.4% for C&B businesses and 9.9% for B2B businesses.
- Consumer & Bazaar (C&B) segment revenue was up 10% YoY at INR28.4b (est. INR27.8b), EBIT grew 11% YoY to INR8.6b (est. INR8.5b), and EBIT margins expanded by 40bp YoY to 30.2%.
- B2B segment revenue rose 8% YoY to INR7.6b (est. INR7.7b), EBIT increased by 11% to INR1.2b (est. INR1.3b), and EBIT margins expanded by 40bp YoY to 15.2%.
- **Gross margins expanded by ~70bp YoY to 55% (est. 54.8%).**
- Employee expenses rose 8% YoY and other expenses were up by 15% YoY.
- EBITDA margin improved marginally 20bp YoY to 23.9% (est. 24.2%).
- **EBITDA grew 11% YoY to INR8.5b (est. INR8.5b).**
- PBT was up 8% YoY at INR7.9b (est. INR8.2b).
- Adj. PAT increased 9% YoY to INR5.8b (est. INR6.1b).
- In 1HFY26, net sales/EBITDA/APAT grew by 10%/13%/14%.

International business

- Domestic subsidiaries' C&B revenue grew 17% YoY and EBITDA grew 41%. Domestic B2B revenue grew 1% YoY, while EBITDA declined 173%.
- Middle East and Africa revenue grew 3% and EBITDA decline 3%. Asia revenue grew 6% and EBITDA grew 4%.

Consolidated - Quarterly Earning

Y/E March	FY25								FY26		FY25	FY26E	FY26 Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	9.3	11.1			
Volume growth (%)	9.6	8.0	9.7	9.8	9.9	10.3	12.0	12.0	9.3	11.1	7.0		
Net Sales	33,954	32,349	33,689	31,411	37,531	35,544	38,379	35,518	1,31,403	1,46,964	35,204	1.0	
YoY change (%)	3.7	5.2	7.6	8.2	10.5	9.9	13.9	13.1	6.1	11.8	8.8		
Gross Profit	18,268	17,583	18,301	17,288	20,314	19,563	21,032	19,658	71,440	80,566	19,292	1.4	
Margin (%)	53.8	54.4	54.3	55.0	54.1	55.0	54.8	55.3	54.4	54.8	54.8		
Total Expenditure	25,826	24,661	25,705	25,086	28,121	27,037	28,962	28,593	41,315	46,338	26,673		
EBITDA	8,127	7,688	7,984	6,326	9,410	8,507	9,417	6,925	30,125	34,228	8,531	-0.3	
YoY change (%)	15.0	13.1	7.5	9.6	15.8	10.7	17.9	9.5	11.3	13.6	11.0		
Margins (%)	23.9	23.8	23.7	20.1	25.1	23.9	24.5	19.5	22.9	23.3	24.2		
Depreciation	844	879	895	967	967	1,000	970	756	3,585	3,692	967		
Interest	118	117	125	144	138	133	135	185	504	591	135		
Other Income	539	571	558	804	857	502	725	977	2,472	3,061	750		
PBT	7,704	7,263	7,522	6,019	9,162	7,877	9,037	6,961	28,509	33,006	8,179	-3.7	
Tax	1,984	1,848	1,947	1,487	2,383	2,027	2,259	1,582	7,265	8,252	2,045		
Rate (%)	25.7	25.4	25.9	24.7	26.0	25.7	25.0	22.7	25.7	25.0	25.0		
Reported PAT	5,669	5,346	5,524	4,223	6,724	5,799	6,722	5,319	20,762	24,534	6,079	-4.6	
Adj PAT	5,669	5,346	5,524	4,473	6,724	5,799	6,722	5,319	21,012	24,534	6,079	-4.6	
YoY change (%)	21.1	18.7	8.2	20.2	18.6	8.5	21.7	18.9	16.7	16.8	13.7		
Margins (%)	16.7	16.5	16.4	14.2	17.9	16.3	17.5	15.0	16.0	16.7	17.3		

E: MOFSL Estimates

Consolidated segmental performance

Consol. revenue (INR m)	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26
Consumer & Bazaar	26,609	25,083	25,413	22,472	27,408	25,805	26,726	23,976	30,067	28,365
% YoY	9%	3%	5%	6%	3%	3%	5%	7%	10%	10%
C&B volume growth (%)	12%	8%	10%	13%	8%	6%	7%	8%	9%	10%
Business to business	6,780	6,153	6,373	7,079	7,256	7,036	7,572	8,089	8,066	7,613
% YoY	-6%	-1%	6%	12%	7%	14%	19%	14%	11%	8%
B2B volume growth (%)	0%	20%	20%	25%	18%	21%	22%	16%	13%	10%
Consol. EBIT (INR m)										
Consumer & Bazaar	7,078	6,935	7,704	5,448	8,039	7,710	7,865	6,178	9,458	8,575
% margin	26.6%	27.6%	30.3%	24.2%	29.3%	29.9%	29.4%	25.8%	31.5%	30.2%
% YoY	32%	32%	43%	19%	14%	11%	2%	13%	18%	11%
Business to business	917	685	757	835	1,103	1,040	1,335	1,415	1,329	1,158
% margin	13.5%	11.1%	11.9%	11.8%	15.2%	14.8%	17.6%	17.5%	16.5%	15.2%
% YoY	22%	38%	93%	18%	20%	52%	76%	69%	20%	11%

Lodha Developers

BSE SENSEX
84,404

S&P CNX
25,878

Conference Call Details



Date: 31 October 2025

Time: 13:00 IST

Dial-in details:

+91-22 22 6280 1197 / +91 22
7115 8098

Financials & Valuations (INR b)

Y/E Mar	FY26E	FY27E	FY28E
Sales	181.1	189.3	193.3
EBITDA	51.6	53.9	55.1
EBITDA Margin (%)	28.5	28.5	28.5
PAT	36.9	40.5	43.0
EPS (INR)	37.0	40.6	43.1
EPS Gr. (%)	33.6	9.8	6.2
BV/Sh. (INR)	235.0	271.3	310.1
Ratios			
RoE (%)	16.9	16.0	14.8
RoCE (%)	13.9	13.8	13.3
Payout (%)	11.5	10.5	9.9
Valuations			
P/E (x)	31.7	28.9	27.2
P/BV (x)	5.0	4.3	3.8
EV/EBITDA (x)	23.2	21.2	20.4
Div yld (%)	0.4	0.4	0.4

CMP: INR1,171

Buy

Strong financials beat and steady presales

Operational performance

- In 2QFY26, presales rose 7%/3% YoY/QoQ to INR45.7b (in line with our estimates). In 1HFY26, they rose 8% YoY to INR90.2b.
- With the Supreme Court approving the Environmental Clearance (EC) process in late August for certain projects, the company is set for significant project launches in the second half of the year.
- Collections rose 13%/21% YoY/QoQ to INR34.8b (13% below our estimates) and are expected to strengthen in 2HFY26. In 1HFY26, collections rose 10% YoY to INR63.6b.
- The company has added one new project in MMR with a GDV of INR23b in 2QFY26. With this, the company was able to achieve its full-year BD guidance of INR250b in 1HFY26 itself (six new projects added in MMR, Pune, and Bengaluru).
- Net debt increased ~INR2.7b to INR53.7b in 2QFY26, yet below the ceiling of 0.5x Net Debt/Equity.

Financial performance

- LODHA reported revenue of INR38b, +45%/+9% YoY/QoQ (17% above estimates). In 1HFY26, it reported INR73b in revenue, rising 33% YoY.
- EBITDA (excl. other income) rose 57% YoY/13% QoQ to INR11.1b (19% above our estimates). Reported EBITDA margin stood at 29%. According to management, the embedded EBITDA margin for presales stood at ~32% in 2Q. Adjusted EBITDA (excluding interest charge-off and capitalized interest) stood at INR13.1b, with a margin of 34.5%. In 1HFY26, EBITDA stood at INR21b, up 43% YoY, with a margin of 29%. Embedded EBITDA margin for presales stood at ~32%. Adjusted EBITDA (excluding interest charge-off and capitalized interest) stood at INR25.1b, with a margin of 34.4%.
- Reported PAT came in at INR7.9b, rising 86% YoY and 17% QoQ (19% above estimates), while adjusted PAT came in at INR7.9b, rising 88% YoY with a 21% margin. In 1HFY26, reported and adjusted PAT rose 63% YoY each at INR14.6b and INR14.7b, respectively, with a 20% adjusted PAT margin.

Quarterly performance

Y/E March	FY25					FY26E				FY25	FY26E	FY26E	2QE Var	
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	2Q Est.	(%/bp)				
Gross Sales	28,465	26,257	40,830	42,243	34,917	37,985	50,707	57,488	1,37,795	1,81,097	32,597	17		
YoY Change (%)	76	50	39	5	23	45	24	36	33.6	31.4	24.1			
Total Expenditure	20,897	19,211	27,771	30,036	25,073	26,897	36,256	41,259	97,915	1,29,484	23,307			
EBITDA	7,568	7,046	13,059	12,207	9,844	11,088	14,452	16,229	39,880	51,613	9,290	19		
Margins (%)	26.6	26.8	32.0	28.9	28.2	29.2	28.5	28.2	28.9	28.5	28.5			
Adj. EBITDA (as per co.)	9,600	9,600	15,900	14,600	12,000	13,100	14,452	12,061	49,700	52,100	9,290	41		
Margins (%)	33.7	36.6	38.9	34.6	34.4	34.5	28.5	21.0	36.1	28.8	28.5			
Depreciation	604	665	672	778	659	714	901	943	2,719	3,216	579			
Interest	1,172	1,365	1,441	1,517	1,478	1,565	923	-669	5,495	3,297	593			
Other Income	718	589	636	1,960	1,330	804	649	-466	3,903	2,317	417			
PBT before EO expense	6,510	5,605	11,582	11,872	9,037	9,613	13,276	15,490	35,569	47,416	8,535	13		
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0			
PBT	6,510	5,605	11,582	11,872	9,037	9,613	13,276	15,490	35,569	47,416	8,535	13		
Tax	1,747	1,368	2,137	2,637	2,284	1,710	2,945	3,578	7,889	10,517	1,893			
Rate (%)	26.8	24.4	18.5	22.2	25.3	17.8	22.2	23.1	0.2	0.2	22.2			
Minority Interest & Profit/Loss of Asso. Cos.	10	8	1	18	6	16	10	5	37	37	7			
Reported PAT	4,753	4,229	9,444	9,217	6,747	7,887	10,321	11,907	27,643	36,862	6,635	19		
Adj PAT (as per co.)	4,800	4,200	9,400	9,200	6,800	7,900	10,321	11,841	27,600	36,862	6,635	19		
YoY Change (%)	182	100	65	37	42	88	10	29	70.4	33.6	58.0			
Margins (%)	16.9	16.0	23.0	21.8	19.5	20.8	20.4	20.6	20.0	20.4	20.4	44bp		

E: MOFSL Estimates

Key operational performance

Key metrics	FY25					FY26E				FY25	FY26E	FY26E	2QE Var	
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	2Q Est.	(%/bp)				
Sale Volume (msf)	2.4	2.4	3.0	3.4	3.3	3.5	4.2	4.0	11	15	3	1.4		
Sale Value (INRb)	40.3	42.9	45.1	48.1	44.5	45.7	54.0	69.1	176	213	47	-2.2		
Collections (INRb)	26.9	30.7	42.9	44.4	28.8	34.8	46.3	73.0	145	183	40	-13.2		
Realization (INR/sft)	14,708	17,716	15,011	13,971	13,390	12,920	12,920	12,920	15,654	14,226	13,390	-3.5		

United Spirits

BSE SENSEX	S&P CNX
84,404	25,878

Concall Details


Date: 31st Oct 2025

Time: 4:00PM IST

Dial in:

+91 22 6280 1250 /
+91 22 7115 8151

[Diamond Pass](#)
[Registration](#)

Financials & Valuations (INR b)

Y/E March	2026E	2027E	2028E
Sales	124.6	136.3	148.4
Sales Gr. (%)	7.7	9.3	8.9
EBITDA	22.1	24.4	27.2
Margin (%)	17.8	17.9	18.3
PAT	15.4	17.1	19.4
EPS (INR)	21.3	23.6	26.7
EPS Gr. (%)	7.7	11.0	13.0
BV/Sh.(INR)	129.7	153.3	181.3
Ratios			
RoE (%)	16.4	15.4	14.7
RoCE (%)	19.2	17.8	16.9
Payout (%)	56.3	67.7	67.4
Valuations			
P/E (x)	63.6	57.3	50.7
P/BV (x)	10.4	8.8	7.5
EV/EBITDA (x)	42.6	38.2	33.8

CMP: INR1,399
Neutral
Beat in performance; all-time high operating margins

Standalone performance

- Standalone net sales up 11.5% YoY to INR31.7b (est. INR30.4b) in 2QFY26 on weak base of 1% decline in 2QFY25.
- Growth was supported by its re-entry into Andhra Pradesh and the strong performance of innovation and renovation launches, partially offset by adverse policy changes in Maharashtra.
- Total volume rose 8% (est. 6%), with P&A volume increased 8% YoY (est. 6% YoY, 9% in 1QFY26) to 13.9m cases. Popular volume rose 6% YoY (est. 5% YoY, 12% in 1QFY26) to 2.7m cases.
- P&A revenue (90% revenue mix) rose 12% YoY and Popular revenue grew 9% YoY.
- Gross margin saw a sharp expansion of 190bp YoY to 47.1% (est. 45.2%, 44% in 1Q).
- GP margin expansion was led by last year's headline pricing, ongoing revenue growth management initiatives, an improved product mix, sustained productivity gains, and relatively stable input cost inflation across key commodities.
- Employee expenses rose 8%, other expenses rose 13%, while A&P spends declined 6%.
- EBITDA margin expanded 340bp YoY to 21.2% (est. 18.5%), recording an all-time high.
- EBITDA rose 32% YoY to INR6.7b (est. INR5.6b).
- PBT increased 48% YoY to INR6.6b (est. INR5.1b).
- APAT rose 48% YoY to INR4.9b (est. INR3.8b).
- There was an exceptional item of INR300m toward severance costs related to a closing unit.
- In 1HFY26, net sales, EBITDA and APAT grew 10%, 13%, and 25%.

Quarterly Performance

(INR m)

Y/E March	FY25					FY26E				FY25	FY26E	FY26	2QE	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE						
Volume growth %	3.5	-4.4	10.2	6.9	9.4	7.7	4.0	2.8	4.1	5.7	5.8			
Total revenues	23,520	28,430	34,320	29,460	25,490	31,700	36,585	30,874	1,15,730	1,24,649	30,385	4.3%		
YoY change (%)	8.3	-0.8	14.8	10.5	8.4	11.5	6.6	4.8	8.2	7.7	6.9			
Gross Profit	10,460	12,850	15,350	13,100	11,210	14,930	16,573	13,130	51,760	55,843	13,734	8.7%		
Margin (%)	44.5	45.2	44.7	44.5	44.0	47.1	45.3	42.5	44.7	44.8	45.2			
Total Exp	18,940	23,360	28,440	24,410	21,340	24,980	29,890	26,314	95,150	1,02,524	24,764			
EBITDA	4,580	5,070	5,880	5,050	4,150	6,720	6,695	4,560	20,580	22,125	5,621	19.5%		
Margins (%)	19.5	17.8	17.1	17.1	16.3	21.2	18.3	14.8	17.8	17.8	18.5			
EBITDA growth (%)	18.9	7.8	19.7	39.5	-9.4	32.5	13.9	-9.7	20.5	7.5	10.9			
Depreciation	650	690	720	680	680	650	685	727	2,740	2,742	685			
Interest	220	250	200	220	490	210	240	250	890	1,190	245			
Other income	320	340	720	750	610	760	700	380	2,130	2,450	385			
PBT	4,030	4,470	5,680	4,900	3,590	6,620	6,470	3,963	19,080	20,643	5,076	30.4%		
Tax	1,040	1,120	1,480	1,340	900	1,600	1,630	1,065	4,980	5,196	1,279			
Rate (%)	25.8	25.1	26.1	27.3	25.1	24.2	25.2	26.9	26.1	25.2	25.2			
Adj. PAT	2,990	3,350	4,203	3,798	2,963	4,945	4,840	2,897	14,341	15,447	3,797	30.2%		
YoY change (%)	24.8	5.3	20.7	62.3	-0.9	47.6	15.1	-23.7	25.8	7.7	13.3			
Extraordinary inc/(Exp)	0	0	527	713	-383	-300	0	0	1,239	857	0			
Reported PAT	2,990	3,350	4,730	4,510	2,580	4,720	4,840	2,897	15,580	15,447	3,797.0			

E: MOFSL Estimate

Coromandel International

BSE SENSEX
84,404

S&P CNX
25,878

Conference Call Details



Date: 31st Oct, 2025

Time: 02:30 pm IST

Concall link:

[Click here](#)

CMP: INR2,174

Buy

Operating performance in line

- CRIN reported overall revenue of INR96.5b (est. INR85.8b) in 2QFY26, up ~30% YoY. Nutrient & other allied business revenue grew 28% YoY to INR86.6b, while crop protection business revenue grew 42% YoY to ~INR10.7b.
- Total manufactured fertilizer volume (NPK + DAP) dipped 1% YoY to ~1.1mmt, and total phosphate fertilizer manufacturing volumes (including SSP) declined 2% YoY to 1.29mmt.
- EBITDA margins contracted 120bp YoY to 11.9% (est. 13%); RM costs as % of sales: 76.3% in 2QFY26 vs. 74.9% in 2QFY25; employee costs: 2.7% vs. 2.5%, freight costs: 4.1% vs. 5% and other expenses: 5% vs. 4.5%. EBITDA grew 18% YoY to INR11.5b (in line).
- EBIT margin for Nutrient & other allied business dipped 130bp YoY to 11.4%, while EBIT margin for crop protection business contracted ~80bp YoY to 13.6%.
- Adj. PAT stood at ~INR8.1b (in line), up 21% YoY for the quarter.
- CRIN's 1HFY26 revenue/EBITDA/Adj. PAT grew 37%/30%/34% to INR167b/INR19.3b/INR13.1b. Total manufactured fertilizer volume (NPK + DAP) grew 4% YoY to ~2mmt, and total phosphate fertilizer manufacturing volumes (including SSP) grew 4% YoY to 2.38mmt.

Quarterly Performance

Y/E March	(INR m)								FY25	FY26E	FY26	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
Consolidated	47,288	74,328	69,352	49,884	70,423	96,541	82,083	58,477	2,40,852	3,07,524	85,817	12
Net Sales												
YoY Change (%)	-16.9	6.4	26.9	27.5	48.9	29.9	18.4	17.2	9.2	27.7	15.5	
Total Expenditure	42,231	64,581	62,134	45,624	62,602	85,076	73,851	53,227	2,14,569	2,74,756	74,641	
EBITDA	5,058	9,748	7,218	4,260	7,821	11,465	8,233	5,249	26,283	32,768	11,176	3
Margins (%)	10.7	13.1	10.4	8.5	11.1	11.9	10.0	9.0	10.9	10.7	13.0	
Depreciation	653	690	708	854	1,206	1,018	1,215	1,220	2,904	4,658	1,210	
Interest	574	661	731	659	680	1,018	550	450	2,624	2,698	660	
Other Income	541	650	1,137	1,260	837	1,165	1,307	1,389	3,587	4,698	900	
PBT before EO expense	4,372	9,047	6,916	4,007	6,773	10,595	7,775	4,968	24,342	30,110	10,206	
Extra-Ord expense	0	0	0	-3,468	0	0	0	0	-3,468	0	0	
PBT	4,372	9,047	6,916	7,475	6,773	10,595	7,775	4,968	27,810	30,110	10,206	
Tax	1,125	2,328	1,752	1,524	1,757	2,660	1,957	1,250	6,728	7,624	2,569	
Rate (%)	25.7	25.7	25.3	20.4	25.9	25.1	25.2	25.2	24.2	25.3	25.2	
MI & P/L of Asso. Cos.	137	79	46	154	-34	-119	-80	100	417	-133	-50	
Reported PAT	3,110	6,641	5,118	5,797	5,050	8,053	5,898	3,618	20,665	22,619	7,687	
Adj PAT	3,110	6,641	5,118	3,036	5,050	8,053	5,898	3,618	18,036	22,619	7,687	5
YoY Change (%)	-37.1	-12.3	121.6	89.4	62.4	21.3	15.2	19.2	9.8	25.4	15.8	
Margins (%)	6.6	8.9	7.4	6.1	7.2	8.3	7.2	6.2	7.5	7.4	9.0	

BSE Sensex 84,404	S&P CNX 25,878
----------------------	-------------------

Conference Call Details



Date: 31st October 2025

Time: 02:30 PM IST

Dial-in details:

[Link](#)

Financials & Valuations (INR b)

Y/E March	FY25	FY26E	FY27E
NII	53.3	57.8	73.3
Total Income	57.5	72.3	88.5
PPoP	27.9	38.4	48.9
PAT (pre-NCI)	5.8	16.7	25.1
PAT (post-NCI)	3.8	15.1	23.3
EPS (INR)	8.9	35.6	54.9
EPS Gr. (%)	-81	299	54
BV (INR)	292	324	374
Ratios (%)			
NIM	6.8	6.5	6.7
C/I ratio	51.5	46.9	44.8
Credit cost	2.8	2.7	2.1
RoA	0.9	2.2	2.8
RoE	3.3	11.5	15.7
Valuations			
P/E (x)	60.7	15.2	9.9
P/BV (x)	1.9	1.7	1.4

CMP: INR542

BUY

Earnings beat with off-book gaining traction; Strong gold loan growth

Asset quality stress persists in MFI, unsecured MSME and micro-LAP

- IIFL Finance's (IIFL) 2QFY26 NII grew 7% YoY and ~11% QoQ to ~INR14.4b (inline). Other income stood at ~INR4.9b (PQ: INR3.8b). This was primarily due to higher assignment income of ~INR3.5b (PQ: INR2.3b).
- Net total income grew ~22% YoY to ~INR19.3b. Opex grew ~19% YoY to INR8.7b (~6% higher than MOSLe), with the cost-income ratio declining to ~45% (PQ: 48% and PY: 46%). PPoP stood at INR10.6b and grew ~24% YoY (~15% beat).
- Credit costs stood at INR5b (inline). This translated into annualized credit costs of ~3.4% (PQ: ~3.65% and PY: ~3.6%). NPAs were impacted by macro trends in MFI, unsecured business/personal and small-ticket LAP.
- PAT (post NCI) in 2QFY26 stood at INR3.8b (~27% beat).

Consol. AUM grew ~35% YoY; Strong 27% QoQ growth in gold loans

- Consol. AUM grew 35% YoY and ~7% QoQ to INR901b. On-book loans grew ~34% YoY. Off-book formed ~32% of the AUM mix, with co-lending forming ~13% of the AUM mix.
- Gold loan AUM stood at ~INR346b and rose ~27% QoQ. Home loan AUM was flat QoQ while MSME loans declined ~4% QoQ and MFI declined ~6% QoQ.

NIM rose ~25bp QoQ; calc. yields rose ~25bp QoQ

- Consolidated yields rose ~25bp QoQ to ~13% while CoB rose 10bp QoQ to ~9.9%.
- NIM (calc.) rose ~25bp QoQ

GS3 declines ~20bp QoQ; Credit costs elevated

- GS3 declined ~20bp QoQ to ~2.14% while NS3 declined ~10bp QoQ to ~1%. PCR rose ~50bp QoQ to ~52.8%. NPAs were impacted by macro trends in MFI, unsecured business/personal loans and small-ticket LAP.
- Portfolio reset** with the company sharing that it has exited unsecured MSME, micro-LAP & high-risk MFI geographies.
- IIFL (standalone) CRAR stood at ~18.6% as of Sep'25.

Valuation & View

- IIFL Finance delivered a mixed performance during the quarter, with robust AUM growth led by the gold loan segment, while momentum across other segments remained subdued. Off-book (assignments) and co-lending (in gold loans) is gaining traction and contributing positively to the off-book income. Although GS3 and NS3 ratios improved sequentially, credit costs remained elevated owing to continued stress in the MFI, unsecured lending, and micro-LAP portfolios. NIMs expanded during the quarter, supported by higher portfolio yields.
- The stock trades at 1.4x FY27E P/BV and ~10x P/E. We might revise our estimates after the earnings call on 31th Oct'25.

IIFL Finance (Consolidated): Quarterly Performance

Y/E March	FY25					FY26E				FY25	FY26E	2QFY26E	v/s Est.
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q					
Interest Income	24,721	23,181	22,308	24,833	25,835	28,209	30,466	30,002	95,043	1,14,513	27,902	1	
Interest Expenses	10,340	9,788	9,957	11,694	12,888	13,819	14,303	15,745	41,695	56,756	13,584	2	
Net Interest Income	14,381	13,394	12,352	13,139	12,947	14,390	16,163	14,257	53,348	57,757	14,318	1	
YoY Growth (%)	9.7	-6.0	-21.6	-20.2	-10.0	7.4	30.9	8.5	-10.4	8.3	6.9		
Other Income	-43	2,467	1,051	810	3,758	4,882	3,415	2,488	4,202	14,543	3,728	31	
Total Income	14,338	15,861	13,402	13,949	16,705	19,272	19,578	16,745	57,550	72,301	18,045	7	
YoY Growth (%)	-1	-2	-21	-10	17	22	46	20	-8.5	25.6	13.8		
Operating Expenses	7,461	7,329	7,478	7,367	8,017	8,702	9,038	8,173	29,634	33,931	8,248	6	
Operating Profit	6,878	8,531	5,925	6,582	8,688	10,570	10,381	8,730	27,916	38,369	9,199	15	
YoY Growth (%)	-14.9	-8.9	-38.2	-16.6	26.3	23.9	75.2	32.6	-19.9	37.4	7.8		
Provisions & Loan Losses	2,516	4,063	4,914	3,487	5,125	5,003	3,753	3,089	14,980	16,969	4,817	4	
Profit before Tax	4,362	4,468	1,011	3,095	3,563	5,567	6,629	5,641	7,070	21,400	4,382	27	
Exceptional items		-5,865				0					0		
Tax Provisions	980	-466	193	581	821	1,388	1,538	951	1,289	4,698	1,017	36	
PAT (Pre NCI)	3,382	-931	818	2,514	2,742	4,179	5,091	4,690	5,782	16,702	3,365	24	
NCI	501	646	410	437	408	416	449	326	1,994	1,600	404	3	
PAT (Post NCI)	2,881	-1,577	408	2,077	2,334	3,763	4,642	4,364	3,788	15,102	2,961	27	
YoY Growth (%)	-32	-133	-92	-44	-19	-339	1,038	110	-79	299	-288		
Key Parameters (%)													
Yield on AUM	13.3	13.58	12.9	13.3	12.7	12.97	13.1	12.2					
Cost of funds	9.5	9.72	9.5	9.7	9.8	9.88	9.8	10.1					
Spread	3.8	3.9	3.4	3.5	3.0	3.1	3.2	2.1					
NIM (on AUM)	7.7	7.8	7.1	7.0	6.4	6.6	6.9	5.9					
Credit cost	2.09	3.61	4.2	2.67	3.65	3.42	2.4	1.8					
Cost to Income Ratio (%)	52.0	46.2	55.8	52.8	48.0	45.2	46.5	48.4					
Tax Rate (%)	22.5	-10.4	19.1	18.8	23.1	24.9	23.2	16.9					
Balance Sheet Parameters	-11.8	-3.8											
Consol. AUM (INR B)	696	670	714	783	839	901	964	1,003					
Change YoY (%)	2	-8	-8	-1	21	35	35	28					
Disbursements - Core (INR B)	43	73	176	197	191	235	212	176					
Change YoY (%)	-71	-54	6	21	345	223	20	-11					
Borrowings (INR B)	414	391	451	509	545	574	588	654					
Change YoY (%)	8	-3	5	11	32	47	30	28					
Borrowings/AUM (%)	59.5	58.4	63.2	65.0	65.0	63.7	61.0	65.2					
Debt/Equity (x)	3.4	3.3	3.7	4.1	4.3	4.5	4.1	4.2					
Asset Quality (%)													
GS 3 (INR M)	10,231	10,687	12,028	12,253	13,170	12,534							
G3 %	2.25	2.40	2.42	2.23	2.34	2.14							
NS 3 (INR M)	4,982	4,756	4,956	5,685	6,295	5,916							
NS3 %	1.1	1.08	1.0	1.0	1.1	1.02							
PCR (%)	51.3	55.5	58.8	53.6	52.3	52.8							
ECL (%)	2.9	3.2	2.8	2.2	2.1	1.9							
Return Ratios - YTD (%)													
ROA (Rep)	2.3	0.8	0.8	0.9	1.6	1.9							
ROE (Rep)	10.3	2.3	2.0	3.4	7.6	9.8							

E: MOSL Estimates

Vedant Fashions

BSE SENSEX	S&P CNX
84,404	25,878

Conference Call Details



Date: 31st Oct 2025

Time: 3:30pm IST

Financials & Valuations (INR b)

Y/E March	FY26E	FY27E	FY27E
Sales	14.8	15.8	17.1
EBITDA	6.7	7.2	8.0
Adj. PAT	4.2	4.5	5.0
EBITDA Margin (%)	45.5	45.8	46.9
Adj. EPS (INR)	17.1	18.7	20.8
EPS Gr. (%)	6.9	9.2	11.3
BV/Sh. (INR)	80.1	90.0	100.1
Ratios			
Net D:E	(0.5)	(0.6)	(0.6)
RoE (%)	20.7	20.1	19.9
RoCE (%)	19.4	19.2	19.2
Payout (%)	50.0	50.0	50.0
Valuations			
P/E (x)	44.1	40.4	36.3
EV/EBITDA (x)	27.3	25.0	22.3
EV/Sales (X)	12.4	11.5	10.5

CMP: INR673

Neutral

Another weak quarter; revenue/EBITDA declines

2%/9% YoY YoY

- Customer sales grew 4.6% YoY to INR3.5b, driven largely by ~5% YoY store additions as SSS declined 2% YoY.
- Consolidated 2Q revenue declined 2% YoY to INR2.6b (weaker vs. our estimate of +1% YoY), due to low wedding days and the transitory impact of GST implementation.
- Vedant Fashions closed net 13 stores (net closure of eight domestic EBOs and seven SIS offset by two EBO additions internationally). However, net area inched up 3.5k sq ft QoQ to 1.79m sq ft (up 5% YoY).
- Gross profit (GP) declined 7% YoY to INR1.9b, as gross margin contracted 375bp YoY to 71.6% (355bp miss). Including job work charges, GP declined ~6% YoY, with margins contracting ~270bp YoY.
- Employee cost increased 14% YoY (8% higher), while other expenses declined ~7% YoY (10% lower).
- EBITDA declined ~9% YoY to INR1.1b (8% miss), driven by weaker revenue growth and lower gross margin.
 - EBITDA margin contracted ~340bp YoY to 42.1% (~220bp miss).
 - Pre-IND AS EBITDA for 1HFY26 came in at INR1.39b (down 8% YoY), with margins at 25.5% (down 420bp YoY).
- Depreciation/Finance cost rose 12%/9% YoY, while other income rose ~3% YoY.
- As a result, reported PAT declined ~16% YoY to INR0.56b (14% miss).
- For 1HFY26, revenue grew at a modest 7% YoY (on a low base), but **remains ~5% below 1HFY23 levels**, while **EBITDA/PAT declined 1%/2% YoY**.
- OCF (post interest and leases) stood at INR186m (vs. INR55m outflow YoY), driven by favorable WC movement. FCF (post interest and leases) came in at INR74m (vs. INR77m outflow YoY).
 - Overall WC capital days declined to 201 (vs. 247 YoY), led by a sharp decline in receivable days to 158 (vs. 220 YoY), partly offset by lower payable days at 20 (vs. 35 YoY). Inventory days were broadly steady YoY at ~63.

Consol P&L (INR m)

	2QFY25	1QFY26	2QFY26	YoY%	QoQ%	2QFY26E	v/s Est (%)
Total Revenue	2,679	2,812	2,632	-2	-6	2,709	-3
Raw Material cost	659	777	746	13	-4	672	11
Gross Profit	2,021	2,035	1,885	-7	-7	2,037	-7
Gross margin (%)	75.4	72.4	71.6	-377.4	-72.9	75.2	-355.7
Employee Costs	145	156	165	14	6	152	8
Other expenses	656	673	613	-7	-9	684	-10
EBITDA	1,220	1,206	1,108	-9	-8	1,201	-8
EBITDA margin (%)	45.5	42.9	42.1	-342.7	-78.5	44.3	-223.0
Depreciation and amortization	373	398	417	12	5	410	2
EBIT	847	808	691	-18	-14	791	-13
EBIT margin (%)	31.6	28.7	26.3	NM	NM	29.2	-294.8
Finance Costs	137	141	150	9	6	141	6
Other income	192	258	199	3	-23	221	-10
Exceptional item	0	0	0	NM	NM	0	NM
Profit before Tax	902	925	740	-18	-20	871	-15
Tax	233	222	180	-23	-19	219	-18
Tax rate (%)	25.8	24.1	24.3	-6.1	0.9	25.2	-3.6
Profit after Tax	669	703	561	-16	-20	652	-14
Adj Profit after Tax	669	703	561	-16	-20	652	-14
	2QFY25	1QFY26	2QFY26	YoY%	QoQ%	2QFY26E	v/s Est (%)

Operating metrics	2QFY25	1QFY26	2QFY26	YoY%	QoQ%
SSSG (%)	17.3%	17.6%	-2.0%		
Retail area (m sqft)	1.70	1.78	1.79	5	1
Total stores	650	684	671	3	-2
Net store adds	-12	6	-13	NM	NM
EBOs	528	530	524	-1	-1
Domestic	512	516	508	-1	-2
International	16	14	16	0	14
SIS	122	154	147	20	-5

Dr. Agarwal's Health Care

BSE SENSEX	S&P CNX
84,404	25,878

Conference Call Details


Date: 31 October 2025

Time: 11:30 am IST

Dial-in details:
[Diamond Pass Link](#)

Financials & Valuations (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Sales	20.5	24.7	29.7
EBITDA	5.4	6.6	8.1
Adj. PAT	1.2	1.6	2.5
EBIT Margin (%)	13.8	15.7	16.7
Cons. Adj. EPS (INR)	3.7	5.1	7.9
EPS Gr. (%)	41.1	37.5	52.7
BV/Sh. (INR)	63.2	68.4	76.2
Ratios			
Net D:E	-0.1	-0.1	-0.1
RoE (%)	6.1	7.8	10.9
RoCE (%)	8.8	10.2	12.7
Payout (%)	0.0	0.0	1.0
Valuations			
P/E (x)	136.9	99.5	65.2
EV/EBITDA (x)	30.3	24.4	19.9
EV/Sales (x)	0.0	0.0	0.0
Div. Yield (%)	-6.4	4.3	2.1
FCF Yield (%)	7.9	6.5	5.4

CMP: INR519

Revenue in line; earnings beat expectations

- DAHL's 2QFY26 revenue grew 19.7% YoY to INR5.0b (in line with our estimate).
- India revenue rose 19.8% YoY to INR4.4b, contributing 89% of total revenue. International revenue grew 18.9% YoY to INR454m (11% of total revenue) during the quarter.
- Mature facilities reported 12.7% YoY growth to INR3.7b (83% of revenue), while new facilities delivered a strong 75% YoY growth to INR0.7b.
- EBITDA margin expanded 160bp YoY to 27.3% (our estimate: 26.2%), driven primarily by lower raw material costs (down 90bp YoY as % of sales) and employee expenses (down 70bp YoY).
- Consequently, EBITDA grew 27.3% YoY to INR1.36b (our estimate: INR1.3b).
- PAT came in at INR297m in 2QFY26, up from INR165m in 2QFY25, backed by improved operational performance, lower finance costs, and a reduced tax rate.
- For 1HFY26, revenue/EBITDA/PAT grew 20%/25%/108% YoY, driven by facility expansion and operational efficiencies.
- The company added 24 new centers during 1HFY26, expanding its network to 258 facilities, while surgeries increased 14.6% YoY to 157,281 during the same period.
- Service sales accounted for 78% of total revenue, whereas product sales contributed 22% in 1HFY26.

Dr. Agarwal Healthcare Quarterly perf. (Consol.) (INRm)

Y/E March	FY25				FY26E				FY25	FY26	2QE	vs Est
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE				
Net Sales	4,035	4,166	4,307	4,602	4,874	4,987	5,169	5,445	17,110	4,958	0.6%	
YoY Change (%)			29.5	31.9	20.8	19.7	20.0	18.3		28.4		19.0
Total Expenditure	2,998	3,096	3,211	3,272	3,596	3,626	3,830	4,059	12,578	3,659		
EBITDA	1,037	1,070	1,096	1,330	1,279	1,361	1,339	1,386	4,532	1,299	4.8%	
YoY Change (%)			23.2	24.2	23.3	27.3	22.1	4.2		25.1		21.4
Margins (%)	25.7	25.7	25.4	28.9	26.2	27.3	25.9	25.4		26.5		26.2
Depreciation	555	572	582	604	630	679	640	587	2,313	630		
EBIT	482	498	514	726	649	683	699	799	2,220	669	2.1%	
YoY Change (%)			10.7	18.4	34.7	37.2	35.9	10.0		15.7		34.4
Interest	270	284	284	250	247	226	340	439	1,088	274		
Other Income	60	119	127	154	134	79	131	147	460	120		
PBT before EO expense	272	333	358	630	536	537	490	507	1,592	515	4.2%	
Extra-Ord expense	0	0	-52	45	0	0	0	0	7	0		
PBT	272	333	409	585	536	537	490	507	1,599	515	4.2%	
Tax	89	119	128	160	155	172	144	129		495		150
Rate (%)	32.6	35.9	31.2	27.3	29.0	32.0	29.4	25.5		31.0		29.2
MI & P/L of Asso. Cos.	62	48	59	100	80	68	75	73	269	97		
Reported PAT	121	165	223	326	301	297	271	306	835	268	11.0%	
Adj PAT	121	165	187	358	301	297	271	306	832	268	11.0%	
YoY Change (%)			-5.6	-7.4	148.3	79.5	44.7	-14.7		0.2		61.7
Margins (%)	3.0	4.0	4.3	7.8	6.2	6.0	5.2	5.6		4.9		5.4
EPS	0.4	0.5	0.6	1.1	1.0	0.9	0.9	1.0	2.7	0.9	11.0%	

BSE SENSEX 84,997 **S&P CNX** 26,054

Conference Call Details



Date: 31st October 2025

Time: 15:00 hrs IST

Concall link:

[Click here](#)

CMP: INR417

BUY

Operating performance beats estimates

- LT Foods reported revenue of INR27.7b (+31% YoY, +12% QoQ) (est. INR36b).
- Consolidated EBITDA was INR 3.1b (+35% YoY, +17% QoQ) (Est. INR2.9b).
- Consolidated EBITDA margin stood at 11.2% (+30bp YoY, +40bp QoQ) (est 11%), led by a gross margin expansion of 80bp YoY, offset by a 60bp YoY increase in other expenses.
- Adjusted PAT stood at INR1.6b (+10% YoY, -3% QoQ) (in line).
- In 1HFY26, Revenue/EBITDA/Adj. PAT grew 25%/22%/10% YoY to INR52.3b/INR5.7b/INR3.3b.

Segmental performance in 2QFY26

- The Basmati & Other Specialty Rice segment's revenue grew 36% YoY to INR23.6b (including the Golden Star acquisition), and EBITDA stood at INR3.1b (up 47%). Gross/EBITDA margin stood at 34%/13%, rising 300bp/100bp YoY, while volumes grew 32% YoY.
- The Organic Foods segment's revenue grew 21% YoY to INR2.9b, and EBITDA stood at INR114m. Gross/EBITDA margins contracted 1100bp/800bp YoY to 33%/3.9% due to the higher initial cost of commissioning a new plant in Europe.
- The Convenience & Health segment's revenue grew 9% YoY to INR480m. Gross margin contracted 1,100bp to 31%, and operating loss stood at INR72m.
- Region-wise, India/North America/EU grew 13%/47%/31%, while the Middle East declined 18% for 1HFY26.

Consolidated - Quarterly Earning Model

(INRm)

Y/E March	FY25				FY26E				FY25	FY26E	FY26 Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			
Gross Sales	20,705	21,078	22,748	22,284	24,639	27,657	27,472	27,497	86,815	1,07,265	25,958
YoY Change (%)	16.4	6.6	17.2	7.4	19	31.2	20.8	23.4	11.7	23.6	23.2
Total Expenditure	18,296	18,785	20,250	19,701	21,985	24,563	24,218	24,107	77,032	94,873	23,095
EBITDA	2,409	2,293	2,498	2,583	2,654	3,094	3,254	3,389	9,783	12,392	2,863
Margins (%)	11.6	10.9	11	11.6	10.8	11.2	11.8	12.3	11.3	11.6	11
Depreciation	420	448	458	531	523	599	540	550	1,857	2,212	530
Interest	187	196	236	257	280	280	180	139	877	880	235
Other Income	175	263	134	313	371	67	250	230	885	918	150
PBT before EO expense	1,977	1,911	1,938	2,107	2,221	2,283	2,784	2,930	7,934	10,218	2,248
PBT	1,977	1,911	1,938	2,107	2,221	2,283	2,784	2,930	7,934	10,218	2,248
Tax	530	494	525	554	598	653	724	762	2,102	2,736	585
Rate (%)	26.8	25.8	27.1	26.3	26.9	28.6	26	26	26.5	26.8	26
Minority Interest & P/L of Asso. Cos.	-84	-66	-19	-52	-62	-8	0	0	-222	-70	0
Reported PAT	1,532	1,484	1,433	1,605	1,685	1,639	2,060	2,168	6,053	7,552	1,664
Adj PAT	1,532	1,484	1,433	1,605	1,685	1,639	2,060	2,168	6,053	7,552	1,664
YoY Change (%)	11.4	-7.2	-5.2	7.9	10	10.4	43.8	35.1	1.3	24.8	12.1
Margins (%)	7.4	7	6.3	7.2	6.8	5.9	7.5	7.9	7	7	6.4

BSE SENSEX
 84,404

S&P CNX
 25,878

CMP: INR144
Neutral
Conference Call Details

Date: 30 Oct 2025

Time: 14:30 HRS IST

Dial in:

+91 22 6280 1145

+91 22 7115 8046

Financials & Valuations (INRb)			
Y/E March	FY26E	FY27E	FY28E
Sales	6.1	6.2	6.6
EBITDA	5.2	5.2	5.5
Adj. PAT	4.7	4.8	5.2
EPS (INR)	5.3	5.4	5.8
EPS Gr.%	13.1	3.4	6.4
BV/Sh. (INR)	14.4	16.6	18.9
Ratios			
Net D:E	(0.2)	(0.3)	(0.4)
RoE (%)	39.4	35.1	32.6
RoCE (%)	38.5	34.4	32.1
Payout (%)	60.0	60.0	60.0
Valuation			
P/E (x)	27.3	26.4	24.8
P/B (x)	10.0	8.6	7.6
EV/EBITDA (x)	24.1	23.6	22.0
Div. yield (%)	2.2	2.3	2.4

Revenue/EBITDA in line; PAT beats on higher other income

- IEX reported standalone revenue in line with our est. at INR1.5b in 2QFY26 (+9.3% YoY, +8.8% QoQ), with traded electricity volumes of 35.2BUs, in line with est.
- EBITDA stood at INR1.3b, marking a 9.7%/15.9% uptick YoY/QoQ, in line with our estimates. EBITDA margin stood at 86.7% (vs. 81.4% in 1QFY26, 86.4% in 2QFY25).
- Standalone PAT was 5% above our estimate at INR1.2b (+14.6% YoY, +7.6% QoQ), mainly on account of higher-than-expected other income.
- IGX recorded a PAT of INR96m, up 57% YoY from INR61m.
- **Operational performance:**
 - Electricity volumes rose 16% YoY to 35.2BUs in 2QFY26.
 - In the electricity segment, day ahead market (DAM) and term ahead market (TAM) volumes were flat YoY, whereas real time market (RTM) volumes registered 39% YoY growth in 2QFY26.
 - Renewable energy certificate (REC) volumes saw a dip in 2QFY26, declining 30% YoY to 4.4m certificates.
 - DAM and RTM prices dropped to INR3.93/unit (-12.5% YoY) and INR3.51/unit (-16% YoY), respectively, on account of increased liquidity due to higher generation from hydro, wind, and sustained coal-based generation.
 - Indian Gas Exchange (IGX) traded gas volumes of 16.1m MMBtu in 2QFY26 (+37% YoY).
 - International Carbon Exchange (ICX) issued over 3.8m I-RECs in 2QFY26 and reported revenue of INR19m.

Y/E March	Standalone quarterly performance								(INR m)					
	FY25				FY26E				FY25	FY26E	FY26E	Var.	YoY	QoQ
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		2QE	%	%	%	
Net Sales	1,236	1,392	1,313	1,413	1,400	1,522	1,558	1,588	5,354	6,068	1,542	-1%	9.3	8.8
YoY Change (%)	18.8	28.3	13.9	16.5	13.3	9.3	18.6	12.4	19.2	13.3	10.7			
EBITDA	1,000	1,203	1,128	1,220	1,139	1,320	1,347	1,378	4,551	5,184	1,315	0%	9.7	15.9
Margin (%)	81.0	86.4	85.9	86.3	81.4	86.7	86.5	86.8	85.0	85.4	85.2			
Depreciation	52	53	54	53	54	57	51	42	212	204	54	5%	6.9	4.7
Interest	7	7	7	6	6	5	7	8	26	26	7	-19%	-19.2	-8.1
Other Income	308	286	285	310	425	345	289	209	1,189	1,269	285	21%	20.6	-18.9
PBT before EO items	1,249	1,429	1,353	1,471	1,504	1,603	1,579	1,537	5,502	6,222	1,539			
PBT	1,249	1,429	1,353	1,471	1,504	1,603	1,579	1,537	5,502	6,222	1,539	4%	12.1	6.6
Tax	315	368	322	351	374	387	389	384	1,356	1,533	379	2%	5.0	3.5
Rate (%)	25.2	25.8	23.8	23.8	24.8	24.1	24.6	25.0	24.6	24.6	24.6			
Reported PAT	934	1,061	1,031	1,120	1,130	1,216	1,190	1,153	4,146	4,689	1,159	5%	14.6	7.6
Adj PAT	934	1,061	1,031	1,120	1,130	1,216	1,190	1,153	4,146	4,689	1,159	5%	14.6	7.6
YoY Change (%)	26.0	28.0	15.5	17.8	21.0	14.6	15.3	3.0	21.4	13.1	9.3			
Margin (%)	75.6	76.2	78.6	79.3	80.8	79.9	76.4	72.6	77.5	77.3	75.2			

BSE SENSEX
84,404

S&P CNX
25,878

Conference Call Details



Date: 31st Oct'25

Time: 11:00am IST

Dial-in details:
[click here](#)

CMP: INR1,674

BUY

Operating performance above our estimates

- Consolidated revenue grew 11.7% YoY to INR10.4b (est. in line).
- Gross margin expanded 70bp YoY to 18.8%.
- Adjusted EBITDA grew 10.1% YoY to INR1.1b (est. INR 1.2b).
- Adjusted EBITDA margin contracted ~20bp YoY to 10.8% (est. 11%).
- Adj. PAT grew 33% YoY to INR960m (est. in line).
- 1HFY26, Revenue/Adj. EBITDA/Adj. PAT grew 13%/16%/36% to INR20.8b/INR2.2b/INR1.9b.

Segmental performance

- Lead business revenue grew 11% YoY to INR9.3b, led by a 5% YoY volume growth. Volume stood at 44.2KMT in 2QFY26. EBITDA/MT stood at INR23,196 (up 7% YoY) for the quarter.
- Aluminum business revenue jumped 37% YoY to INR942m. Volumes stood at 4.5KMT, up 27% YoY, while EBITDA/MT declined 20% YoY to INR14,785.
- Plastic business revenue declined 32% YoY to INR130m, and its volume dipped 32% YoY to 2KMT. EBITDA/MT declined 4% YoY to INR10,122.

Consolidated - Quarterly Earning Model

(INR m)

Y/E March	FY25				FY26				FY25	FY26E	FY26E	Var %	
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE					
Sales	9,079	9,274	9,964	10,371	10,399	10,355	12,062	12,488	38,688	45,305	10,655	-3	
YoY Change (%)	29.1	10.9	31.5	20.1	14.5	11.7	21.1	20.4	22.4	17.1	17.1	17.4	
Total Expenditure	8,166	8,259	8,942	9,286	9,282	9,237	10,780	11,209	34,652	40,508	9,480		
Adjusted EBITDA	912	1,015	1,023	1,085	1,117	1,118	1,282	1,279	4,036	4,797	1,174	-5	
Margins (%)	10.1	10.9	10.3	10.5	10.7	10.8	10.6	10.2	10.4	10.6	10.6	11.0	
Depreciation	65	72	76	78	87	92	110	122	291	412	100		
Interest	130	120	128	56	61	78	55	60	434	254	60		
Other Income	33	23	73	194	190	165	160	150	324	665	100		
PBT before EO expense	751	847	891	1,146	1,159	1,113	1,277	1,247	3,635	4,797	1,114		
PBT	751	847	891	1,146	1,159	1,113	1,277	1,247	3,635	4,797	1,114		
Tax	71	128	111	197	229	153	192	132	506	706	167		
Rate (%)	9.4	15.1	12.4	17.2	19.7	13.8	15.0	10.6	13.9	14.7	15.0		
MI & P/L of Asso. Cos.	7	-1	1	-2	-2	0	1	2	5	1	1		
Reported PAT	673	720	779	951	933	960	1,085	1,113	3,124	4,090	946		
Adj PAT	673	720	779	951	933	960	1,085	1,113	3,124	4,090	946	1	
YoY Change (%)	29.3	24.4	29.3	37.9	38.5	33.3	39.2	17.0	30.6	30.9	40.5		
Margins (%)	7.4	7.8	7.8	9.2	9.0	9.3	9.0	8.9	8.1	9.0	8.9		

E: MOFSL Estimates

Restaurant Brands

BSE SENSEX 84,404 **S&P CNX** 25,878

Conference Call Details



Date: 31st Oct 2025

Time: 9:30am IST

Dial-in details:

[Diamond Pass Registration](#)

Financials & Valuations (INR b)

Y/E March	2026E	2027E	2028E
Sales	28.9	33.7	38.8
Sales Gr. (%)	13.1	16.9	15.0
EBITDA	3.6	5.4	6.9
EBITDA Margin (%)	12.6	16.0	17.7
Adj. PAT	-1.4	-0.4	0.2
Adj. EPS (INR)	-2.4	-0.6	0.4
EPS Gr. (%)	N/M	N/M	L/P
BV/Sh. (INR)	13.0	12.3	12.7
Ratios			
RoE (%)	-16.8	-5.1	3.1
RoCE (%)	0.8	5.1	7.7
Valuations			
P/E (x)	N/M	N/M	188.3
P/BV (x)	5.5	5.8	5.7
EV/EBITDA (x)	11.2	7.4	5.6
pre Ind-AS			
EV/EBITDA (x)	56.7	18.5	12.3
EV/ Sales (x)	1.4	1.2	1.0

CMP: INR72

Buy

Inspiring India performance with 3% SSSG & 16% EBITDA growth

Consolidated performance

- India business revenue grew 16% YoY to INR5.7b (est. INR5.6b), led by 15% YoY store additions.
- Same-store sales growth (SSSG) stood at 2.8% (est. 2.5%), led by consistent growth across dine-in & delivery channels.
 - India business ADS rose 1% YoY to INR119k.
 - The company added 14 stores in 2QFY26 in India, taking the total store count to 533.
 - The BK Café store count reached 507 (95% of total BK stores).
- India GP was up 17% YoY to INR3.9b (est. INR3.8), while margin improved 80bp YoY and 60bp QoQ to 68.3%, backed by a change in menu mix and supply chain efficiencies.
- **India ROM (Pre-Ind-AS) increased 14% YoY to INR592m, while the margin dipped 20bp YoY to 10.4% (est. 10.2%).**
- **EBITDA (Pre-Ind-AS) rose 16% YoY to INR284m. The margin was flat YoY at 5%.**
- **EBITDA (Post-Ind-AS) was up 16% YoY to INR813m (est. INR794m). The margin improved 10bp YoY to 14.3% (est. 14.1%).**
- Higher operating costs and interest led to a loss in the India business of INR202m in 2QFY26 (vs. the estimated loss of INR146m).

Indonesia business

- Indonesia revenue declined by 4% YoY to INR1,348m due to store rationalization (7% YoY dip in BK store count) and geopolitical headwinds.
 - BK's ADS was up 7% YoY at IDR18.1m.
 - The company closed three BK stores during the quarter (136 BK stores/25 Indonesia Popeyes stores).
- Indonesia GP declined 2% YoY to INR767m, with gross margin expanding 110bp YoY to 56.9% (56.7% in 1QFY26).
- **EBITDA (Post-Ind-AS) was a loss of INR51m in 2QFY26 vs. a loss of INR87m in 2QFY25 and a profit of INR10m in 1QFY26.**
- **Indonesia ROM (Pre-Ind-AS) reported a loss of INR63m in 2QFY26 vs. a loss of INR67m in 2QFY25 and a profit of INR2m in 1QFY26.**
- **EBITDA (Pre-Ind-AS) posted a loss of INR170m vs. a loss of INR206m in 2QFY25.**

Consolidated business

- Consolidated revenue grew 11% YoY to INR7b, led by healthy India business performance, while the Indonesia business continued to be a laggard.
- Consolidated GP grew 13% YoY to INR4.65b, and the margin expanded 120bp YoY and 70bp QoQ to 66.1%.
- Consolidated reported EBITDA (Post-Ind-AS) rose 24% YoY to INR762m, and the margin improved 110bp YoY to 10.8%.
- **High operating costs and interest costs led to a consolidated loss of INR633m.**

Quarterly Standalone Performance (INR m)												
Y/E March	FY25				FY26E				FY25	FY26E	FY26	Var.
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE		2QE	(%)	
SSSG (%)	3.1%	-3.0%	-0.5%	5.1%	2.6%	2.8%	5.0%	3.6%	1.1%	3.5%	2.5%	
No. of stores	456	464	510	513	519	533	563	573	513	573	531	
Net Sales	4,905	4,921	4,954	4,898	5,523	5,687	5,819	5,808	19,678	22,836	5,613	1.3
YoY change (%)	16.2	8.5	11.2	11.6	12.6	15.6	17.5	18.6	11.8	16.1	14.1	
Gross Profit	3,318	3,322	3,361	3,322	3,739	3,884	3,974	3,931	13,322	15,529	3,817	1.8
Margin (%)	67.6	67.5	67.8	67.8	67.7	68.3	68.3	67.7	67.7	68.0	68.0	
EBITDA	618	700	789	777	745	813	951	863	2,890	3,373	794	2.5
EBITDA growth %	27.5	10.3	11.5	41.1	20.6	16.2	20.6	11.0	784.1	274.0	13.4	
Margin (%)	12.6	14.2	15.9	15.9	13.5	14.3	16.4	14.9	14.7	14.8	14.1	
Depreciation	633	611	632	670	663	690	710	735	2,546	2,797	689	
Interest	319	326	364	403	410	404	400	405	1,411	1,618	400	
Other Income	64	71	21	42	212	78	120	182	192	592	150	
PBT	-269	-166	-186	-254	-116	-202	-39	-95	-876	-451	-146	
Tax	0	0	0	0	0	0	0	0	0	0	0	
Rate (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Adjusted PAT	-269	-166	-186	-254	-116	-202	-39	-95	-876	-451	-146	
YoY change (%)	NM	NM	NM									

E: MOFSL Estimates

Quarterly Consolidated Performance (INR m)												
Y/E March	FY25				FY26E				FY25	FY26E	FY26	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		2QE	(%)	
No. of stores	630	638	682	681	683	694	725	746	681	746	696	
Net Sales	6,467	6,324	6,391	6,325	6,977	7,034	7,371	7,472	25,508	28,854	7,058	-0.3
YoY change (%)	5.9	1.2	5.8	5.9	7.9	11.2	15.3	18.1	4.7	13.1	11.6	
Gross Profit	4,171	4,104	4,191	4,129	4,564	4,651	4,867	4,878	16,595	18,959	4,638	0.3
Margin (%)	64.5	64.9	65.6	65.3	65.4	66.1	66.0	65.3	65.1	65.7	65.7	
Other expenses	3,513	3,492	3,465	3,357	3,809	3,889	3,814	3,803	13,858	15,316	3,832	
EBITDA	658	612	727	772	755	762	1,053	1,074	2,737	3,643	806	-5.5
EBITDA growth %	36.3	0.0	2.8	-11.4	14.7	24.4	44.9	39.2	2.9	33.1	31.5	
Margin (%)	10.2	9.7	11.4	12.2	10.8	10.8	14.3	14.4	10.7	12.6	11.4	
Depreciation	916	907	934	958	934	969	1,035	1,081	3,715	4,020	1,009	
Interest	374	380	397	457	468	456	420	257	1,609	1,601	420	
Other Income	145	21	57	38	193	30	120	182	259	592	150	
PBT	-488	-655	-547	-604	-454	-633	-282	-82	-2,328	-1,385	-474	
Tax	0	0	0	0	0	0	0	0	0	0	0	
Rate (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Adjusted PAT	-488	-655	-547	-604	-454	-633	-282	-82	-2,328	-1,385	-474	
YoY change (%)	NM	NM	NM									

E: MOFSL Estimates

Indostar Capital Finance

BSE SENSEX
 84,404

S&P CNX
 25,878

Concall details :

Date : 31st Oct'25

[Link for the call](#)

Time: 12:00 pm IST

 Dial in : +91 22 6280 1550 /
+91 22 7115 8378

Financials & Valuations (INR b)

Y/E March	FY25	FY26E	FY27E
NII	4.6	6.2	7.3
PPP	1.9	3.2	4.3
PAT	0.5	7.5	2.9
EPS (INR)	3.9	46.6	18.0
EPS Gr. (%)	-27	1,106	-61
BV (INR)	252	271	289
Ratios			
NIM (%)	6.1	9.0	10.1
C/I ratio (%)	71.7	62.4	56.8
RoA (%)	0.5	6.6	2.3
RoE (%)	1.6	19.3	6.4
Payout (%)	0.0	0.0	0.0
Valuations			
P/E (x)	63.7	5.3	13.7
P/BV (x)	1.0	0.9	0.9
Div. Yield (%)	0.0	0.0	0.0

CMP: INR246
Buy
Muted disbursements and weak AUM growth

GS3 declined ~1pp QoQ; credit costs elevated

- IndoStar's 2QFY26 consolidated PAT declined 67% YoY to INR105m.
- NII grew 40% YoY to INR1.5b. Other income stood at INR396m during the quarter (PQ: INR291m)
- Opex declined ~5% YoY to INR1.2b translating into a cost-to-income ratio of ~64% in 2QFY26 (PY: 77% and PQ: 88%). Credit costs stood at ~INR586m (PQ: ~INR4.9b). This translated into annualized credit costs of ~3% in 2QFY26 (PY: ~1%)

Muted disbursements; AUM declines 3% QoQ

- AUM stood at ~INR75.6b and was flat YoY. Disbursements declined ~56% YoY and grew 8% QoQ to ~INR9.3b
- GS3 declined ~1pp QoQ to ~3.05%, whereas NS3 declined ~55bp QoQ to 1.14%.
- CRAR was healthy at ~37.2%; Debt-equity ratio stood at 1.4x.

Valuation and view

- IndoStar focuses on expanding its retail business, specifically in the Commercial Vehicle (CV) lending segment. The company plans to target the lucrative used CV market, with an increasing emphasis on light commercial vehicles in tier II and III towns.
- IndoStar aims to boost its disbursement capabilities by expanding its distribution presence. It trades at 0.9x FY27E P/BV and is transitioning into a significant used-CV and MSME lender. We might review our estimates after the earnings call on 31st Oct'25.

Quarterly Performance

Y/E March							(INR M)	
	FY25		FY26				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q		
Interest Income	2,703	2,956	3,125	3,184	3,146	3,172	11,965	13,523
Interest Expenses	1,668	1,878	1,930	1,933	1,855	1,667	7,408	7,341
Net Interest Income	1,035	1,078	1,196	1,251	1,291	1,506	4,557	6,182
YoY Growth (%)	-12.2	40.5	47.9	44.6	24.7	39.7	36.6	35.7
Other Income	387	565	611	566	291	396	2,159	2,275
Total Income	1,422	1,643	1,806	1,817	1,582	1,902	6,716	8,457
YoY Growth (%)	-1.9	75.6	93.1	-21.7	11.3	15.7	23.4	25.9
Operating Expenses	1,106	1,272	1,212	1,198	1,393	1,210	4,815	5,279
Operating Profit	317	371	594	619	189	692	1,901	3,178
YoY Growth (%)	6.4	333.5	1,044.5	-49.1	-40.2	86.3	22.9	67.1
Provisions & Loan Losses	210	193	479	494	4,904	586	1,375	5,727
Profit before Tax and exceptional item	297	363	331	442	-4,579	105	526	-2,550
Exceptional item (post-tax)	0	0	0	0	11,760	0	0	10,070
PBT (incl. exception gain/loss)	297	363	331	442	7,181	105	526	7,520
Tax Provisions	48	46	54	80	1,725	0	0	0
Reported PAT	249	317	277	362	5,456	105	526	7,520
YoY Growth (%)	-36.0	27.9	64.3	2.6	2,088.4	-66.9	-26.6	1,330.0



Laurus Labs : CDMO Growth, Margin Expansion & ₹8,000 Cr Capex Plans; Satyanarayana Chava, CEO

- Strong Q2 led by CDMO and ARV business growth.
- EBITDA margin expands on operating leverage and mix gains.
- Plans ₹1,000 cr Capex in FY26, part of a ₹8,000 cr roadmap.
- Investing in spray drying, flow hydrogenation, API scale-up.
- Focused on diversified supply chain and robust balance sheet.

[Read More](#)

Midwest: EBITDA Is Being Driven By Innovation & Conversion From Fossil Fuels; Ramachandra Kollareddy, Promoter & CEO

- EBITDA margin steady at ~27%; sustainable per management.
- Diversifying from black granite (70% rev) to quartz and mineral sands.
- Quartz plant to double capacity; solar glass tailwind strong.
- Target ₹1,200 cr revenue, 35–36% margin by FY30.
- China share declining; India & Middle East growing fast.

[Read More](#)

Jain Resource Recycling: Revenue Growth, 7.6% EBITDA Margin & Expansion in Non-Ferrous Recycling

- Q2FY26 growth driven by raw material sourcing and capacity ramp-up.
- Total capacity: 250,000 MT; expansion planned beyond 80% utilization.
- Foray into value-added metal products to boost margins.
- EBITDA margin at 7.6% (vs 4–5%) sustainable.
- FY26 revenue likely above ₹8,000 cr.

[Read More](#)

Gulshan Poly : ₹1,185 Cr Ethanol Order Boosts FY26 Topline; Aditi Pasari, Joint MD

- Guides for FY26 revenue of ₹2,400–2,500 cr.
- Ethanol to form 50%+ of topline, aided by byproducts.
- Receives ₹5 cr+ PLI, expects ₹20 cr total incentives.
- Maintains stable pricing, strong margin and growth outlook.

[Read More](#)



Company	Reco	CMP	TP	% Upside	EPS (INR)			EPS Gr. YoY (%)			P/E (x)	P/B (x)	ROE (%)
		(INR)	(INR)	Downside	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY26E
Automobiles													
Amara Raja Ener.	Neutral	1017	1039	2	45.4	54.7	60.7	-5.8	20.5	11.0	22.4	18.6	2.3
Apollo Tyres	Buy	502	551	10	24.0	29.1	32.1	22.6	21.3	10.2	20.9	17.2	1.6
Ashok Ley.	Buy	141	166	18	6.0	7.2	8.5	10.1	19.7	17.0	23.3	19.4	6.3
Bajaj Auto	Neutral	8923	9197	3	329.0	362.1	396.5	9.9	10.1	9.5	27.1	24.6	7.1
Balkrishna Inds	Neutral	2326	2379	2	83.6	103.5	111.7	-13.3	23.8	7.9	27.8	22.5	3.8
Bharat Forge	Neutral	1317	1109	-16	24.2	33.0	40.9	13.0	36.3	24.1	54.5	39.9	6.3
Bosch	Neutral	37202	36375	-2	824.3	976.1	1,113.4	20.8	18.4	14.1	45.1	38.1	7.1
CEAT	Buy	4103	4523	10	161.3	210.5	241.8	32.1	30.5	14.9	25.4	19.5	3.4
Craftsman Auto	Neutral	6660	6391	-4	156.2	229.2	303.4	69.6	46.7	32.4	42.6	29.1	5.0
Eicher Mot.	Sell	6889	5772	-16	192.1	213.0	241.2	11.3	10.9	13.2	35.9	32.3	7.7
Endurance Tech.	Buy	2851	3311	16	72.0	84.4	99.5	22.5	17.2	17.9	39.6	33.8	6.1
Escorts Kubota	Neutral	3714	3683	-1	119.5	128.6	134.4	18.8	7.6	4.5	31.1	28.9	3.9
Exide Ind	Neutral	383	404	5	15.3	16.7	17.7	21.1	9.1	5.7	25.0	22.9	2.1
Happy Forgings	Buy	1022	1147	12	30.2	37.5	49.6	6.3	24.2	32.2	33.9	27.3	4.6
Hero Moto	Buy	5514	6315	15	258.3	283.1	311.5	14.3	9.6	10.0	21.3	19.5	5.1
Hyundai Motor	Buy	2413	2801	16	73.6	87.5	105.6	6.0	18.9	20.7	32.8	27.6	9.5
M&M	Buy	3501	4091	17	120.7	143.7	163.0	22.3	19.0	13.5	29.0	24.4	5.8
CIE Automotive	Buy	440	502	14	21.5	23.2	25.7	-1.0	8.2	10.8	20.5	19.0	2.3
Maruti Suzuki	Buy	16206	18501	14	490.2	607.4	714.1	10.4	23.9	17.6	33.1	26.7	4.8
MRF	Sell	158125	125764	-20	5,100.45	5,918.46	6,658.0	15.7	16.0	12.5	31.0	26.7	3.3
Samvardh. Motherson	Buy	107	123	15	3.2	4.7	5.7	-11.2	47.8	21.0	33.8	22.9	3.1
Motherson Wiring	Buy	47	53	12	1.0	1.3	1.6	8.8	35.1	19.3	47.7	35.3	15.9
Sona BLW Precis.	Neutral	483	448	-7	11.2	12.4	13.9	13.8	10.6	11.7	42.9	38.8	4.9
Tata Motors	Neutral	412	687	67	41.9	54.5	74.7	-33.7	30.1	36.9	9.8	7.6	1.2
TVS Motor	Buy	3491	4159	19	76.2	96.4	121.9	33.6	26.5	26.5	45.8	36.2	12.9
Tube Investments	Buy	3066	3716	21	41.6	47.1	52.1	7.9	13.2	10.5	73.6	65.1	10.0
Aggregate					1.3	21.6	18.9	28.7	23.6	4.6	4.0	16.0	17.1
Banks - Private													
AU Small Finance	Buy	878	925	5	35.2	47.5	62.6	18.0	35	31.8	25.0	18.5	3.3
Axis Bank	Neutral	1239	1300	5	78.3	99.0	119.6	-8.2	26.4	20.8	15.8	12.5	1.9
Bandhan Bank	Neutral	171	175	3	9.8	18.2	23.5	-42.5	86	29.1	17.4	9.3	1.1
DCB Bank	Buy	155	165	7	23.5	30.9	38.5	20.0	31.7	24.3	6.6	5.0	0.8
Equitas Small Fin.	Buy	59	70	18	0.2	5.5	8.8	-84.0	2,586.1	59.1	287.2	10.7	1.1
Federal Bank	Buy	235	260	11	16.4	19.9	24.4	-1.2	21.6	22.4	14.3	11.8	1.6
HDFC Bank	Buy	998	1175	18	49.1	54.7	64.7	11.5	11.5	18.3	20.3	18.2	2.8
ICICI Bank	Buy	1362	1700	25	72.8	82.7	95.7	9.0	13.6	15.8	18.7	16.5	2.9
IDFC First Bk	Neutral	79	80	1	2.7	5.3	7.7	29.8	92.3	45.9	28.7	14.9	1.4
IndusInd	Neutral	802	800	0	13.7	49.8	73.5	-58.5	262.5	47.6	58.4	16.1	1.0
Kotak Mah. Bk	Buy	2138	2500	17	105.3	126.0	152.4	-5.4	19.6	21.0	20.3	17.0	2.5
RBL Bank	Buy	325	350	8	16.8	14.5	20.0	47.2	-13.9	37.9	19.3	22.4	1.2
Aggregate					4.9	19.7	20.2	19.5	16.3	2.5	2.2	13.0	13.5
Banks - PSU													
BOB	Neutral	273	275	1	35.4	41.0	50.7	-6.4	15.9	23.6	7.7	6.6	1.0
Canara Bank	Buy	133	153	15	21.4	22.9	25.6	14.0	7.0	11.8	6.2	5.8	1.1
Indian Bank	Buy	855	900	5	93.1	96.4	107.2	14.9	3.5	11.2	9.2	8.9	1.6
Punjab Natl.Bank	Buy	120	135	12	14.4	18.9	22.1	-2.5	31.4	16.5	8.3	6.3	1.0
SBI	Buy	934	1000	7	87.4	101.1	119.6	0.5	16	18.3	10.7	9.2	1.6
Union Bank (I)	Neutral	142	155	9	21.8	24.0	27.5	-7.5	10	14.6	6.5	5.9	0.9
Aggregate					1.1	16	17	9	8.0	1.3	1.2	14.4	15.0
NBFCs													
AAVAS Financiers	Neutral	1680	1800	7	80.3	97.6	117.4	10.6	21.6	20.3	20.9	17.2	2.7
Aditya Birla Cap	Buy	327	380	16	15.2	19.5	25.3	18.9	28.3	29.7	21.5	16.8	2.5
Bajaj Fin.	Neutral	1052	1090	4	32.9	42.6	53.8	21.8	29.4	26.5	32.0	24.7	5.7
Bajaj Housing	Neutral	111	120	8	3.1	3.8	4.7	19.0	22.9	23.1	35.8	29.2	4.1



Company	Reco	CMP	TP	% Upside	EPS (INR)			EPS Gr. YoY (%)			P/E (x)		P/B (x)		ROE (%)	
		(INR)	(INR)	Downside	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Can Fin Homes	Neutral	875	915	5	75.9	79.5	92.8	18.0	4.7	16.7	11.5	11.0	2.0	1.7	18.4	16.7
Cholaman.Inv.&Fn	Buy	1713	1920	12	61.3	79.0	97.5	21.2	28.7	23.4	27.9	21.7	4.8	3.9	19.4	19.9
CreditAccess	Buy	1469	1690	15	51.7	88.4	116.3	55.4	70.9	31.6	28.4	16.6	3.0	2.6	11.2	16.6
Fusion Finance	Buy	183	240	31	0.6	19.9	27.2	-100.5	3,464.6	36.6	327.9	9.2	1.4	1.1	0.4	13.4
Five-Star Business	Buy	642	710	11	40.3	45.2	54.6	10.6	12.3	20.6	15.9	14.2	2.5	2.2	17.3	16.5
IIFL Finance	Buy	541	-		35.6	54.9	67.4	298.7	54.3	22.9	15.2	9.9	1.7	1.4	11.5	15.7
HDB Financial	Neutral	735	820	12	31.4	40.8	50.5	15.0	29.8	23.6	23.4	18.0	2.9	2.5	14.2	15.0
Home First Finan	Buy	1208	1530	27	51.7	64.2	77.4	21.8	24.3	20.6	23.4	18.8	2.9	2.6	15.7	14.5
IndoStar	Buy	246	-		46.6	18.0	26.9	1,106.0	-61.3	49.4	5.3	13.7	0.9	0.9	19.3	6.4
L&T Finance	Buy	268	320	19	11.9	16.1	20.2	12.6	34.9	25.4	22.5	16.7	2.4	2.2	11.1	13.6
LIC Hsg Fin	Neutral	570	630	10	99.3	103.3	111.9	0.7	4.0	8.3	5.7	5.5	0.8	0.7	14.2	13.3
Manappuram Fin.	Neutral	275	305	11	11.3	19.2	24.9	-20.5	69.9	29.7	24.3	14.3	1.6	1.5	7.5	11.3
MAS Financial	Buy	308	400	30	19.4	25.5	29.0	15.2	31.2	13.8	15.9	12.1	2.0	1.7	13.1	15.1
M&M Fin.	Buy	316	350	11	20.2	24.7	28.4	6.5	22.4	14.6	15.6	12.7	1.8	1.6	12.6	13.2
Muthoot Fin	Neutral	3192	3100	-3	195.5	221.5	250.0	50.9	13.3	12.9	16.3	14.4	3.7	3.0	24.7	23.0
Piramal Enterp.	Buy	1124	1460	30	63.7	106.8	177.6	195.9	67.7	66.3	17.7	10.5	0.9	0.8	5.2	8.2
PNB Housing	Buy	935	1080	16	88.2	96.4	117.3	18.4	9.3	21.7	10.6	9.7	1.3	1.1	12.8	12.4
Poonawalla Fincorp	Buy	483	605	25	8.7	21.8	32.0	-783.5	150.2	46.9	55.5	22.2	3.8	3.3	7.6	15.8
PFC	Buy	405	490	21	59.4	61.1	69.7	12.9	3.0	14.1	6.8	6.6	1.3	1.1	20.0	18.1
REC	Buy	378	465	23	65.9	70.6	80.8	10.4	7.0	14.5	5.7	5.4	1.1	1.0	20.7	19.2
Repco Home Fin	Neutral	416	400	-4	69.9	73.6	84.4	-0.5	5.3	14.7	6.0	5.7	0.7	0.6	12.4	11.7
Spandana Sphoorty	Neutral	259	280	8	-83.1	30.1	48.7	-42.7	LP	61.4	NM	8.6	1.1	0.9	-27.7	11.1
Shriram Finance	Buy	738	770	4	49.4	59.9	71.3	12.4	21.2	19.0	14.9	12.3	2.2	1.9	15.4	16.4
Aggregate					22.5	20.5	21.1	17.2	14.2	2.6	2.2	15.0	15.7			
NBFC-Non Lending																
360 ONE WAM	Buy	1119	1400	25	31.1	36.9	43.7	20.4	18.7	18.4	36.0	30.3	5.5	4.6	16.5	17.0
Aditya Birla AMC	Buy	778	1100	41	37.1	42.3	48.1	14.8	14.0	13.8	21.0	18.4	5.3	4.8	26.9	27.3
Anand Rathi Wealth	Neutral	3138	2800	-11	46.8	59.8	73.5	29.3	27.9	22.8	67.1	52.5	26.7	18.9	47.0	42.0
Angel One	Buy	2511	2900	15	91.1	136.0	187.2	-29.9	49.4	37.6	27.6	18.5	3.4	3.0	14.0	18.7
BSE	Neutral	2443	2250	-8	50.8	56.3	65.4	56.7	10.8	16.1	48.0	43.4	16.5	12.8	34.4	29.5
Cams Services	Buy	3956	4900	24	95.0	112.1	131.9	0.2	17.9	17.7	41.6	35.3	14.9	12.7	38.4	38.8
CDSL	Neutral	1615	1520	-6	21.8	28.5	33.8	-13.0	30.8	18.5	74.1	56.7	17.3	15.2	24.5	28.6
HDFC AMC	Buy	5362	6800	27	134.6	153.2	177.1	16.8	13.8	15.6	39.8	35.0	12.9	11.8	33.9	35.3
KFin Technologies	Neutral	1111	1300	17	21.8	26.4	31.6	12.0	21.0	19.8	50.9	42.1	13.2	11.5	27.4	29.2
MCX	Neutral	9104	8500	-7	169.9	203.4	234.4	54.3	19.7	15.3	53.6	44.8	22.5	20.5	43.8	47.9
NSDL	Neutral	1172	1200	2	18.0	21.6	26.0	5.9	19.8	20.1	65.0	54.2	10.0	8.5	16.6	16.9
Nippon Life AMC	Buy	871	1060	22	23.9	27.9	32.0	17.1	16.7	14.7	36.6	31.2	12.8	12.5	35.1	41.0
Nuvama Wealth	Buy	7226	7900	9	292.9	351.2	416.2	5.8	19.9	18.5	24.7	20.6	6.5	5.7	28.1	29.7
Prudent Corp.	Neutral	2627	2600	-1	53.4	67.3	85.8	12.9	26.2	27.4	49.2	39.0	63.0	49.2	28.9	28.3
UTI AMC	Buy	1249	1700	36	54.7	78.1	90.4	-14.4	42.9	15.7	22.8	16.0	3.0	2.8	13.2	18.0
Aggregate					13.7	20.4	18.3	40.2	33.4	10.0	8.7	24.9	26.0			
Insurance																
HDFC Life Insur.	Buy	746	910	22	8.4	10.0	11.5	0.2	18.9	14.7	88.9	74.7	2.5	2.2	15.4	16.5
ICICI Lombard	Buy	2014	2300	14	62.5	72.6	82.9	22.7	16.1	14.3	32.2	27.8	6.0	5.1	19.9	19.9
ICICI Pru Life	Buy	600	720	20	8.7	11.0	13.2	6.6	26.1	19.9	68.6	54.4	1.6	1.4	11.7	13.0
Life Insurance Corp.	Buy	901	1080	20	79.9	87.9	95.6	5.0	10.0	8.8	11.3	10.2	0.7	0.6	11.6	11.4
Max Financial	Buy	1556	2000	29	11.9	14.1	15.6	26.5	17.8	11.0	130.5	110.7	2.2	1.9	19.2	19.4
Niva Bupa Health	Buy	75	100	34	0.7	1.7	3.3	-37.2	132.9	93.0	102.0	43.8	3.5	3.2	3.8	7.7
SBI Life Insurance	Buy	1969	2240	14	24.1	25.7	28.0	-0.3	6.7	9.0	81.9	76.7	2.4	2.0	18.1	18.3
Star Health Insu	Buy	481	570	19	11.4	16.3	21.7	3.9	42.6	33.3	42.1	29.5	3.7	3.3	9.1	11.7
Chemicals																
Alkyl Amines	Neutral	1883	2000	6	38.7	44.5	47.3	6.6	14.9	6.4	48.6	42.3	6.2	5.6	13.5	14.0
Atul	Buy	5823	7520	29	216.8	250.5	270.7	28.1	15.5	8.1	26.9	23.2	2.8	2.5	10.9	11.4
Clean Science	Neutral	1015	1175	16	31.1	39.2	44.7	25.0	26.0	14.1	32.7	25.9	6.4	5.3	21.3	22.3
Deepak Nitrite	Sell	1741	1540	-12	47.9	61.7	64.1	-6.2	28.6	3.9	36.3	28.2	4.0	3.6	11.5	13.3



Company	Reco	CMP	TP	% Upside	EPS (INR)			EPS Gr. YoY (%)			P/E (x)		P/B (x)		ROE (%)	
		(INR)	(INR)	Downside	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Ellenbarrie Industrial	Buy	466	640	37	9.4	15.6	18.7	59.3	65.3	20.2	49.5	29.9	6.4	5.3	17.5	19.3
Fine Organic	Sell	4450	3980	-11	136.8	138.7	158.2	7.7	1.4	14.1	32.5	32.1	5.2	4.6	17.4	15.2
Galaxy Surfact.	Buy	2234	2630	18	89.7	105.2	118.8	4.3	17.3	13.0	24.9	21.2	3.0	2.8	12.8	13.6
Navin Fluorine	Neutral	4976	5400	9	108.2	129.8	149.4	85.9	20.0	15.1	46.0	38.3	6.7	5.9	17.2	16.3
NOCIL	Neutral	187	160	-14	5.2	6.5	7.5	-19.9	26.4	15.0	36.1	28.6	1.7	1.6	4.8	5.9
PI Inds.	Buy	3597	4310	20	98.8	118.0	134.3	-9.6	19.4	13.9	36.4	30.5	4.8	4.2	13.9	14.7
SRF	Buy	2981	3650	22	68.1	91.8	105.7	47.9	34.7	15.1	43.8	32.5	6.3	5.4	15.2	17.9
Tata Chemicals	Neutral	901	960	7	34.8	54.4	60.6	111.1	56.4	11.4	25.9	16.6	1.0	1.0	4.1	6.1
Vinati Organics	Buy	1700	2050	21	50.4	58.5	69.7	26.0	16.0	19.0	33.7	29.1	5.5	4.7	17.3	17.4
Aggregate					14.5	21.5	11.4	36.8	30.3	4.4	3.9	11.9	12.9			
Capital Goods																
ABB India	Buy	5275	6000	14	80.0	95.1	111.9	-9.5	18.8	17.6	65.9	55.5	14.4	13.0	22.8	24.6
Bharat Electronics	Buy	410	490	20	8.2	9.8	11.7	13.6	19.6	19.2	49.9	41.7	12.0	9.6	24.0	22.9
Bharat Dynamics	Buy	1515	1900	25	28.2	37.8	52.0	88.4	34.0	37.4	53.6	40.0	11.5	9.3	21.5	23.3
Cummins India	Buy	4387	4500	3	83.2	98.0	114.0	16.0	17.9	16.3	52.7	44.8	15.3	13.5	30.8	32.0
Hind.Aeronautics	Buy	4649	5800	25	141.2	161.2	197.9	13.0	14.2	22.7	32.9	28.8	7.4	6.3	22.6	21.8
Hitachi Energy	Sell	17917	16500	-8	177.4	238.4	319.9	129.1	34.3	34.2	101.0	75.2	15.2	12.6	15.9	17.6
Kalpataru Proj.	Buy	1262	1450	15	57.0	74.9	87.0	44.8	31.6	16.1	22.2	16.8	2.7	2.3	12.8	14.8
KEC International	Neutral	824	950	15	34.9	44.2	53.6	62.6	26.9	21.1	23.6	18.6	3.6	3.1	16.2	17.9
Kirloskar Oil	Buy	1017	1230	21	33.6	40.9	47.6	16.7	21.8	16.5	30.3	24.9	4.4	3.8	15.3	16.4
Larsen & Toubro	Buy	3988	4500	13	130.2	154.9	184.9	21.9	19.0	19.4	30.6	25.7	5.0	4.4	17.2	18.1
Siemens	Neutral	3126	3300	6	75.8	66.9	77.8	33.5	-11.7	16.3	41.3	46.7	6.2	5.4	14.9	11.7
Siemens Energy	Buy	3208	3800	18	32.4	41.5	61.4	65.3	28.2	47.8	99.0	77.3	26.1	19.5	26.4	25.3
Thermax	Sell	3260	3450	6	68.0	79.8	94.6	20.5	17.5	18.5	48.0	40.8	6.6	5.9	14.6	15.2
Triveni Turbine	Buy	528	620	17	11.8	14.0	16.8	4.4	19.0	19.8	44.9	37.7	11.3	9.3	27.7	27.1
Zen Technologies	Neutral	1377	1400	2	21.6	40.5	53.3	-26.0	87.6	31.8	63.9	34.0	6.6	5.5	10.9	17.7
Aggregate					20.7	17.8	21.2	40.0	34.0	7.4	6.4	18.6	18.9			
Cement																
Ambuja Cem.	Buy	568	730	28	10.2	14.5	17.4	28.0	42.3	20.5	55.9	39.3	2.5	2.4	4.6	6.3
ACC	Neutral	1859	2000	8	89.9	117.2	135.6	26.3	30.3	15.7	20.7	15.9	1.8	1.6	8.9	10.6
Birla Corp.	Buy	1195	1600	34	67.9	84.8	95.9	60.7	25.0	13.1	17.6	14.1	1.2	1.1	7.2	8.4
Dalmia Bhar.	Buy	2099	2660	27	68.0	72.8	84.7	83.5	7.0	16.4	30.9	28.8	2.1	2.0	7.1	7.2
Grasim Inds.	Buy	2952	3540	20	85.1	105.5	127.4	14.8	24.0	20.7	34.7	28.0	3.5	3.4	-4.1	-1.1
India Cem	Sell	400	300	-25	-1.2	3.8	11.3	-95.2	LP	195.1	NM	104.9	1.3	1.3	-0.4	1.2
JSW Cement	Neutral	136	150	10	2.3	2.9	3.6	-510.2	27.0	21.5	58.9	46.4	3.0	2.8	7.4	6.2
J K Cements	Buy	6247	7500	20	155.8	193.5	219.5	50.5	24.2	13.4	40.1	32.3	6.8	5.7	18.2	19.2
JK Lakshmi Ce	Buy	871	1150	32	43.2	52.4	53.4	68.0	21.3	1.8	20.2	16.6	2.6	2.3	13.8	14.8
Ramco Cem	Neutral	1056	1050	-1	15.8	24.7	34.3	302.3	56.5	39.3	67.0	42.8	3.2	3.0	4.9	7.3
Shree Cem	Neutral	28734	30030	5	529.5	561.8	676.6	56.7	6.1	20.4	54.3	51.1	4.6	4.3	8.7	8.7
Ultratech	Buy	12051	14460	20	272.7	350.5	423.9	31.4	28.5	20.9	44.2	34.4	4.7	4.3	11.0	13.0
Aggregate					41.1	26.7	20.3	41.0	32.4	3.4	3.2	8.2	9.8			
Consumer																
Asian Paints	Neutral	2524	2500	-1	44.2	51.8	58.3	4.1	17.3	12.5	57.1	48.7	12.3	11.8	21.7	24.8
Britannia	Neutral	5856	6500	11	103.6	121.6	138.3	12.8	17.4	13.7	56.5	48.2	28.3	23.5	53.4	53.3
Colgate	Buy	2255	2850	26	51.9	57.8	63.0	1.0	11.5	8.9	43.5	39.0	38.8	39.0	87.0	99.7
Dabur	Neutral	501	525	5	10.8	12.2	13.4	6.3	13.0	9.8	46.1	41.0	7.6	7.4	17.2	18.4
Emami	Buy	543	725	34	20.7	22.7	24.6	2.2	9.5	8.4	26.2	23.9	7.9	7.0	31.7	31.1
Godrej Cons.	Buy	1114	1450	30	21.8	26.7	31.1	17.5	22.9	16.3	51.2	41.6	9.1	8.7	18.1	21.3
HUL	Buy	2470	3050	24	45.8	52.1	56.4	3.3	13.8	8.2	53.9	47.4	11.5	11.2	21.6	24.0
ITC	Buy	419	515	23	16.9	18.5	19.8	5.8	9.5	7.0	24.9	22.7	7.2	7.0	29.6	31.3
Indigo Paints	Buy	1011	1350	34	31.3	36.5	42.2	5.1	16.4	15.6	32.3	27.7	4.2	3.7	13.7	14.1
Jyothy Lab	Neutral	320	365	14	10.7	11.9	13.3	4.7	11.8	11.2	30.0	26.8	5.6	5.1	18.8	19.8
L T Foods	Buy	418	-		21.8	27.7	32.1	25.2	27.0	15.7	19.1	15.1	3.3	2.8	18.3	19.9
Marico	Buy	722	850	18	14.0	16.3	18.1	13.4	15.8	11.4	51.4	44.4	22.3	20.6	44.5	48.2
Nestle	Neutral	1280	1300	2	16.9	20.1	22.5	5.4	19.6	11.8	75.9	63.5	56.9	52.3	77.9	85.8



Company	Reco	CMP (INR)	TP (INR)	% Upside	EPS (INR)			EPS Gr. YoY (%)			P/E (x)		P/B (x)		ROE (%)	
	Downside	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Page Inds	Buy	40864	50000	22	725.3	830.8	937.2	11.1	14.5	12.8	56.3	49.2	26.8	22.5	47.7	45.6
Pidilite Ind.	Neutral	1485	-		24.1	27.7	31.6	16.8	14.6	14.3	61.6	53.7	13.7	12.2	23.6	24.0
P&G Hygiene	Neutral	13403	15000	12	269.5	297.0	330.7	37.6	10.2	11.4	49.7	45.1	47.7	39.4	106.2	95.7
Radico Khaitan	Buy	3142	3600	15	41.9	53.3	65.5	62.4	27.2	22.9	75.0	58.9	13.4	11.3	17.9	19.2
Tata Consumer	Buy	1177	1320	12	16.7	19.9	21.8	19.3	18.9	9.5	70.4	59.2	5.2	4.9	8.1	9.1
United Brew	Neutral	1785	1750	-2	16.4	26.9	34.8	-7.1	64.0	29.4	109.2	66.6	10.3	9.5	9.7	14.9
United Spirits	Neutral	1393	-		21.3	23.6	26.7	7.7	11.0	13.0	65.4	58.9	10.7	9.1	16.4	15.4
Varun Beverages	Buy	485	580	20	9.1	10.7	12.8	18.3	18.4	18.9	53.4	45.1	8.7	7.6	17.3	18.0
Aggregate								8.6	14.2	10.5	45.5	39.9	10.9	10.2	24.0	25.6
Consumer Durables																
Havells India	Neutral	1508	1640	9	24.5	31.2	37.5	4.5	27.2	20.4	61.5	48.4	10.1	8.9	16.5	18.4
KEI Industries	Buy	4118	4960	20	92.2	108.5	128.9	26.5	17.7	18.8	44.7	38.0	6.0	5.2	14.2	14.6
LG Electronics	Buy	1657	1800	9	33.2	39.0	45.1	2.4	17.2	15.8	49.9	42.6	15.1	12.3	33.7	31.9
Polycab India	Buy	7848	9110	16	176.2	199.0	237.5	31.2	12.9	19.4	44.5	39.4	9.9	8.3	22.2	21.1
R R Kabel	Neutral	1410	1340	-5	37.0	40.9	48.2	34.1	10.7	17.7	38.2	34.5	6.4	5.5	18.0	17.2
Volta	Neutral	1418	1340	-6	23.0	31.4	38.0	-9.4	36.3	21.0	61.6	45.2	6.6	5.9	10.8	13.1
Aggregate								12.7	19.1	18.7	50.0	42.0	9.5	8.1	19.0	19.4
EMS																
Amber Enterp.	Buy	8087	9000	11	116.2	181.4	262.9	61.4	56.1	44.9	69.6	44.6	10.2	8.3	15.8	20.6
Avalon Tech	Buy	1202	1220	1	15.6	24.6	33.8	63.1	57.1	37.5	76.9	48.9	11.1	9.1	15.6	20.4
Cyient DLM	Buy	461	550	19	9.5	16.8	23.7	2.4	76.0	41.1	48.3	27.4	3.5	3.1	7.6	12.0
Data Pattern	Neutral	2711	2500	-8	48.2	62.8	80.6	21.6	30.3	28.5	56.3	43.2	8.6	7.2	16.4	18.1
Dixon Tech.	Buy	15651	22500	44	174.9	276.9	363.8	49.3	58.3	31.4	89.5	56.5	23.5	16.8	30.0	34.7
Kaynes Tech	Buy	6799	8300	22	82.2	132.9	196.2	79.6	61.6	47.6	82.7	51.1	8.7	7.4	14.1	16.4
Syrma SGS Tech.	Buy	823	940	14	15.3	22.4	30.6	58.3	46.4	36.8	53.9	36.8	7.3	6.2	14.5	18.3
Aggregate								53.2	55.1	37.6	77.1	49.7	12.2	9.8	15.8	19.8
Healthcare																
Alembic Phar	Neutral	901	955	6	34.9	45.4	52.1	19.9	29.9	14.9	25.8	19.8	3.1	2.7	12.4	14.4
Alkem Lab	Neutral	5524	5270	-5	206.3	182.6	209.5	13.9	-11.5	14.7	26.8	30.3	4.8	4.4	19.2	15.1
Ajanta Pharma	Buy	2469	2940	19	83.8	97.0	109.3	13.2	15.8	12.6	29.5	25.4	6.8	5.7	25.1	24.3
Apollo Hospitals	Buy	7788	8990	15	126.7	152.2	188.8	26.0	20.2	24.0	61.5	51.2	10.9	9.0	20.1	19.9
Aurobindo	Buy	1103	1300	18	63.8	77.7	93.0	4.6	21.7	19.7	17.3	14.2	1.8	1.6	10.8	11.8
Biocon	Buy	377	408	8	4.1	8.8	11.6	99.0	117.4	31.7	92.8	42.7	2.0	2.0	2.2	4.7
Blue Jet Health	Buy	648	1100	70	25.3	32.1	38.6	43.6	27.1	20.1	25.6	20.2	7.3	5.5	32.8	30.9
Cipla	Neutral	1541	1500	-3	61.3	61.8	68.7	-2.3	0.8	11.2	25.1	24.9	3.5	3.1	13.8	12.4
Divis Lab	Neutral	6654	6020	-10	90.5	120.3	140.2	11.5	33.0	16.5	73.5	55.3	10.6	9.4	15.2	18.0
Dr Reddy's	Neutral	1202	1250	4	68.9	63.1	68.5	2.4	-8.4	8.6	17.4	19.0	2.6	2.3	15.8	12.7
Dr Agarwal's Hea	Buy	519	-		3.7	5.1	7.9	41.1	37.5	52.7	138.9	101.0	8.2	7.6	6.1	7.8
ERIS Lifescience	Neutral	1619	1635	1	37.7	54.4	62.5	47.1	44.3	14.9	43.0	29.8	6.8	5.6	16.8	20.6
Gland Pharma	Buy	1913	2340	22	55.6	68.4	81.1	31.2	23.0	18.6	34.4	28.0	3.1	2.8	9.5	10.6
Glenmark	Buy	1884	2400	27	58.9	77.9	91.1	23.3	32.3	17.0	32.0	24.2	5.1	4.3	17.2	19.2
GSK Pharma	Neutral	2619	2830	8	57.6	67.2	76.4	5.2	16.7	13.6	45.5	39.0	18.0	14.2	39.7	36.4
Global Health	Buy	1372	1590	16	24.2	30.3	36.8	24.9	25.5	21.5	56.8	45.2	9.4	8.0	17.7	19.1
Granules India	Buy	575	625	9	23.0	30.7	37.6	16.7	33.7	22.4	25.0	18.7	3.3	2.8	14.1	16.3
IPCA Labs	Buy	1289	1570	22	40.9	50.8	60.1	13.7	24.2	18.4	31.5	25.4	4.2	3.7	14.0	15.4
Laxmi Dental	Buy	317	400	26	8.8	12.2	15.0	84.4	38.5	23.6	36.1	26.0	6.8	5.4	20.7	23.0
Laurus Labs	Buy	970	1110	14	13.4	16.8	19.6	131.5	25.0	16.8	72.2	57.8	10.0	8.7	14.7	16.2
Lupin	Neutral	1945	2040	5	95.1	97.3	99.8	32.7	2.4	2.6	20.5	20.0	4.0	3.3	21.9	18.2
Mankind Pharma	Buy	2446	2930	20	44.9	60.9	73.8	-10.1	35.6	21.2	54.4	40.1	6.4	5.7	12.3	15.0
Max Healthcare	Buy	1178	1350	15	18.7	24.3	25.6	23.6	30.1	5.5	63.1	48.5	9.4	8.0	16.0	17.8
Piramal Pharma	Buy	202	230	14	0.9	2.3	5.2	38.0	143.1	124.2	212.7	87.5	2.9	2.8	1.5	3.6
Sun Pharma	Buy	1704	1900	12	51.1	59.5	66.2	8.5	16.3	11.3	33.3	28.7	5.0	4.4	15.9	16.3
Torrent Pharma	Neutral	3601	3580	-1	69.9	84.5	104.1	20.9	21.0	23.1	51.5	42.6	6.7	5.6	28.3	28.6
Zydus Lifesciences	Neutral	986	1020	3	45.1	42.8	47.1	-2.0	-5.2	10.2	21.9	23.1	3.5	3.1	17.5	14.4
Aggregate								11.0	14.3	14.4	34.8	30.5	4.9	4.3	14.1	14.2



Company	Reco	CMP	TP	% Upside	EPS (INR)			EPS Gr. YoY (%)			P/E (x)	P/B (x)	ROE (%)
		(INR)	(INR)	Downside	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY26E
Infrastructure													
G R Infraproject	Buy	1184	1433	21	79.9	101.1	116.5	7.0	26.4	15.2	14.8	11.7	1.3
IRB Infra	Neutral	45	45	1	2.2	2.8	3.9	92.9	27.6	39.7	20.6	16.2	1.3
KNR Constructions	Neutral	184	210	14	8.7	14.4	15.1	-38.2	65.9	5.2	21.3	12.8	1.2
Aggregate										18.8	14.4	1.3	1.2
Logistics													
Adani Ports	Buy	1458	1700	17	62.7	73.1	82.0	24.9	16.6	12.2	23.3	19.9	4.3
Blue Dart Express	Buy	6682	7200	8	134.1	201.1	215.8	30.1	49.9	7.4	49.8	33.2	8.4
Concor	Buy	550	670	22	18.3	22.8	26.4	7.5	24.4	16.1	30.0	24.1	3.2
Delhivery	Buy	475	540	14	4.8	6.1	8.0	115.6	25.0	32.9	98.2	78.5	3.6
JSW Infra	Buy	296	360	22	7.5	8.9	12.6	7.3	18.6	42.1	39.4	33.3	5.6
Mahindra Logistics	Neutral	363	330	-9	2.5	17.2	22.3	-149.9	595.7	29.3	146.6	21.1	3.0
Transport Corp.	Buy	1206	1500	24	61.5	66.9	76.2	14.9	8.8	14.0	19.6	18.0	3.6
TCI Express	Neutral	677	730	8	26.1	33.2	36.3	16.5	27.4	9.1	25.9	20.4	3.1
VRL Logistics	Buy	270	350	30	12.6	14.8	16.5	20.6	17.4	11.6	21.4	18.2	3.9
Aggregate										27.3	22.9	4.2	3.7
Media													
PVR Inox	Neutral	1239	1245	1	25.1	31.0	39.3	-262.6	23.6	26.5	49.3	39.9	1.7
Sun TV	Neutral	566	645	14	43.4	44.4	46.3	0.0	2.2	4.2	13.0	12.8	1.8
Zee Ent.	Neutral	102	100	-2	6.3	7.5	8.8	-22.8	18.6	17.1	16.1	13.6	0.8
Aggregate										9.4	8.1	10.0	17.5
Metals													
Coal India	Buy	388	440	13	51.3	57.7	60.3	-10.6	12.4	4.6	7.6	6.7	2.1
Hindalco	Buy	862	890	3	69.2	74.0	80.2	-7.6	7.0	8.3	12.5	11.6	1.7
Hind. Zinc	Neutral	478	510	7	27.5	32.2	35.1	11.3	17.3	8.8	17.4	14.8	10.2
JSPL	Buy	1069	1240	16	58.8	87.1	97.9	41.9	48.1	12.5	18.2	12.3	2.1
JSW Steel	Buy	1210	1350	12	44.2	72.4	89.9	184.0	63.7	24.2	27.4	16.7	3.3
Jindal Stainless	Buy	783	875	12	36.4	44.7	49.2	19.2	23.0	10.0	21.5	17.5	3.3
Nalco	Neutral	238	230	-3	19.1	19.4	20.1	-33.3	1.3	3.6	12.5	12.3	2.1
NMDC	Buy	76	88	16	8.6	9.5	10.2	15.8	10.4	7.3	8.8	8.0	1.9
SAIL	Neutral	137	150	9	8.4	13.2	14.2	159.1	57	7.6	16.4	10.4	0.9
Tata Steel	Buy	184	210	14	9.2	14.2	15.6	174.9	54	9.7	19.9	12.9	2.3
Vedanta	Neutral	507	480	-5	38.9	47.7	55.5	12.0	23	16.3	13.0	10.6	4.1
Aggregate										14.1	26.4	10.6	14.4
Oil & Gas													
Aegis Logistics	Neutral	770	725	-6	22.0	24.1	25.5	16.3	9.7	5.7	35.0	31.9	5.3
BPCL	Neutral	358	320	-11	39.0	29.5	31.1	22.5	-24.3	5.3	9.2	12.1	1.6
Castrol India	Buy	196	251	28	9.5	9.6	10.3	1.2	1.4	7.3	20.7	20.4	7.9
GAIL	Buy	183	205	12	12.8	14.5	15.3	-10.8	13.0	5.7	14.3	12.6	1.5
Gujarat Gas	Buy	411	500	22	16.3	18.8	21.7	-1.8	15.1	15.6	25.2	21.9	3.1
Gujarat St. Pet.	Neutral	312	327	5	12.9	13.6	14.3	-10.2	5.6	5.3	24.3	23.0	1.6
HPCL	Buy	470	535	14	77.1	60.5	43.3	143.7	-21.6	-28.5	6.1	7.8	1.6
IOC	Neutral	163	152	-7	18.6	14.6	10.6	140.0	-21.7	-27.2	8.8	11.2	1.1
IGL	Buy	212	250	18	10.9	12.8	13.8	3.8	17.9	7.6	19.5	16.5	2.9
Mahanagar Gas	Buy	1272	1700	34	98.5	102.8	113.8	-7.2	4.4	10.7	13.0	12.4	1.9
Oil India	Neutral	435	426	-2	32.7	32.0	28.4	-12.9	-2.4	-11.1	13.3	13.6	1.4
ONGC	Neutral	254	240	-6	31.0	32.0	32.6	1.4	3.1	2.0	8.2	8.0	0.9
PLNG	Buy	283	400	41	24.3	30.9	26.3	-7.1	27.1	-15.0	11.6	9.1	2.0
Reliance Ind.	Buy	1488	1700	14	55.6	61.2	67.8	8.0	10.1	10.8	26.8	24.3	2.2
Aggregate										19.4	-0.9	0.5	16.3
Real Estate													
Anant Raj	Buy	644	831	29	14.7	13.0	31.9	18.2	-11.5	146.1	43.9	49.6	4.8
Brigade Enterpr.	Buy	1039	1494	44	38.1	54.0	78.1	35.9	41.7	44.6	27.2	19.2	3.9
DLF	Buy	777	-		16.7	17.3	18.1	-5.5	3.7	4.5	46.6	44.9	3.0
Godrej Propert.	Buy	2300	2843	24	82.3	80.0	126.4	78.4	-2.8	57.9	27.9	28.7	3.5



Company	Reco	CMP	TP	% Upside	EPS (INR)			EPS Gr. YoY (%)			P/E (x)		P/B (x)		ROE (%)	
		(INR)	(INR)	Downside	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY26E	FY27E	FY26E	
Kolte Patil Dev.	Buy	431	514	19	41.6	38.6	78.6	196.7	-7.2	103.8	10.4	11.2	2.4	2.0	30.2	19.1
Oberoi Realty	Neutral	1749	1779	2	78.8	99.7	109.3	28.7	26.6	9.6	22.2	17.5	3.5	2.9	16.9	18.2
Lodha Developers	Buy	1172	-		36.6	38.8	38.7	32.1	6.2	-0.3	32.1	30.2	5.0	4.4	16.7	15.4
Mahindra Lifespace	Neutral	384	347	-10	2.7	12.8	15.1	-32.4	380.6	17.6	143.9	29.9	2.4	2.3	2.2	7.8
SignatureGlobal	Buy	1095	1760	61	55.7	125.3	184.8	674.8	124.7	47.5	19.6	8.7	10.2	4.7	70.0	73.6
Sri Lotus	Buy	184	250	36	6.1	12.0	15.8	30.5	97.7	31.6	30.3	15.3	4.6	3.5	20.5	26.0
Sunteck Realty	Buy	454	574	26	9.4	8.4	15.8	-8.5	-10.5	88.5	48.4	54.1	2.0	1.9	4.1	3.6
Sobha	Buy	1577	1877	19	33.7	50.6	72.4	281.0	49.9	43.2	46.7	31.2	3.4	3.1	7.6	10.5
Prestige Estates	Buy	1754	2038	16	27.5	32.1	35.7	116.0	16.6	11.3	63.8	54.7	4.3	4.0	6.9	7.5
Phoenix Mills	Buy	1702	2044	20	49.7	62.1	83.6	80.6	24.8	34.7	34.2	27.4	5.0	4.3	15.8	16.8
Aggregate					37.9	18.8	25.3	35.3	29.7	4.2	3.7	11.9	12.5			
Retail																
Aditya Birla Fashion	Neutral	83	95	14	-5.0	-5.0	-4.0	-18.4	Loss	Loss	NM	NM	1.4	1.5	-9.4	-10.3
Aditya Birla Lifestyle	Neutral	135	150	11	2.0	2.3	2.6	55.0	13.8	12.0	67.1	58.9	10.8	9.1	17.5	16.8
Avenue Supermarts	Buy	4162	5000	20	45.0	53.9	64.8	8.1	19.9	20.2	92.6	77.2	11.1	9.7	12.8	13.4
United Foodbrands	Neutral	208	265	28	-8.1	-7.6	-7.1	16.6	Loss	Loss	NM	NM	2.4	2.7	-9.5	-9.9
Bata India	Neutral	1072	985	-8	16.3	21.4	25.6	-15.9	31.3	19.6	66.2	50.4	8.3	7.7	12.9	15.8
Campus Activewe.	Buy	280	315	13	4.8	6.2	7.8	20.1	29.5	27.1	58.9	45.5	9.8	8.3	16.7	18.3
Devyani Intl.	Buy	168	200	19	0.3	1.4	2.3	62.5	369.2	63.9	551.5	117.6	30.8	37.0	4.2	28.6
Go Fashion (I)	Buy	654	912	40	16.2	21.2	24.4	-6.3	31.0	14.9	40.3	30.8	4.6	4.1	10.8	12.6
Jubilant Food.	Neutral	613	700	14	5.8	8.2	10.8	62.1	41.3	32.5	106.0	75.0	19.5	19.1	18.4	25.5
Kalyan Jewellers	Buy	513	650	27	11.1	13.6	16.2	41.9	22.7	19.1	46.2	37.6	9.4	8.1	21.9	23.1
Metro Brands	Buy	1136	1400	23	14.9	17.8	20.9	6.9	19.1	17.7	76.2	64.0	15.3	13.2	22.1	22.8
P N Gadgil Jewellers	Buy	649	825	27	23.8	29.0	35.4	36.6	21.9	22.1	27.3	22.4	4.7	3.9	18.8	19.0
Raymond Lifestyle	Buy	1186	1405	18	35.2	54.5	66.7	113.5	54.6	22.5	33.7	21.8	0.7	0.7	4.8	7.1
Restaurant Brand	Buy	72	-		-2.4	-0.6	0.4	-40.5	Loss	LP	NM	NM	5.5	5.8	-16.8	-5.1
Relaxo Footwear	Sell	442	400	-10	8.3	9.4	10.6	21.6	12.8	12.9	53.1	47.1	4.9	4.5	9.5	10.0
Sapphire Foods	Buy	301	350	16	-0.3	2.0	3.1	-128.6	LP	54.6	NM	149.4	7.0	6.7	-0.7	4.6
Senco Gold	Neutral	328	385	17	17.2	18.4	22.7	38.9	6.9	23.5	19.1	17.9	2.4	2.2	13.4	12.8
Shoppers Stop	Neutral	520	520	0	1.4	-0.4	-1.3	127.4	PL	Loss	373.4	NM	12.2	12.4	4.4	-1.3
Titan Company	Buy	3751	4150	11	55.1	65.5	77.7	30.4	18.8	18.6	68.0	57.3	22.2	17.4	36.8	34.1
Trent	Buy	4744	6315	33	49.7	57.8	64.6	15.2	16.1	11.8	95.4	82.1	22.4	17.8	28.3	25.8
Vedant Fashions	Neutral	671	-		17.1	18.7	20.8	6.9	9.2	11.3	39.2	35.9	8.4	7.5	20.7	20.1
Vishal Mega Mart	Buy	146	170	17	1.8	2.3	2.8	30.6	27.5	24.1	81.1	63.6	9.3	8.1	12.2	13.6
V-Mart Retail	Buy	838	1055	26	13.7	22.5	33.1	429.1	64.2	46.9	61.1	37.2	7.2	6.1	12.6	17.7
Westlife Foodworld	Neutral	603	750	24	1.1	4.2	7.6	41.5	280.1	80.0	544.1	143.1	14.7	13.3	2.8	9.8
Aggregate					29.6	24.0	21.6	79.5	65.3	11.4	10.2	14.3	15.6			
Technology																
Cyient	Sell	1177	1050	-11	60.7	75.5	93.6	9.5	24.4	24.1	19.4	15.6	2.3	2.2	11.4	13.5
HCL Tech.	Buy	1550	1800	16	65.9	73.6	77.0	3.2	11.6	4.6	23.5	21.1	6.1	6.2	25.8	29.3
Hexaware Tech.	Buy	704	900	28	23.9	27.8	32.0	24.1	16.0	15.4	29.4	25.4	7.0	6.2	25.8	26.3
Infosys	Neutral	1494	1650	10	69.1	72.4	76.7	8.4	4.7	5.9	21.6	20.6	6.4	6.4	29.9	31.3
KPIT Technologies	Buy	1171	1500	28	29.8	37.2	45.6	2.6	24.7	22.7	39.3	31.5	9.1	7.6	25.4	26.5
LTI Mindtree	Buy	5699	6650	17	185.8	207.1	234.1	19.6	11.5	13.0	30.7	27.5	6.5	5.7	22.6	22.1
L&T Technology	Neutral	4111	4400	7	128.4	154.6	176.6	7.9	20.4	14.2	32.0	26.6	6.3	5.4	20.9	21.9
Mphasis	Neutral	2895	3000	4	100.3	112.0	126.1	12.4	11.7	12.6	28.9	25.8	5.3	4.9	19.1	19.8
Coforge	Buy	1808	2400	33	44.7	58.7	74.3	77.3	31.4	26.5	40.5	30.8	8.4	7.4	17.4	20.7
Persistent Sys	Buy	5960	6550	10	119.1	147.0	172.7	32.0	23.4	17.5	50.1	40.6	12.5	10.5	27.1	28.3
TCS	Buy	3036	3500	15	141.8	149.5	156.1	5.6	5.5	4.4	21.4	20.3	11.1	10.7	53.1	53.8
Tata Elxsi	Sell	5540	4400	-21	105.4	136.6	156.3	-16.4	29.6	14.4	52.6	40.6	10.4	9.5	21.3	24.5
Tata Technologies	Sell	700	570	-19	16.8	19.8	22.5	1.4	17.7	13.5	41.6	35.4	7.1	6.7	18.0	19.4
Tech Mah	Buy	1434	1900	33	60.1	78.0	86.3	25.3	29.8	10.7	23.9	18.4	4.5	4.4	19.2	24.1
Wipro	Sell	242	200	-17	12.5	12.6	13.1	-0.2	1.2	3.6	19.4	19.1	3.0	3.0	15.7	15.6
Zensar Tech	Neutral	803	760	-5	32.1	34.3	36.9	12.9	7.1	7.5	25.0	23.4	4.1	3.8	17.4	17.2
Aggregate					7.3	8.2	6.6	23.5	21.7	6.8	6.6	29.1	30.4			



Company	Reco	CMP	TP	% Upside	EPS (INR)			EPS Gr. YoY (%)			P/E (x)	P/B (x)	ROE (%)
		(INR)	(INR)	Downside	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY26E
Telecom													
Bharti Airtel	Buy	2066	2285	11	48.9	65.3	86.1	61.4	33.5	31.9	42.3	31.7	8.7
Bharti Hexacom	Neutral	1864	1900	2	38.0	54.8	71.9	48.4	44.0	31.3	49.0	34.0	12.7
Indus Towers	Neutral	368	390	6	25.9	30.1	30.3	41.3	15.9	0.8	14.2	12.2	2.5
Vodafone Idea	Neutral	9	10	15	-2.5	-2.4	-2.0	-35.8	Loss	Loss	NM	NM	-0.5
Tata Comm	Neutral	1916	1750	-9	42.0	61.5	75.3	46.0	46.6	22.5	45.7	31.1	15.9
Aggregate													
Utilities													
Acme Solar	Buy	288	370	28	9.0	10.7	24.5	99.8	18.3	129.9	32.0	27.0	3.5
Indian Energy Exchange	Neutral	144	-		5.2	5.4	5.7	12.6	2.6	6.5	27.4	26.7	10.0
Inox Wind	Buy	155	168	9	3.9	6.6	7.4	11.0	69.8	12.7	39.8	23.4	4.7
JSW Energy	Buy	538	655	22	10.9	15.3	23.8	1.8	41.0	55.3	49.6	35.2	3.2
NTPC	Neutral	345	372	8	22.5	27.7	31.1	8.2	23.1	12.3	15.3	12.5	1.7
Power Grid Corpn	Buy	292	346	19	18.7	19.8	20.8	12.2	5.8	4.8	15.6	14.7	2.7
Suzlon Energy	Buy	59	80	37	1.3	2.3	2.4	17.6	78.0	6.5	46.2	25.9	10.2
Tata Power Co.	Buy	410	480	17	13.4	17.5	20.3	9.2	31.1	16.0	30.6	23.4	3.3
Aggregate													
Others													
APL Apollo Tubes	Buy	1784	2100	18	42.0	54.9	64.5	54.0	30.6	17.3	42.4	32.5	9.5
Astral	Buy	1463	1600	9	21.2	28.6	34.3	8.6	35.4	19.6	69.2	51.1	7.3
Cello World	Buy	659	700	6	16.3	22.1	25.2	6.5	35.1	14.2	40.3	29.9	5.6
Coromandel Intl	Buy	2173	-		75.6	97.3	110.1	23.4	28.7	13.2	28.7	22.3	5.0
Dreamfolks Services	Buy	130	160	24	14.6	17.7	0.0	22.3	21.3	-100.0	8.9	7.3	1.8
EPL	Buy	201	280	39	13.8	16.7	19.4	21.7	21.5	15.7	14.6	12.0	2.4
Eternal	Buy	329	410	24	0.8	2.7	5.6	32.2	246.9	107.7	423.6	122.1	9.5
Godrej Agrovet	Buy	665	900	35	27.1	35.2	39.6	21.1	30.0	12.5	24.5	18.9	7.2
Gravita India	Buy	1674	-		55.2	72.9	90.9	30.5	32.0	24.7	30.3	23.0	5.0
Indiamart Inter.	Buy	2468	2900	17	81.9	93.7	109.1	-10.6	14.3	16.4	30.1	26.3	5.7
Indian Hotels	Buy	750	880	17	13.1	15.9	17.7	13.8	21.6	11.0	57.2	47.0	8.2
Info Edge	Neutral	1382	1450	5	16.2	19.3	20.3	35.8	19.4	5.2	85.4	71.5	3.1
Interglobe	Buy	5722	7290	27	222.1	246.4	276.2	18.1	10.9	12.1	25.8	23.2	12.6
Kajaria Ceramics	Buy	1216	1451	19	33.6	38.4	44.6	91.4	14.2	16.2	36.2	31.7	6.3
Lemon Tree Hotel	Buy	168	195	16	3.5	4.4	4.9	39.3	26.0	13.2	48.7	38.6	9.3
MTAR Tech	Buy	2466	2250	-9	33.2	54.7	72.4	92.9	64.9	32.3	74.4	45.1	9.1
One 97	Neutral	1310	1025	-22	9.8	19.0	26.6	-194.0	94.1	39.8	133.7	68.9	5.6
Prince Pipes	Buy	315	420	33	8.0	13.9	19.5	104.0	73.3	41.0	39.4	22.7	0.9
Quess Corp	Neutral	246	280	14	14.8	16.7	19.2	-2.4	12.8	15.0	16.6	14.7	3.0
SBI Cards	Neutral	886	1000	13	24.8	35.4	43.7	22.9	42.8	23.7	35.8	25.1	5.3
Safari Inds.	Buy	2146	2700	26	42.7	50.0	59.1	46.3	17.0	18.3	50.2	42.9	9.2
SIS	Buy	337	430	28	31.5	37.3	42.6	43.0	18.4	14.3	10.7	9.0	0.8
Supreme Inds.	Buy	3805	4850	27	78.5	107.8	129.6	3.8	37.2	20.3	48.4	35.3	7.8
Swiggy	Buy	418	550	32	-17.2	-8.8	3.8	26.3	Loss	Loss	NM	NM	13.5
Team Lease Serv.	Buy	1703	2050	20	93.9	111.6	130.3	44.8	18.8	16.7	18.1	15.3	2.7
Time Technoplast	Buy	208	289	39	10.6	13.1	16.0	24.4	23.7	21.7	19.6	15.8	2.8
Updater Services	Buy	238	310	30	20.3	22.9	24.5	14.2	13.2	6.9	11.8	10.4	1.5
UPL	Neutral	722	679	-6	38.4	57.1	64.0	53.5	48.7	12.0	18.8	12.6	1.2
VIP Inds.	Buy	410	530	29	2.4	9.3	13.4	-145.4	288.2	44.9	171.6	44.2	8.9
VA Tech Wabag	Buy	1417	1900	34	61.3	73.1	87.8	28.7	19.2	20.2	23.1	19.4	3.5

Index	1 Day (%)	1M (%)	12M (%)
Sensex	-0.7	5.2	5.6
Nifty-50	-0.7	5.1	6.3
Nifty Next 50	-0.2	3.3	-0.3
Nifty 100	-0.6	4.8	5.3
Nifty 200	-0.5	5.1	5.5
Company	1 Day (%)	1M (%)	12M (%)
Automobiles	-0.4	1.1	13.7
Amara Raja Ener.	0.3	2.7	-25.1
Apollo Tyres	-0.5	6.4	1.1
Ashok Leyland	0.9	-1.3	34.5
Bajaj Auto	-1.2	2.8	-10.2
Balkrishna Inds	0.0	1.5	-19.1
Bharat Forge	-0.4	8.6	-7.3
Bosch	-0.5	-2.5	2.9
CEAT	2.2	21.3	45.0
Craftsman Auto	2.8	-2.1	32.0
Eicher Motors	-0.9	-1.7	41.5
Endurance Tech.	0.4	3.9	21.8
Escorts Kubota	-0.2	7.8	2.2
Exide Inds.	-0.4	-2.0	-17.7
Happy Forgings	-1.1	10.3	-6.3
Hero Motocorp	-0.7	0.8	12.3
Hyundai Motor	2.4	-6.6	31.7
M & M	-0.9	2.2	29.3
CIE Automotive	0.1	9.2	-10.6
Maruti Suzuki	0.4	1.1	44.0
MRF	-1.1	8.4	29.6
Sona BLW Precis.	0.0	17.3	-29.5
Motherson Sumi	-0.8	1.2	-13.4
Motherson Wiring	-0.9	3.7	13.7
Tata Motors	0.3	0.2	-18.9
TVS Motor Co.	-0.2	1.5	42.0
Tube Investments	-2.6	-1.2	-31.4
Banks-Private	-0.7	6.8	11.3
AU Small Fin. Bank	-0.7	19.8	43.8
Axis Bank	-0.8	9.5	5.8
Bandhan Bank	-1.0	5.2	-3.9
DCB Bank	-2.7	22.2	29.5
Equitas Sma. Fin	-1.5	3.6	-16.4
Federal Bank	0.0	21.7	15.5
HDFC Bank	-1.0	5.0	15.1
ICICI Bank	-0.6	1.1	3.8
IDFC First Bank	-0.5	13.1	14.7
IndusInd Bank	-0.8	8.9	-24.2
Kotak Mah. Bank	-0.6	7.3	23.2
RBL Bank	0.4	17.2	85.0
SBI Cards	-2.8	1.0	29.5
Banks-PSU	-0.4	7.1	19.5
BOB	-0.7	5.5	8.5
Canara Bank	3.2	7.4	28.6
Indian Bank	0.0	13.9	45.4
Punjab Natl.Bank	-0.8	6.4	20.1
St Bk of India	-0.6	7.1	13.6

Index	1 Day (%)	1M (%)	12M (%)
Nifty 500	-0.5	4.9	4.8
Nifty Midcap 100	-0.1	6.3	6.7
Nifty Smallcap 100	-0.1	5.2	0.4
Nifty Midcap 150	-0.2	5.3	5.9
Nifty Smallcap 250	-0.1	4.3	-0.4
Union Bank (I)	-2.6	2.8	22.0
NBFCs	-0.8	5.2	13.9
Aditya Birla Capital Ltd	5.1	11.8	51.7
AAVAS Financiers	0.9	2.9	0.5
Bajaj Fin.	-1.0	5.3	51.3
Bajaj Housing	0.1	0.6	-17.6
Cholaman.Inv.&Fn	0.1	6.3	34.3
Can Fin Homes	1.4	14.6	-1.1
CreditAcc. Gram.	4.9	8.8	49.7
Fusion Microfin.	0.0	-3.6	-7.9
Five-Star Bus.Fi	6.2	19.8	-16.0
HDB FINANC SER	-0.1	-2.1	
Home First Finan	-0.2	-0.5	-0.1
Indostar Capital	1.1	0.5	-10.6
IIFL Finance	3.6	19.9	28.5
L&T Finance	-0.1	7.5	82.9
LIC Housing Fin.	-3.9	1.0	-9.9
MCX	-0.8	16.7	42.4
M & M Fin. Serv.	-0.6	14.7	18.4
Muthoot Finance	0.3	3.7	62.1
Manappuram Fin.	-0.6	-2.1	70.4
MAS Financial Serv.	1.6	2.2	8.0
PNB Housing	-0.4	8.2	1.3
Power Fin.Corpn.	-0.9	-1.3	-12.6
REC Ltd	-1.9	1.5	-29.2
Repco Home Fin	-0.2	15.1	-13.0
Shriram Finance	0.0	19.8	15.9
Spandana Sphoort	3.2	3.3	-34.0
Nippon Life Ind.	1.6	0.4	27.0
UTI AMC	-2.3	-4.3	-3.2
Nuvama Wealth	-1.8	14.6	7.8
Prudent Corp.	-0.2	1.9	-3.2
NBFC-Non Lending			
360 One	-0.6	9.3	5.5
Aditya AMC	-0.6	-1.9	0.8
Anand Rathi Wea.	1.7	11.1	61.0
Angel One	0.1	17.8	-17.0
BSE	-0.2	19.7	68.8
C D S L	-0.1	10.7	6.3
Cams Services	2.6	5.3	-9.7
HDFC AMC	-0.6	-3.0	22.3
KFin Technolog.	-1.5	5.7	16.1
MCX	-0.8	16.7	42.4
N S D L	1.4	-3.0	
Nippon Life Ind.	1.6	0.4	27.0
Nuvama Wealth	-1.8	14.6	7.8
Prudent Corp.	-0.2	1.9	-3.2
UTI AMC	-2.3	-4.3	-3.2

Company	1 Day (%)	1M (%)	12M (%)
Insurance			
HDFC Life Insur.	-1.9	-1.3	2.7
ICICI Pru Life	-0.1	0.9	-19.7
ICICI Lombard	-0.8	6.6	4.5
Life Insurance	-0.9	0.0	-3.7
Max Financial	2.5	-1.3	24.2
Niva Bupa Health	-0.4	-8.6	
SBI Life Insuran	-0.1	9.9	21.2
Star Health Insu	0.1	7.7	-6.7
Chemicals			
Alkyl Amines	-1.0	-1.5	-8.6
Atul	-1.3	-4.0	-24.6
Clean Science	-3.3	-7.6	-32.3
Deepak Nitrite	-0.4	-5.2	-35.8
Ellen.Indl.Gas	2.4	-1.0	
Fine Organic	-0.8	-0.4	-6.7
Galaxy Surfact.	-1.6	1.4	-23.0
Navin Fluo.Intl.	0.0	7.7	49.2
NOCIL	0.1	7.1	-33.8
P I Inds.	-0.3	2.3	-20.0
SRF	-1.5	5.6	31.8
Tata Chemicals	-1.3	-2.1	-20.4
Vinati Organics	-0.4	-2.4	-12.4
Capital Goods	0.1	2.7	3.6
A B B	-0.2	1.8	-28.9
Bharat Dynamics	-0.7	1.5	42.4
Bharat Electron	0.7	1.5	42.1
Cummins India	0.6	11.7	24.9
Hind.Aeronautics	-1.0	-2.0	9.8
Hitachi Energy	2.6	-0.4	30.9
K E C Intl.	-0.3	-5.6	-13.2
Kalpataru Proj.	0.3	0.6	0.1
Kirloskar Oil	-0.1	10.6	-8.9
Larsen & Toubro	0.7	9.0	17.0
Siemens	-0.7	-0.1	-9.2
Siemens Ener	2.3	-6.6	
Thermax	-0.5	2.5	-34.7
Triveni Turbine	-1.4	1.8	-21.4
Zen Technologies	1.1	-3.9	-23.8
Cement			
Ambuja Cem.	-0.7	-0.4	-2.0
ACC	-1.1	1.9	-20.3
Birla Corp.	1.3	-2.0	4.1
Dalmia Bhar.	-1.5	-5.8	14.1
Grasim Inds.	-0.3	7.0	10.4
India Cem	2.2	4.2	11.1
JSW Cement	-0.7	-1.5	
J K Cements	-1.4	-0.9	44.0
JK Lakshmi Cem.	2.7	1.7	8.4
The Ramco Cement	-0.5	6.8	19.3
Shree Cement	-1.6	-1.8	13.4
UltraTech Cem.	0.5	-1.4	7.6

Company	1 Day (%)	1M (%)	12M (%)
Consumer	-0.5	3.0	-5.7
Asian Paints	-0.6	7.4	-15.8
Britannia Inds.	0.1	-2.2	1.3
Colgate-Palm.	-0.5	1.5	-27.0
Dabur India	-1.3	2.1	-8.3
Emami	-0.2	0.8	-18.7
Godrej Consumer	0.6	-4.6	-14.4
Hind. Unilever	-0.7	-1.8	-3.3
ITC	-0.7	4.3	-9.9
Indigo Paints	-0.3	-4.0	-37.5
Jyothy Lab.	-0.7	1.2	-38.1
L T Foods	-1.3	2.8	10.1
Marico	0.0	3.5	10.8
Nestle India	0.5	11.0	12.5
Page Industries	-1.0	0.6	-5.3
Pidilite Inds.	-1.4	1.3	-5.7
P & G Hygiene	-0.3	-5.2	-17.4
Radico Khaitan	-0.6	8.9	30.4
Tata Consumer	0.0	4.2	15.0
United Breweries	-2.8	-0.6	-7.3
United Spirits	0.4	5.2	-3.7
Varun Beverages	-2.1	9.4	-19.9
Consumer Durables	-0.2	5.7	-0.4
Havells	-0.2	0.3	-9.4
KEI Industries	0.5	1.1	6.3
LG Electronics	0.1		
Polycab India	1.4	7.7	22.7
R R Kabel	-1.1	11.7	-4.9
Volta	0.1	4.9	-16.4
EMS			
Amber Enterp.	-2.7	0.0	33.6
Avalon Tech	-0.1	19.1	102.3
Cyient DLM	1.0	9.4	-27.2
Data Pattern	-1.6	6.2	9.3
Dixon Technolog.	0.9	-4.2	10.4
Kaynes Tech	-1.7	-3.6	29.0
Syrma SGS Tech.	0.8	7.3	63.0
Healthcare	-0.6	3.9	-0.3
Ajanta Pharma	0.3	2.6	-17.6
Alembic Pharma	-0.1	-0.2	-16.9
Alkem Lab	-0.5	1.6	-4.9
Apollo Hospitals	-0.9	5.1	11.6
Aurobindo	-0.8	1.7	-21.5
Biocon	0.8	10.4	17.4
Blue Jet Health	-0.7	2.7	35.3
Cipla	-2.6	2.4	8.6
Divis Lab	2.2	17.0	13.1
Dr Agarwals Health	1.3	2.1	
Dr Reddy's	-3.9	-1.8	-3.8
ERIS Lifescience	-0.6	2.1	25.6
Gland Pharma	0.3	-4.1	16.3
Glenmark	2.1	-3.6	12.7
Global Health	-0.2	4.5	26.8
Granules	0.4	10.9	3.4

Company	1 Day (%)	1M (%)	12M (%)
GSK Pharma	-0.8	-1.4	-2.0
IPCA Labs	-0.4	-4.0	-17.8
Laurus Labs	0.9	15.3	99.9
Laxmi Dental	1.4	-2.2	
Lupin	-0.5	1.8	-9.8
Mankind Pharma	0.1	0.4	-6.9
Max Healthcare	-0.9	5.7	18.8
Piramal Pharma	-1.1	5.6	-20.0
Sun Pharma	-0.7	6.8	-8.0
Torrent Pharma	0.1	0.0	14.8
Zydus Lifesci.	-1.7	0.4	0.1
Infrastructure	-0.6	6.7	9.3
G R Infraproject	-0.6	-3.2	-24.0
IRB Infra.Devl.	-0.3	8.3	-17.4
KNR Construct.	-1.2	-7.2	-36.4
Logistics			
Adani Ports	0.2	3.9	4.4
Blue Dart Exp.	1.9	17.4	-14.6
Delhivery	-1.9	5.6	34.1
Container Corpn.	-0.8	4.5	-17.8
JSW Infrast	-0.3	-6.3	-6.5
Mahindra Logis.	2.1	5.7	-2.7
Transport Corp.	-1.9	2.0	12.5
TCI Express	0.1	-7.6	-30.5
VRL Logistics	-1.1	-1.3	-3.0
Media	-0.3	1.0	-21.4
PVR INOX	0.6	15.4	-20.5
Sun TV	-1.6	8.4	-23.9
Zee Ent.	-1.9	-9.3	-16.6
Metals	-0.4	6.9	14.8
Hindalco	0.6	13.0	25.1
Hind. Zinc	-1.2	-1.0	-14.8
JSPL	0.0	0.6	16.5
JSW Steel	0.2	5.9	26.4
Jindal Stainless	-2.6	6.1	15.3
Nalco	0.0	11.3	4.8
NMDC	-1.1	-0.6	1.5
SAIL	-2.5	1.9	18.1
Tata Steel	-0.5	9.2	23.7
Vedanta	-1.8	8.8	8.2
Oil & Gas	0.2	6.2	4.0
Aegis Logistics	-1.9	0.6	-2.4
BPCL	2.7	5.3	14.9
Castrol India	-0.8	-1.7	-8.2
GAIL	-0.8	3.9	-10.1
Gujarat Gas	0.2	-4.2	-22.0
Gujarat St. Pet.	-0.5	1.0	-19.6
HPCL	0.2	5.9	24.4
IOCL	0.3	9.2	14.0
IGL	-0.2	1.6	0.7
Mahanagar Gas	-1.8	-1.8	-11.8
Oil India	3.4	5.1	-7.7
ONGC	-0.4	6.3	-2.7

Company	1 Day (%)	1M (%)	12M (%)
PLNG	-0.6	1.2	-14.8
Reliance Ind.	-1.0	9.1	10.8
Real Estate	0.0	9.6	-5.0
Anant Raj	1.2	-7.9	-7.1
Brigade Enterpr.	0.4	15.9	-13.2
DLF	-0.3	8.9	-6.0
Godrej Propert.	-0.5	16.8	-20.0
Kolte Patil Dev.	0.5	-0.6	16.9
Mahindra Life.	-0.9	8.7	-14.2
Macrotech Devel.	-0.7	3.1	-0.7
Oberoi Realty Ltd	2.2	10.6	-9.2
SignatureGlobal	0.2	4.1	-20.9
Sri Lotus	0.1	-2.8	
Sobha	1.1	2.3	-1.8
Sunteck Realty	2.2	9.5	-16.2
Phoenix Mills	-0.3	9.5	8.8
Prestige Estates	0.1	16.2	6.6
Retail			
Aditya Bir. Fas.	-1.9	-1.8	-25.8
A B Lifestyle	-0.8	1.2	
Avenue Super.	-1.6	-7.0	5.8
United Foodbrands	0.0	-10.5	-62.5
Bata India	-0.5	-8.0	-21.4
Campus Activewe.	0.4	3.9	-2.6
Devyani Intl.	0.0	-0.1	-0.2
Go Fashion (I)	-1.5	-2.9	-41.7
Jubilant Food	0.0	-0.7	6.0
Kalyan Jewellers	-0.1	12.9	-23.9
Metro Brands	-0.3	-11.9	-4.1
P N Gadgil Jewe.	-0.9	7.6	-9.3
Raymond Lifestyl	-2.5	1.9	-46.4
Relaxo Footwear	0.1	-1.1	-41.0
Restaurant Brand	1.1	-6.7	-21.2
Sapphire Foods	3.4	2.6	-7.2
Senco Gold	0.8	-4.4	-46.0
Shoppers St.	-0.1	0.0	-22.5
Titan Co.	0.1	11.4	13.4
Trent	-0.8	1.4	-34.6
Vedant Fashions	-2.0	-2.7	-50.0
V-Mart Retail	1.4	18.0	-25.2
Vishal Mega Mart	-1.2	-2.3	
Westlife Food	2.3	-12.6	-22.2
Technology	-0.5	6.7	-13.8
Cyient	-0.8	2.6	-35.8
HCL Tech.	-0.5	11.9	-15.7
Hexaware Tech.	-0.8	5.0	
Infosys	-1.1	3.6	-17.1
KPIT Technologi.	-1.9	6.7	-15.4
LTIMindtree	0.4	10.5	-1.7
L&T Technology	0.1	-0.1	-20.3
Mphasis	0.7	9.0	-3.8
Coforge	0.6	13.6	16.7
Persistent Sys	1.2	23.6	6.1

Company	1 Day (%)	1M (%)	12M (%)
TCS	-0.7	5.1	-25.7
Tata Technolog.	-0.2	4.5	-30.4
Tata Elxsi	0.0	6.0	-22.0
Tech Mah	-1.3	2.4	-14.9
Wipro	-0.1	1.1	-14.4
Zensar Tech	0.3	5.3	14.6
Telecom	-2.5	8.2	4.9
Bharti Airtel	-1.6	10.0	26.5
Indus Towers	-3.4	7.4	7.4
Idea Cellular	-6.7	7.4	13.7
Tata Comm	0.2	18.6	7.1
Utilities	-0.2	4.2	-10.5
ACME Solar Hold.	1.1	4.2	
Coal India	1.5	-0.6	-13.7
Indian Energy Ex	-3.4	3.1	-18.6
Inox Wind	-1.0	10.3	-28.3
JSW Energy	0.7	1.4	-20.2
NTPC	-0.7	1.4	-15.5
Power Grid Corpn	-1.3	4.0	-8.5
Suzlon Energy	0.5	6.3	-14.1
Tata Power Co.	-0.2	5.4	-4.0
Others			
APL Apollo Tubes	-1.1	5.8	19.7
Astral	0.0	7.2	-16.1
Cello World	-0.2	14.5	-20.1
Coromandel Intl	-3.6	-3.3	32.1
Dreamfolks Servi	0.0	25.6	-71.4
EPL Ltd	-1.1	-2.1	-25.0
Eternal Ltd	-0.3	1.2	33.4
Godrej Agrovet	-0.3	-3.6	-6.5
Gravita India	1.9	6.7	-16.3
Havells	-0.2	0.3	-9.4
Indiamart Inter.	-0.5	4.9	-3.1
Indian Hotels	0.4	4.1	9.5
Info Edge	-0.4	5.7	-9.9
Interglobe	-1.5	2.3	41.1
Kajaria Ceramics	0.0	4.3	0.5
Lemon Tree Hotel	1.9	1.1	45.3
MTAR Technologie	4.9	33.3	51.1
One 97	0.0	16.6	74.2
Prince Pipes	-0.5	-1.3	-35.0
Quess Corp	-2.1	-3.4	-28.1
Safari Inds.	-0.6	-1.9	-1.9
SIS	-1.0	-3.7	-16.1
Supreme Inds.	-1.0	-9.7	-13.2
Swiggy	-0.2	-1.2	
Time Technoplast	-0.6	-0.8	1.0
Team Lease Serv.	-1.0	-4.6	-39.4
Updater Services	1.7	-4.0	-37.8
UPL	0.2	10.0	37.7
Volta	0.1	4.9	-16.4
VIP Inds.	-2.3	-1.5	-14.7
Va Tech Wabag	0.0	-1.4	-16.8

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	> - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

MOFSL, its associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report..

In the past 12 months, MOFSL or any of its associates may have:

received any compensation/other benefits from the subject company of this report
 managed or co-managed public offering of securities from subject company of this research report,
 received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
 received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

MOFSL and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.

Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.

Research Analyst may have served as director/officer/employee in the subject company.

MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.
 (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement

Analyst ownership of the stock No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and

under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Disclaimer:

This report is intended for distribution to Retail Investors.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028 . AMFI: ARN :. 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrivances@motilaloswal.com.